close

January 2022

Medical products

These Are The Top 10 Competitive Medical Products And Equipment…

(MENAFN-ValueWalk) Bru-nO / Pixabay

The medical products and equipment industry has experienced remarkable growth over the past decade. This industry consists of businesses that sell instruments, devices, or machines used in the prevention, diagnosis, or treatment of disease or ailment. The medical products and equipment industry, in turn, depends on many other industries to maintain its competitive edge, including telecommunications, software development, biotechnology and more. Let’s take a look at the top ten medical product and equipment companies.

Get the complete Henry Singleton series in PDF

Get the complete 4-part series on Henry Singleton in PDF. Save it to your desktop, read it on your tablet, or email it to co-workers

Q4 2021 Hedge Fund Letters, Talks & More

This fund focused on the financial sector has performed well in 2021

The Arbiter Global Financials fund generated an estimated return of 26%, compared to its benchmark, the MSCI ACWI Financials Index, which generated a return of 25.1%. In their year-end letter, which was obtained by ValueWalk, Arbiter’s Matthew Hankin and Ross Levin said they believe their portfolio is well positioned in the current environment. Q4 2021 Hedge Fund Letters, Conferences and Read More

Contents Pin up

  • 1. Ten largest medical products and equipment companies

  • 2. Dentsply Sirona (>$4 billion)

  • 3. Edwards Lifesciences (>$4.3 billion)

  • 4. Intuitive surgery (>$4.4 billion)

  • 5. Zimmer Biomet Holdings (>$7.9 billion)

  • 6. Boston Scientific (>$10.7 billion)

  • 7. Baxter International (>$11.3 billion)

  • 8. Stryker (>$14.8 billion)

  • 9. Becton Dickinson & Co. (>$17.2 billion)

  • 10. Danaher (>$20.5 billion)

  • 11. Abbott Laboratories (>$31.9 billion)

Ten largest medical products and equipment companies

We used the latest disposable income figures to rank the ten largest medical products and equipment companies. We only used Fortune 1000 companies for our list. Here are the ten largest medical products and equipment companies:

  • Dentsply Sirona (>$4 billion)
  • Founded in 1899 and based in Charlotte, North Carolina, this company designs, manufactures, sells and distributes professional dental products and technologies. Dentsply (NASDAQ: XRAY) has the following business segments: Technologies and Equipment and Consumables. Its shares are down more than 8% in the last three months and more than 6% in the last month. Dentsply Sirona reported a net loss of over $80 million in 2021 and a net profit of over $260 million in 2020.

  • Edwards Lifesciences (>$4.3 billion)
  • Founded in 1958 and based in Irvine, Calif., this company is dedicated to patient-focused medical innovations related to critical care monitoring and heart disease. Edwards Lifesciences Corp (NYSE: EW) products are classified into three categories: surgical structural heart, critical care and transcatheter heart valves. Its shares are down more than 9% in the last three months and more than 18% in the last month. Edwards Lifesciences reported net income of over $1.5 billion in 2021 and over $800 million in 2020.

  • Intuitive surgery (>$4.4 billion)
  • Founded in 1995 and based in Sunnyvale, California, this company develops, manufactures and markets da Vinci Surgical Systems and related instruments and accessories for invasive surgery. Intuitive Surgical, Inc. (NASDAQ: ISRG) products include da Vinci and Ion. Its shares are down more than 23% in the last three months and more than 24% in the last month. Intuitive Surgical reported net income of over $1.7 billion in 2021 and over $1 billion in 2020.

  • Zimmer Biomet Holdings (>$7.9 billion)
  • Founded in 1927 and based in Warsaw, Indiana, this company offers musculoskeletal health services. Zimmer Biomet Holdings Inc (NYSE: ZBH) has the following geographic segments: Americas and Global, EMEA and Asia Pacific. Its shares are down more than 17% in the last three months and more than 6% in the last month. Zimmer Biomet Holdings reported a net loss of over $130 million in 2021 and a net profit of over $1.10 billion in 2020.

  • Boston Scientific (>$10.7 billion)
  • Founded in 1979 and based in Marlborough, Mass., this company is an innovator of medical solutions that help improve patient health. Boston Scientific Corporation (NYSE: BSX) has the following business segments: Rhythm and Neuro, Cardiovascular and MedSurg. Its shares are down nearly 1% in the past three months, but up nearly 19% in the past year. Boston Scientific announced a net loss of more than $80 million in 2021 and a net profit of more than $4.70 billion in 2020.

  • Baxter International (>$11.3 billion)
  • Founded in 1931 and based in Deerfield, Illinois, this company markets kidney and hospital essential products, such as sterile intravenous solutions, infusion systems and devices, acute and chronic dialysis, etc. Shares of Baxter International Inc (NYSE: BAX) are up nearly 7% in the past three months, but down nearly 2% in the past month. Baxter International reported net income of over $1 billion in 2021.

  • Stryker (>$14.8 billion)
  • Founded in 1941 and based in Kalamazoo, Michigan, this company deals in technology products and services. Stryker Corporation (NYSE: SYK) has the following business segments: Orthopedics, MedSurg and Neurotechnology & Spine. Its shares are down more than 7% in the past three months. Stryker reported net income of over $1.90 billion in 2021 and over $1.50 billion in 2020.

  • Becton Dickinson & Co. (>$17.2 billion)
  • Founded in 1897 and based in Franklin Lakes, NJ, this company develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products. Becton Dickinson and Co (NYSE: BDX) has the following business segments: BD Medical, BD Life Sciences and BD Interventional. Its shares are up more than 5% in the past three months and nearly 1% in the past month. Becton Dickinson reported net income of over $2 billion in 2021 and over $800 million in 2020.

  • Danaher (>$20.5 billion)
  • Founded in 1969 and based in Washington, DC, this company designs, manufactures and markets medical, commercial, professional and industrial products and services. Danaher Corporation (NYSE: DHR) has the following business segments: life sciences, environmental and applied diagnostics and solutions. Its shares are down more than 9% in the past three months and nearly 11% in the past month. Danaher reported net income of over $6.30 billion in 2021 and over $3.60 billion in 2020.

  • Abbott Laboratories (>$31.9 billion)
  • Founded in 1888 and based in Abbott Park, Illinois, this company discovers, develops, manufactures and sells a line of health care products. Abbott Laboratories (NYSE:ABT) includes the following business segments: diagnostics, medical devices, established pharmaceuticals and nutritional products. Its shares are down nearly 3% in the past three months and nearly 10% in the past month. Abbott reported net income of over $7 billion in 2021 and over $4.40 billion in 2020.

    Updated January 31, 2022 at 10:22 a.m.

    MENAFN31012022005205011743ID1103620332


    Legal disclaimer: MENAFN provides the information “as is” without warranty of any kind. We assume no responsibility for the accuracy, content, images, videos, licensing, completeness, legality or reliability of any information in this article. If you have any complaints or copyright issues related to this article, please contact the provider above.

    read more
    Prescription drugs

    Prescription Drug Consumption Market Size 2022 and Analysis by 2029

    New Jersey, United States,-The report attempts to offer an accurate and high-quality analysis of the global Prescription Drug Consumption Market, keeping in mind market forecast, competitive intelligence, risks and technological advancements, and other important topics. Its carefully crafted market insights enable market players to understand the most significant developments in the global Prescription Drug Consumption market that are impacting their business. Readers can become aware of crucial opportunities available in the Global Prescription Drug Consumption Market along with key factors driving and restraining the market growth. The research study also provides an in-depth geographical analysis of the global Prescription Drug Consumption market and sheds light on important applications and products that market players can focus on to achieve high growth.

    Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=419994

    You can thoroughly assess the strengths and weaknesses of your competitors with our competitive analysis. The report also provides access to a comprehensive analysis of production and shipment, from origin to end-user purchase. Plus, you’ll be updated on the latest industry developments to help you stay ahead of your competition. Our analysts are always on their toes to continuously monitor and analyze any changes or developments in the quality prescription drug consumption industry. The report is filled with statistical announcements, market figures related to annual revenue, volume, average and share, as well as global and regional market forecasts.

    The report includes a detailed segmentation study of the global Prescription Drug Consumption market, in which all the segments are analyzed in terms of market growth, share, growth rate and other important factors. It also provides the attractiveness index of the segment, allowing players to inform about the profitable revenue pockets of the global Prescription Drug Consumption market. A broad assessment of the segments provided in the report enables investments, strategy, and teams to focus in the right areas of the global Prescription Drug Consumption Market.

    Key Players Covered in the Prescription Drug Consumption Markets:

    • Pfizer
    • rock
    • Sanofi
    • Johnson & Johnson
    • Merck & Co. (MSD)
    • Novartis
    • AbbVie
    • Gilead Sciences
    • GlaxoSmithKline (GSK)
    • Amgen
    • Astra Zeneca
    • Bristol Myers Squibb
    • Eli Lily
    • Suits you
    • Bayer
    • Novo Nordisk
    • Allergan
    • County
    • Boehringer Ingelheim
    • Takeda

    Prescription Drug Consumption Market Breakdown by Type:

    Prescription Drug Consumption Market Split By Application:

    The Prescription Drug Consumption Market report has been segregated into distinct categories such as product type, application, end-user, and region. Each segment is valued based on CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is expected to generate opportunities in the Global Prescription Drug Consumption Market in the coming years. This segmental analysis will surely prove to be a useful tool for readers, stakeholders, and market players to get a complete picture of the global Prescription Drug Consumption market and its growth potential in the years to to come.

    Get | Discount on the purchase of this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=419994

    Scope of Prescription Drug Consumption Market Report

    Report attribute Details
    Market size available for years 2021 – 2028
    Base year considered 2021
    Historical data 2015 – 2019
    Forecast period 2021 – 2028
    Quantitative units Revenue in USD Million and CAGR from 2021 to 2027
    Segments Covered Types, applications, end users, and more.
    Report cover Revenue Forecast, Business Ranking, Competitive Landscape, Growth Factors and Trends
    Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
    Scope of customization Free report customization (equivalent to up to 8 analyst business days) with purchase. Added or changed country, region and segment scope.
    Pricing and purchase options Take advantage of personalized purchasing options to meet your exact research needs. Explore purchase options

    Regional Market Analysis Prescription Drug Consumption can be represented as follows:

    Each regional Prescription Drug Consumption industry is carefully researched to understand its current and future growth scenarios. This helps players strengthen their position. Use market research to get a better perspective and understanding of the market and target audience and ensure you stay ahead of the competition.

    Based on geography, the global prescription drug consumption market has been segmented as follows:

      • North America includes the United States, Canada and Mexico
      • Europe includes Germany, France, UK, Italy, Spain
      • South America includes Colombia, Argentina, Nigeria and Chile
      • Asia Pacific includes Japan, China, Korea, India, Saudi Arabia and Southeast Asia

    Answers to key questions in the report:

    • What is the growth potential of the consumer prescription drug markets?
    • Which product segment will take the lion’s share?
    • Which regional market will impose itself as a precursor in the years to come?
    • Which application segment will grow at a rapid pace?
    • What are the growth opportunities that may emerge in the Lock Washers industry in the coming years?
    • What are the major challenges that the global prescription drug consumption markets may face in the future?
    • Who are the leading companies in the Global Prescription Drug Consumption Market?
    • What are the key trends that are positively impacting market growth?
    • What are the growth strategies considered by the players to sustain their hold in the global Prescription Drug Consumption market?

    For more information or query or customization before buying, visit @ https://www.marketresearchintellect.com/product/global-prescription-drugs-consumption-market-size-and-forecast/

    The study thoroughly explores the profiles of major market players and their major financial aspects. This comprehensive business analyst report is useful for all existing and new entrants when designing their business strategies. This report covers the Prescription Drug Consumption market production, revenue, market share and growth rate for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Historical breakdown data of prescription drug use from 2016 to 2020 and forecast to 2021-2029.

    About Us: Market Research Intellect

    Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations, in addition to the goal of providing customized and in-depth research studies. range of industries including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. etc Our research studies help our clients to make decisions based on higher data, to admit deep forecasts, to grossly capitalize with opportunities and to optimize efficiency by activating as their belt in crime to adopt a mention precise and essential without compromise. clients, we have provided expert behavior assertion research facilities to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

    Contact us:
    Mr. Edwyne Fernandes
    USA: +1 (650)-781-4080
    UK: +44 (753)-715-0008
    APAC: +61 (488)-85-9400
    US toll free: +1 (800)-782-1768

    Website: –https://www.marketresearchintellect.com/

    read more
    Generic drugs

    Prescribe generic drugs

    Notwithstanding the code of ethics of the Medical Council of India and clear government orders regarding the prescription of generic drugs for patients, doctors continue to flout these instructions under pretexts unclear to health administrators who have now demanded prescription audits to check if patients are being prescribed these drugs which are less expensive than general drugs. Generic drugs are drugs created with the same ingredients as brand name drugs. MCI’s recent guideline under Code of Medical Ethics 1.5 states that every physician should, whenever possible, prescribe drugs with generic names and should ensure that there is a prescription and a rational use of drugs. By default, most drugs sold in India are generic. However, they are marketed under a brand given by the manufacturer. This directive transfers the responsibility for the selection of the brand name of the medicine and the manufacturer to the pharmacist, as is the practice in Europe and in many developed countries. This advice is downplayed by the licensed doctors of India, stating that this advice will put the health of the patients in the hands of the pharmacists instead of the doctor. The generic drug must have the same destination as the branded product that serves as its prototype. It relates to the name of the salt or the active ingredient of a drug delivery form. Generic drugs are drugs designed to work exactly the same way as brand name drugs, but are often less expensive. Although not associated with any particular company, generics are generally subject to government regulations in the countries in which they are issued. They are labeled with the manufacturer’s name and a generic nonproprietary name. The directive from MCI or any other regulatory body favoring the writing of generic names only should be carefully evaluated by the clinician practitioner. Patient safety must be of paramount importance. Every effort should be made by professional bodies to achieve syncretism with government regulations based on a thorough understanding of the issues. The solution to the brand versus generic problem lies in strengthening the country’s existing quality control structure. Generic drugs are available at Jan Aushadhi Kendras across Jammu and Kashmir and doctors have to prescribe them to patients. There is a need for awareness among the masses as Kendras are functional in the district while other Kendras are in preparation. The new format regarding “prescription verification” would review collected prescriptions and see if generic drugs are prescribed and preference is given to drugs available free of charge from hospital supplies. It will also check unnecessary tests, diagnoses; procedures and referrals to private/specialist clinics without requirement.

    read more
    Medical supplies

    Comprehensive report on Medical Supplies Market predicted to gain significant value by 2026





    A latest report titled Global Medical Devices Market, the report has been prepared by expert and knowledgeable market analysts and researchers. They have explored the competitive landscape, segmentation, geographic expansion, and revenue, production, and consumption growth of the global Medical Supplies Market and added in the report. The major key players can use the accurate market facts, figures and analytical studies provided in the report to understand the current and future growth of the global market. The report contains data on the competitive scenario, supply and demand situation, and market growth challenges.

    The main objective of the Medical Supplies market report is to predict the performance of the industry for the upcoming years to help the stakeholders to take right decisions and improve their revenue flow. Moreover, key trends and growth opportunities are discussed in detail in the document followed by comprehensive data on the approaches to tackling the challenges faced by the industry. Also, it provides recent updates on the business scenario across the globe along with concise details regarding the revenue outlook post Covid-19 pandemic.

    Request a sample copy of this report @ https://www.getnewsalert.com/request-sample/10243

    Main highlights of the Covid-19 impact analysis:

    • Impact of Covid-19 on the global economy.
    • Changes in the share of supply and demand.
    • Predictions of the long-term effects of the Covid-19 pandemic on the growth matrix.

    An overview of the regional landscape:

    • The medical supplies market is segmented into several regional markets, namely North America, Europe, Asia-Pacific, South America, Middle East and Africa.
    • Each region’s contribution to overall growth is calculated by looking at important metrics like total sales and net income.
    • The growth rate of each regional market over the forecast period is also provided.

    Other key takeaways from the Medical Supplies Market report:

    • The report fragments the product scope of the Medical Supplies market into
      • Diagnostic
      • Dialysis
      • Wound care
      • Inhalation
      • infection control
      • Infusion
      • Intubation and PPE

      .

    • Data supporting revenue share and volume estimates for each product category are provided.
    • The study highlights the market share, production model and growth rate of each product type over the forecast period.
    • In terms of scope, the medical supplies market is categorized into
      • Hospital
      • Clinical
      • Rest house
      • Geographically
      • detailed production analysis
      • the trade of the following countries is covered in chapter 4.2
      • 5:
      • United States
      • Europe
      • China
      • Japan and India

      .

    • The market share and growth rate forecasts of each application segment are extensively discussed.
    • Major companies influencing the medical supplies market trends are
      • Baxter International Inc.
      • Thermo Fisher Scientific Inc.
      • Medtronic plc
      • Cardinal Health
      • Inc.
      • Dickinson and company
      • Johnson & Johnson
      • stryker
      • Abbott
      • Boston Scientific Society
      • B. Braun Melsungen AG
      • 3M Company and BD

      .

    • Evaluation of companies based on their production models, product and service portfolio, pricing model, gross margins, market compensation and market share is included.
    • Major competitive trends and their business implications are elaborated.
    • A granular assessment of the industry supply chain, with details on manufacturers, raw material and equipment suppliers, and consumers, is housed in the document.
    • The report also has a dedicated section for determining the feasibility of a new project using various methods such as Porter’s five forces analysis and SWOT analysis.

    Contents

    1. Global Medical Supplies Market Research Report
    2. Overview of the global medical supplies market
    3. Global economic impact on the industry
    4. Global Medical Supplies Market Competition by Manufacturer
    5. Global production, revenue by region
    6. Global Market Analysis by Application
    7. Medical Supplies Market Manufacturing Cost Analysis
    8. Marketing Strategy Analysis, Distributors/Traders
    9. Global Medical Supplies Market Forecast
    10. Global Medical Supplies Market competition by players/vendors, revenue, market share, growth rate
    11. Conclusion

    Customization request on this report @ https://www.getnewsalert.com/request-for-customization/10243





    read more
    Prescription drugs

    Pfizer, Gilead Sciences, Johnson & Johnson, Roche, – Oxford Spokesperson

    Backed by comprehensive primary and secondary research, the Global report Medicines without a prescription Industry 2021 presents profitable market prospects. This market research report has deployed suggestions from numerous industry experts and also presents valuable recommendations from expert and experienced market analysts. Top decision makers in this industry have added their own thoughts from around the world.

    Some Major actors are listed in the report and we will add more as needed. (This report is customizable).

    Pfizer, Gilead Sciences, Johnson & Johnson, Roche, AbbVie, Sanofi, Amgen, Novartis, Merck & Co. (MSD), GlaxoSmithKline (GSK), Bayer, Takeda, AstraZeneca, Takeda, Novo Nordisk, Teva, Bristol-Myers Squibb, Boehringer Ingelheim, Allergan, Eli Lilly

    We have recent OTC Drug Market Updates in sample copy @ https://www.maccuracyreports.com/report-sample/91240

    Non-prescription drugs market

    Hospital, Clinic, Other.

    Application as below

    Brand name drugs, generic drug

    MRA Reports uncovered the report which incorporates restraints, market drivers, opportunities, challenges, investment potential, future roadmap, new innovations, vendor profiles, market trends and strategies . The report also details market size forecast for the global non-prescription drugs market. Additionally, further forecasts have been presented regarding the dominating segments of the Non-prescription Drugs market. The report is deployed with numerous charts, tables, and graphs for a better and vivid understanding of the market data.

    Browse Full Report with Facts and Figures of Non-Prescription Drugs Market Report at @ https://www.maccuracyreports.com/reportdetails/reportview/91240

    To add answers to some key questions to the report, which are:

    What are the drivers impacting the market growth of the Non-prescription Drugs Market?

    What will be the estimated Non-Prescription Drugs market size, and the CAGR at which the market will expand, by the end of the forecast horizon?

    Which geographic segments (regions) as well as sub-areas will grow at the fastest rate over the forecast horizon?

    What are the key strategies adopted by emerging organizations in the Non-prescription Drugs Market?

    How will the market dynamics be shaped by the end of the forecast horizon?

    A detailed assessment of major vendors in the Non-Prescription Drugs market is provided and a description of how these major companies focus in emerging markets around the globe is presented in this report. In addition to this, the recent strategic mergers, partnerships, collaborations, and acquisitions taking place in the global Non-prescription Drugs market have been incorporated into this report.

    Make a request before purchase @ https://www.maccuracyreports.com/checkout/91240

    A section demonstrating the main recommendations for established players and new entrants is also presented in this study. Strategic recommendations from senior analysts provide a clear perspective regarding the key strategies to adopt to make the most of entering the non-prescription drug market. MR Accuracy Reports focused on customer requirements. There was a huge demand to add some chapters, so the experts successfully added.

    read more
    Prescription drugs

    Pfizer, Gilead Sciences, Johnson & Johnson, Roche, AbbV – The Oxford Spokesperson

    The Global Prescription drugs The industry report gives a comprehensive report on the global prescription drugs market. Details such as market size, key players, segmentation, SWOT analysis, pestle, carrier 5, most influential trends and business environment are mentioned in this report. Additionally, this report contains tables and figures that give a clear outlook of the prescription drugs market. With the help of this report, an organization can achieve its goals and build its unique strategy. A sample report is available in 20 different formats, so let us know your exact requirements so we can focus on your area.

    These are the few market players in this industry-

    Pfizer, Gilead Sciences, Johnson & Johnson, Roche, AbbVie, Sanofi, Amgen, Novartis, Merck & Co. (MSD), GlaxoSmithKline (GSK), Bayer, Takeda, AstraZeneca, Takeda, Novo Nordisk, Teva, Bristol-Myers Squibb, Boehringer Ingelheim, Allergan, Eli Lilly

    We have recent updates from the Prescription Drugs Market in sample copy @ https://www.maccuracyreports.com/report-sample/91238

    prescription drug market

    Hospital, Clinic, Other.

    Application as below

    Brand drugs, generic drugs.

    Fundamental is well established in the important study. The report features up-to-date data on product details, roadmap, investment strategy, revenue figures and sales of major companies. In addition, the details also give the global prescription drugs market revenue and its forecast. Business model strategies of key companies in the Prescription Drugs market are also included. The key strengths, weaknesses and threats shaping the major market players have also been included in this research report. You can make a plan just by looking at this market research.

    Browse Full Report with Facts and Figures of Prescription Drugs Market Report at @ https://www.maccuracyreports.com/reportdetails/reportview/91238

    MR Accuracy Reports has published the report which gives a detailed overview of the key segments of the market. Both fastest and slowest growing market segments are covered in this report. Key emerging opportunities of the fastest growing global prescription drug market segments are also discussed in this report. The market size, share and forecast of each segment and sub-segment are available in this report. Additionally, the region segmentation and trends driving the major geographic region and emerging region have been presented in this report.

    Regional assessment and diversification of segments.

    North America (United States, Canada, Mexico)
    Europe (UK, France, Germany, Spain, Italy, Central and Eastern Europe, CIS)
    Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)
    Latin America (Brazil, Rest of LA)
    Middle East and Africa (Turkey, GCC, Rest of Middle East)

    Make a request before purchase @ https://www.maccuracyreports.com/checkout/91238

    The research team has gathered the study on the Global Prescription Drugs Market and also presents a history of the tactical activities of mergers, acquisitions, collaborations and partnerships in the market. Senior analysts’ valuable recommendations on strategic investment in research and development can help new entrants or established players to penetrate emerging sectors of the Prescription Drugs Market. Investors will get a clear insight into the dominating players in this industry and their future predictions. Additionally, readers will get a clear perspective on the high demand and unmet consumer needs that will drive the growth of this market. This material has been very useful for all TOP players.

    read more
    Medical supplies

    Steady growth in the medical supplies market will be witnessed by 2021 to 2028 – The Oxford Spokesman

    Global medical supplies market research is an intelligence report with meticulous efforts undertaken to study the correct and valuable information. The data that has been reviewed takes into account both existing top players and upcoming competitors. The business strategies of key players and new industries entering the market are studied in detail. A well-explained SWOT analysis, revenue share and contact information are shared in this report analysis. It also provides market information in terms of development and its capabilities.

    MR Accuracy Reports authored the report, titled Global Medical Supplies Market 2021 is a methodical research study based on the Medical Supplies Market analyzing the competitive landscape of the industry across the globe. Using effective analytical tools such as SWOT analysis and Porter’s Five Forces analysis, the report provides a comprehensive assessment of the Medical Supplies market. Our large research team was able to capture all the important chapters of the final report as they strived for it.

    Download a free PDF sample report with a full table of contents, figures and graphs (with covid 19 impact analysis): https://www.maccuracyreports.com/report-sample/476944

    At the time of this report, official counts of COVID-19 cases and deaths have exceeded 4,000,000 and 280,000. Many governments have announced plans to reopen the national economy, but many countries are still in the process. at the ascent stage. It should be noted that the impact of the epidemic has accelerated the trend of localization, regionalization and decentralization of the global industrial chain and supply chain, so it is inevitable to rebuild the global industrial chain. . Faced with the global industrial mutation of the post-epidemic era, enterprises in different countries need to take precautions.

    The chemical and petrochemical industries have noticed the adverse effects of the COVID-19 outbreak. They are in the midst of a two-pronged crisis, besides the impact of COVID-19, another is the oil price war. Oil prices are falling due to the failure of agreements on production cuts between OPEC and Russia in April and the need for chemicals and refined products is slowing due to industrial slowdowns and travel restrictions at the following this global pandemic.

    The chemical industry plays an important role in the production of countless products such as plastics, fertilizers, medicines, packaging products, etc., with the spread of the coronavirus, many production facilities of several industries in downstream have been stopped. However, an increase in the demand for packaging materials has been raised to prevent contamination of food, drugs, personal care and medical products, thus creating a large demand for chemicals used in the packaging industry .

    In such an environment, XYZ-research has published a comprehensive analysis of key market trends in the global 3160 Medical Supplies Market. It includes discussion of historical trends, current market status, competitive landscape, opportunities for growth and challenges that are supported by factual commentary.

    According to MRA analysis, the medical supplies market will reach xx million USD by the end of 2020, growing at a CAGR of xx% during the forecast period 2021-2026, the XX segment of the medical supplies market is expected to reach a market value of xx million USD by 2020 from an initial market value of xx million USD in 2019. The market value of China in 2019 is around xx million USD and the production of medical supplies is xx. The US market value in 2019 is around xx million USD and the production of medical supplies is xx. The market value of Europe in 2019 is around xx million USD and the production of medical supplies is XX.

    Regional Segmentation (Value; Revenue, USD Million, 2015 – 2026) of the Medical Supplies Market by MRA Include

    China

    EU

    United States

    Japan

    India

    South East Asia

    South America

    Competitive analysis; Who are the major players in the Medical Supplies market?

    Medtronic (Ireland)

    Cardinal Health (USA)

    comics (US)

    Johnson & Johnson (USA)

    B. Braun Melsungen AG (Germany)

    Boston Scientific Corporation (USA)

    Thermo Fisher Scientific (USA)

    Baxter International Inc. (US)

    Avanos Medical Inc. (US)

    3M (USA)

    Smith & Nephew (Ireland)

    ConvaTec Group Plc. (UK)

    Abbott (USA)

    Medical cook (USA)

    Merit Medical Systems (USA)

    Stryker (USA)

    Terumo Corporation (Japan)

    Teleflex Incorporated (USA)

    Fresenius Medical Care (Germany)

    Coloplast Group (Denmark)

    Major Types of Medical Supplies Covered in MRA Report:

    Diagnostic supplies

    Dialysis consumables

    Inhalation products

    Consumables for wound care

    Radiology consumables

    Infection control supplies

    Infusion products

    Intubation and ventilation supplies

    Personal Protective Equipment (PPE)

    Others

    Application segments covered in the ARM market

    Urology

    Wound care

    Radiology

    Respiratory

    infection control

    Cardiology

    DIV

    Other

    For any other requirements, do not hesitate to contact us and we will provide you with a personalized report.

    Get an exclusive discount on this report: https://www.maccuracyreports.com/check-discount/476944

    Key questions answered by the report include:

    • What will be the market size and growth rate by the end of the forecast period?
    • What are the key trends in the global medical supplies market impacting market growth?
    • What are the potential growth opportunities and threats faced by the major market competitors?
    • What are the key findings of Porter’s Five Forces analysis and SWOT analysis of key players operating in the global medical supplies market?
    • This report gives all the information regarding the industry overview, analysis and revenue of this market.
    • What are the market opportunities and threats faced by the vendors in the global Medical Supplies Market?

    If you have any special requirements, please let us know and we will offer the report as you wish.

    You can buy the full report @ https://www.maccuracyreports.com/checkout/476944

    About Us:

    MR Accuracy Reports’ well-researched contributions that encompass areas ranging from IT to healthcare enable our valued clients to capitalize on key growth opportunities and protect against credible threats prevailing in the market in the scenario current and those expected in the near future. Our research reports provide our clients with macro-level insights in various key regions of the world that provide them with a broader perspective to align their strategies to take advantage of lucrative growth opportunities in the market.

    Contact us:
    MR Accuracy Reports,
    USA: +1 804 500 1224
    UK: +44 741841 3666
    ASIA: +91 747888728100
    Email: [email protected]
    Website: https://www.maccuracyreports.com

    read more
    Prescription drugs

    F Hoffmann La Roche Ltd, Alizyme, Arena Pharmaceuticals, Orex – The Oxford Spokesperson

    MRI Accuracy Reports published a new report on Global Anti-obesity prescription drugs Industry. This report is in high demand as TOP as well as emerging players leverage this report. This is the most accurate and qualitative research study collected by a team carrying out primary and secondary research. This report is based on briefings and interviews conducted with product manufacturers and their consumers, along with demand research. The mixture of checks and balances combined with the involvement of industry players provides a clear and accurate picture of the entire global prescription anti-obesity drugs market.

    Some players mentioned below for your reference-

    F Hoffmann La Roche Ltd, Alizyme, Arena Pharmaceuticals, Ordemanden Therapeutics, Boehringer Ingelheim, Novo Nordisk A/s, Vivus, Glaxosmithkline

    We Have Recent Anti-Obesity Prescription Drugs Market Updates In Sample Copy @ https://www.maccuracyreports.com/report-sample/92092

    Prescription Anti-Obesity Drugs Market

    Pediatric, Adult.

    Application as below

    Orlistat, Phentermine and Topiramate, Bupropion and Naltrexone, Lorcaserin, Liraglutide.

    Furthermore, the research data contained in the report after working closely with investment bankers and financial analyst presents a clear idea about the investment scenario in the global Prescription Anti-Obesity Drugs market. The report assesses market prospects for public companies, assesses business cases of several private companies, and discusses investment trends in the global anti-obesity prescription drugs market. The analyst suggested that there would be a turning point in this market, so it needs to draw attention away in order to sustain in the market.

    The global Prescription Anti-Obesity Drugs market report covers current and future trends in consumer preferences that will shape the industry. The report assesses the buying trends along with the buying process, technology preference, expenditure, and end-user manufacturer and service provider preferences in the global Prescription Anti-Obesity Drugs Market.

    Browse Full Report with Facts and Figures of Prescription Anti-Obesity Drugs Market Report at @ https://www.maccuracyreports.com/reportdetails/reportview/92092

    The report digs deeper by providing consumer preferences by region and their impact on market revenue and growth. The report also presents the current regulatory scenario of individual regional sectors in the global Prescription Anti-obesity Drugs market. Furthermore, the current regulatory scenario as well as the upcoming regulations that will come into force in the coming years have also been mentioned in this report.

    Regional assessment and diversification of segments.

    North America (United States, Canada, Mexico)
    Europe (UK, France, Germany, Spain, Italy, Central and Eastern Europe, CIS)
    Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)
    Latin America (Brazil, Rest of LA)
    Middle East and Africa (Turkey, GCC, Rest of Middle East)

    Several key players operating in the global Prescription Anti-obesity Drugs market have been profiled in this report. The business overview of key players, product offering, revenue share, business strategies and latest innovations have been included in this report. The in-depth competitive framework of the Global Prescription Anti-Obesity Drugs Market will help clients to formulate the best strategies for a desired business outcome. Therefore, contact us to get the sample basic report.

    Please click here today to purchase the full report @ https://www.maccuracyreports.com/checkout/92092

    We have published over 2 million reports and are recognized as the best market research reporting company in the world. As EDITOR, we are always focused on your needs, advice and growth.

    read more
    Medical products

    COVID-19 Trade Policy Database: Food and Medical Products

    Many governments are using trade policy measures to increase the availability of medical and food products during the COVID-19 pandemic. It is important to monitor them to assess their impact, effectiveness and potential international spillovers, especially on countries that depend on imports of these essential products. This database is derived from official sources, media reports and other public sources and is updated monthly. the the underlying data can be found here.

    Medical sector


    Food sector

    Picture

    The data on this page is the result of a partnership between the Global Governance Program of the Robert Schuman Center for Advanced Study at the European University Institute, the Global Trade Alert initiative at the University of St. Gallen and the Trade and Regional Integration Unit of the World Bank Group. The project collects information on trade policy changes affecting medical and food products since the beginning of 2020. Its objective is to document the cumulative use of trade policies and changes between countries over time. A methodological note describing the specific products and types of policies covered by the monitoring exercise, and how the data is collected and processed, is available here.

    ⬇️Download Excel with underlying data

    ⬇️Download the zip file with additional digits

    read more
    Medical supplies

    PNP steps up crackdown on fake COVID-19 test kits and other medical supplies – UNTV News

    PNP steps up crackdown on fake COVID-19 test kits and other medical supplies

    Robie de Guzman • January 26, 2022 • 19

    Manila, Philippines – The Philippine National Police (PNP) announced on Wednesday that it will be stepping up its intelligence network following the seizure of 150 million pesos of fake COVID-19 antigen tests, face masks and drugs used to treat COVID symptoms. -19 in a warehouse in Manila.

    In a statement, PNP Police Chief General Dionardo Carlos said he had ordered all police units to further monitor stores and warehouses in their areas of responsibility that sell and store medical supplies. not recorded.

    The Bureau of Customs (BOC) announced on Monday that it confiscated thousands of Clungene COVID-19 antigen test kits, counterfeit LianHua Chinese herbal medicines and fake 3M N95 face masks during a raid on a warehouse in San Miguel. last January 21.

    The authorities also found that intellectual property rights infringed on goods such as clothing from brands such as Nike, Fila, Converse, Adidas, as well as Louis Vuitton and Gucci bags, wallets, phone accessories, etc. A Chinese national, believed to be the owner of the establishment, was arrested during the operation.

    “We want to know the extent of their operation given the large number of confiscated items,” Carlos said.

    “If these products have not been regulated by government agencies, we don’t know if they are safe to use,” he added.

    The head of the PNP pledged to take more aggressive action to curb the proliferation of these products, under the leadership of the Ministry of Health.

    “The PNP will wage a crackdown campaign to curb the proliferation of these fake medical items,” Carlos said.

    The public is advised to purchase medical items only from licensed pharmacies and other related outlets.

    NCR COVID-19 alert status for Pebrero, possibly lost over weekend – Malakanyang

    Manila, Philippines – On Malakanyang Weekend over the weekend, the status of COVID-19 alert level was established in the National Capital Region (NCR) for residents of Pebrero.

    In 31 years, Alert Level 3 only applies to the NCR.

    Ayon kay Cabinet Secretary Karlo Nograles, Head of the Inter-Agency Task Force for the Management of Emerging Infectious Diseases (IATF-MEID) to talk about the NCR’s alert level in the fight against COVID- 19.

    Ayon kay Nograles, sisiyasatin IATF hospital bed utilization rate pati average daily attack rate at two-week growth rate of COVID-19 compared to COVID-19.

    Health Secretary Francisco Duque III was unlikely to be on alert at NCR Alert Level 2, with coronavirus infections trending downward.

    Hired for the Philippine Medical Association (PMA), he manages the official publication of health protocols and restrictions related to COVID-19 in the NCR.

    “The naming of palagis emphasizes the level of alert and respecting minimum health protocols and natin mapatupad…Important pa rin is magpabakuna tayo,” said Dr. Benito Atienza, the best of the PMA.

    “Yun po sinasabi natin na sana hindi matulad po yung pagbaba ng alert bago po mag noel at mag new year na talagang pag alert 2 po eh yung mga tao wala na sila pakundangan na makahawa and mahawa kasi dikit dikit ang mga tao kahit sinabi namin nung una pa na kahit an alert level of gawin natin kung hindi naman nasusunod ang patakaran eh ganun pa rin ang mangyayari”, dagdag pa niya.

    Maliban in the NCR, established the Pandemic Task Force which deals with the COVID-19 situation within the framework of analysis and control of the disease.

    Specially located in CALABARZON, Central Luzon, Ilocos Region, and Cordillera Administrative Region.

    Ayon malakanyang, establish the IATF regional working groups which have determined the COVID-19 bed capacities in all capacities necessary to master the challenges of the case.

    Many patients with severe and critical cases need to be admitted to hospital in isolation facilities as they are moderate to mild cases of COVID-19.

    PNP pockets more than 90 million pesos worth of illegal drugs and nabs 36 suspects in a series of operations

    Manila, Philippines – The Philippine National Police (PNP) announced on Wednesday that it had seized more than 90 million pesos worth of illegal drugs in a series of operations this month.

    In a statement, the PNP said the week-long Simultaneous Anti-Crime Law Enforcement (SACLEO) operations conducted from January 17 to 23 also resulted in the arrest of 36 prime drug suspects.

    These coordinated anti-drug operations included 14 buy-bust operations, 18 service of arrest warrants and two marijuana eradication operations at clandestine cannabis farms in separate locations in different parts of the country, it said. -he adds.

    “We scored again in the campaign against illegal drugs. The arrest of drug figures in various parts of the country is a reflection of our intensified strategies to eradicate the supply chain of this illicit activity,” said PNP Police Chief Dionardo Carlos.

    The PNP leader also commended the efforts and intelligence gathering of the officers involved in the operation, as well as working with their village counterparts to address the problem of illegal drugs in their community.

    “They provided the police with material information so that we could better follow the movements of those who engage in this illegal trade,” Carlos said, referring to an action program called “Double Barrel Finale”.

    The PNP said the double barrel finale focuses on drug trafficking and addiction in each barangay. It also seeks to help the community find ways to avoid such a vice and redirect residents’ attention to more productive pursuits.

    Carlos pledged to carry out the program during his tenure as head of the PNP.

    PH records 3 more deaths among patients with COVID-19 Omicron variant

    Manila, Philippines – Three additional deaths among patients who contracted the COVID-19 Omicron variant have been recorded in the country, the Department of Health (DOH) announced on Wednesday.

    In a message to reporters, Health Undersecretary Maria Rosario Vergeire said the additional deaths were elderly and all had underlying medical conditions.

    The new deaths brought the death toll from the Omicron variant to five.

    “Three are elderly and all have comorbidities. One partially vaccinated, one unvaccinated and the other three are still being checked,” Vergeire said.

    The DOH said earlier that the highly transmissible variant of Omicron is now prevalent in Metro Manila and other areas, with its BA.1 and BA.2 subvariants detected in the country.

    The agency also pointed out that while the Omicron variant primarily presents with asymptomatic and mild disease, the data showed that the elderly, those with comorbidities and unvaccinated people are still most at risk of death.

    The first two deaths linked to the Omicron variant also involved elderly people with comorbidities and not vaccinated against COVID-19.

    The DOH said there are 535 confirmed cases of Omicron variants in the country.

    read more
    Prescription drugs

    Overview, Opportunities, Key Companies and Forecasts to 2028 – Pfizer, Merck, Isis Pharmaceuticals, Immuron Limited, GlaxoSmithKline Pharmaceuticals, Formac Pharmaceuticals, Esperion Therapeutics, Eli Lilly, and more. – Oxford Spokesperson

    The research report, titled “Global Prescription Drugs for Hyperlipidemia Market 2022, presents crucial insights and statistical data on the Prescription Hyperlipidemia Drugs Market with respect to the world. The Market Report provides an all-inclusive analytical study of the Prescription Drugs for Hyperlipidemia Market, considering the growth drivers, restraints, and future prospects. The prevailing trends and opportunities are also discussed in this study.

    The report analyzes the global Prescription Drugs for Hyperlipidemia market on the basis of various key segments on the basis of product types, applications and end users. The regional Prescription Hyperlipidemia Drugs market is also considered for the analysis, the results of which are used to predict the performance of the Prescription Hyperlipidemia Drugs market globally over the period of 2022 to 2028.

    Each of the market verticals of the Prescription Drugs for Hyperlipidemia Market is qualitatively and quantitatively analyzed to present a comparative assessment of the market. Basic information such as definition, industry chain powering the market, and policies are also covered in the report.

    Request a sample copy of Prescription Drugs for Hyperlipidemia Market Report (Use company email id for higher priority) @ https://www.maccuracyreports.com/report-sample/519367

    Summary

    According to GRD survey data, the global Hyperlipidemia Drugs market is estimated to be worth million US$ in 2021 and is expected to reach million US$ by the end of 2028, growing at a CAGR % during the forecast period between 2022 and 2028.

    This report studies the Prescription Drugs for Hyperlipidemia market dynamics from angles such as new entries, mergers and acquisitions, financings, exits, and major technological advancements. Market performance is evaluated through market size (value and volume) by players, regions, product types and end industries. This report also studies the global market competitive landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Five Forces Analysis. Carry.

    Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth rate of Hyperlipidemia Drugs in these regions, from 2016 to 2027, covering

    North America (United States, Canada and Mexico)

    Europe (Germany, France, UK, Italy, Spain and Russia, etc.)

    Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)

    South America (Brazil, Argentina, Colombia, etc.)

    Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)

    Market Overview, By Product Type

    HMG COA reductase inhibitors

    Fibric acid derivatives

    nicotinic acid

    Bile acid sequestering agents

    Cholesterol absorption inhibitors

    Combination drug therapy

    Market Overview, By Application

    Hospital

    Clinical

    Key Market Players Analyzed In This Report Including:

    Pfizer

    Merck

    Isis Pharmaceuticals

    Immuron Limited

    GlaxoSmithKline Pharmaceuticals

    Formac Pharmaceuticals

    Therapeutic Hope

    Eli Lily

    Dr. Reddy’s Laboratories

    Amgen

    The research objectives of this report are:

    To study and analyze the global Prescription Drugs for Hyperlipidemia market size (value & volume) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.

    To understand the structure of the Prescription Drugs for Hyperlipidemia market industry by identifying its various subsegments.

    Share detailed information on key factors influencing market growth (growth potential, opportunities, drivers, industry-specific challenges and risks).

    To identify the major global Hyperlipidemia Drugs manufacturers and typical regional players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans over the next few years.

    To analyze the Prescription Drugs for Hyperlipidemia market with respect to individual growth trends, future prospects, and their contribution to the total market.

    To project the value and volume of Hyperlipidemia Drugs submarkets, with respect to key regions (along with their respective key countries).

    Analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.

    Establish a strategic profile of key players and analyze in depth their growth strategies.

    In this study, the years considered to estimate the market size of Hyperlipidemia Prescription Drugs are as follows:

    Historical year: 2016-2020

    Reference year: 2020

    Estimated year: 2021

    Forecast year 2021 to 2027

    This report includes the estimation of market size in terms of value (USD Million) and volume from top-down approach by analyzing major sub-markets and their key driving factors, and verified from bottom-up approaches . Major market players have been identified through secondary research and their market shares have been determined through primary and secondary research. All shares, breakdowns and percentage breakdowns have been determined using secondary sources and verified from primary sources.

    For data information by region, company, type and application, 2020 is taken as the base year. Whenever data information was not available for the reference year, the previous year was taken into account.

    Main stakeholders taken into account in the study:

    commodity sellers

    Distributors/Traders/Wholesalers/Suppliers

    Regulatory authorities, including government agencies and NGOs

    Commercial research and development (R&D) institutions

    Importers and exporters

    Government organizations, research organizations and consulting firms

    Trade/industry associations

    End-use industries

    Get up to 30% off the first purchase of Hyperlipidemia Prescription Drugs Market Rreport @: https://www.maccuracyreports.com/check-discount/519367

    The products available in the market are studied on the basis of their manufacturing chain, the price of the products and the profit they generate. An in-depth analysis is then carried out on the various regional Prescription Hyperlipidemia Drugs markets, examining the production volume and efficiency of the Prescription Hyperlipidemia Drugs market globally. The demand and supply statistics for the Prescription Hyperlipidemia Drugs market along with the growth figures recorded by the Prescription Hyperlipidemia Drugs market are also presented for each regional market in this report.

    Various analytical tools are applied in the analysis of the Prescription Drugs for Hyperlipidemia Market to reach a precise understanding of the market players in the potential development of this market. These tools include feasibility analysis, ROI analyses, as well as SWOT analysis of key market players.

    Key questions answered in the Prescription Hyperlipidemia Drugs market report include:
    • What will be the market size and growth rate by the end of the forecast period?
    • What are the key trends in the Global Prescription Hyperlipidemia Drugs Market impacting the growth of the market?
    • What are the potential growth opportunities and threats faced by the major market competitors?
    • What are the key findings of Porter’s Five Forces analysis and SWOT analysis of key players operating in the global Prescription Hyperlipidemia Drugs market?
    • This report gives all the information regarding the industry overview, analysis and revenue of this market.
    • What are the market opportunities and threats faced by the vendors in the global Prescription Drugs for Hyperlipidemia Market?
    If you have any special requirements, please let us know and we will offer the report as you wish.
    Buy Now @ https://www.maccuracyreports.com/checkout/519367

    About Us:

    MRI Accuracy Reports provides customization of reports according to your needs. This report can be customized to meet your needs. Get in touch with our sales team, who will guarantee you get a report tailored to your needs.

    Contact us:

        Call: +1 804 500 1224 / +44 741841 3666 (International)

    E-mail: [email protected]

    Website: www.maccuracyreports.com

    read more
    Medical supplies

    Better Health brings medical supplies to patients’ homes

    The workplace isn’t the only thing building a permanent presence in our homes in the wake of the pandemic – health also finds its place in our personal spaces.

    After years of working in healthcare, Naama Stauber Beckler realized that the existing system was failing some people, especially those dealing with health issues that required home supplies. So she set out to found Better Health, a direct-to-consumer service provider that delivers medical supplies directly to patients’ doors.

    “I have identified a gap in the market for people with chronic conditions who need to use [medical devices at home]says Stauber Breckler of the operation, which she launched in 2019. ideal product for you, learning how to use them and integration into your life is really broken.

    Read more: Long story short: get ready for big changes in healthcare this year

    Traditionally, sending medical products home with patients from hospitals was a lengthy process – it started with a doctor’s referral, then required a lot of work on the patient’s part to find suppliers who would transport the product. Then they had to connect distributors and doctors, contact the insurers themselves, and finally, go out and collect their supplies.

    With Better Health, medical supplies, such as catheters and colostomy bags, are delivered directly to patients once approved by doctors and distributors, and comes with telehealth tools including education and peer support.

    More than 4.5 million people receive home health care and relying on businesses to provide and maintain their oxygen machines, wheelchairs, hospital beds, prosthetics and other durable home medical equipment, according to the CDC. And between 725,000 and one million people in the United States currently live with a stoma (a surgical opening to help waste material leave the body), according to the United Ostomy Associations of America. It is estimated that 100 million urinary catheters are sold worldwide each year.

    Read more: As long as employers control employee healthcare, life-saving technologies will be underutilized

    Before the pandemic, the the traditional method left a lot of room for error, says Stauber Beckler, noting that patients often had to travel to the hospital just to get needed supplies. COVID-19, of course, amplified the problem: as access to hospitals and doctors dwindled, patients with chronic illnesses at home found themselves looking for solutions.

    “What we’ve really seen over the last two years, and especially during the pandemic, is how far telehealth has evolved,” says Stauber Beckler, noting that using telehealth to educate patients is not will not only make life easier for consumers, but also alleviate unnecessary stress and demand on hospitals. “By serving underserved, perhaps smaller-volume populations — like those enrolled in Medicaid, the LGBTQ community, women — we’re already seeing better solutions emerge for them.”

    read more
    Medical supplies

    Navajo Nation launches drone to deliver medical supplies to Navajo residents

    WINDOW ROCK, Arizona– The Navajo Veterans Memorial Park “Healing Eagle Feather” drone, designed to bring medical supplies and other essentials to Navajo residents, was launched on Sunday.

    President Jonathan Nez and Vice President Myron Lizer attended the launch along with Dr. Rudy Shebala, Executive Director of the Division of Natural Resources, and officials from ZappCare, a Native American-owned technology company, and officials from MissionGo.

    MissionGo founder Scott Plank and ZappCare CEO Mark Atlan simulated four deliveries with a variety of food, medical and emergency items using the mini-like MG Velos 100 aircraft helicopter. Each of the 14-pounder deliveries was successful and proved the drone’s ability to deliver to those residing in the most remote areas.

    The packages were assembled by pharmacists, veterinarians, members of the Navajo Technical University Culinary Arts Program and first responders. They included items such as pre-packaged meals, emergency communication devices, large animal medications, insulin kits and anti-venoms.

    “It is truly an honor to be part of this historic day where we see the coming together of government thinking and the entrepreneurial world to serve our great Navajo people. Working with world-renowned entrepreneurial minds like Mark Atlan and Scott Plank always pushes me to ask how we can find parallel opportunities to maximize our land, resources and workforce. I am grateful to serve as a link between these people and hope that we can continue to think outside the box as we overcome the nation’s challenges,” Vice President Lizer said.

    Vice President Lizer coordinated with these companies to secure the resources needed to make these drone deliveries possible.

    President Nez predicts the new drone effort will prove essential in emergency situations, saving valuable time.

    “We are now over 402,000 people as Navajo people, and we have a lot of professionals and young people who know how to use this technology to help our people. I see this opportunity as one of many ways to bring our bright young minds home to serve their people using disciplines ranging from engineering to emergency medical care,” said President Nez. “Just yesterday, it took us a whole team to help a family, who had found themselves stranded in a rural area, get them food and get them out of the mud. You can imagine how many more of our employees find themselves in the same boat that this technology will help.

    The drones use the latest technology with a flight range of over 20 miles and solar powered technology. They are designed to follow automated flight paths despite varying weather conditions.

    President Nez plans to use this technology to improve geological surveys, rural addressing, and perhaps even to deliver ballots. The drones were used in the summer of 2021 to assess monsoon flood damage in Birdsprings, Arizona, and again when a wildfire hit Shiprock, New Mexico.

    read more
    Medical products

    150 million worth of fake COVID test kits and other medical products seized

    BDC

    Fake coronavirus antigen test kits, face masks, Chinese medicines and other counterfeit goods worth 150 million pesos were seized from a warehouse in Manila on Friday, the customs office reported. .

    Among the confiscated goods were “Clungene COVID-19 antigen test kits, counterfeit LianHua Chinese herbal medicines and fake 3M N95 face masks,” the office said in a statement on Monday.

    The brand of the test kit is not one of those approved by the Philippine Food and Drug Administration (FDA). A list of certified test kits is available at https://www.fda.gov.ph/fda-advisory-no-2021-2094-list-of-covid-19-test-kits-with-fda-special-certification-and-performance-validation-conducted- and-or-recommended-by-the-research-institute-in-tropical-medicine-ritm/.

    Other goods found in the warehouse were “goods infringing intellectual property rights, such as clothing from brands such as Nike, Fila, Converse, Adidas, as well as Louis Vuitton bags, wallets, phone accessories and Gucci and others”.

    The Bureau of Customs said the warehouse owner, a Chinese national, has been arrested and will face charges of violating the Customs Modernization and Tariffs Act as well as FDA rules.

    “It is certain that the owner of the warehouse will face the weight of the law. This is neither the first nor the last time that we will see these groups operating on our shores, ”said the deputy commissioner of customs at the Intelligence, Raniel T. Ramiro.

    “Our job here is to make sure these don’t make it to local markets.”

    read more
    Generic drugs

    Mark Cuban launches digital pharmacy promising deep discounts on generic drugs

    Consumer-facing digital pharmacies are facing new competition in the form of Mark Cuban’s pharmaceutical company, which recently launched an online pharmacy promising deep discounts on 100 generic drugs.

    Why is this important: The new offering is likely to put increased pressure on existing digital pharmacies – such as Ro and Amazon Pharmacy – and contributes to growing dissatisfaction with pharmacy benefit managers (PBMs), who are increasingly seen as intermediaries that increase costs.

    • “Not everyone sets a goal to be the cheapest producer and supplier,” Cuban told Axios in an email. “My goal is to make profit while maximizing impact.”

    Details: The Mark Cuban Cost Plus Drug Company (MCCPDC) accepts cash only and uses Truepill’s platform to fill and deliver prescriptions.

    • The company presents its approach as a way to reduce drug costs by working both as a retailer and as its own PBM.
    • The MCCPDC will sell drugs for cancer, diabetes, gastrointestinal and heart disorders, and more.
    • For example, the company says it will charge $47 per month for imatinib, a common leukemia drug that sells for over $9,600 per month and costs around $120 per month with a typical voucher.
    • Prices include a 15% flat fee plus a $3 pharmacist labor fee.
    • The company is building an $11 million, 22,000 square foot factory in Dallas that it hopes to complete by April, Forbes reports.

    What we are looking at: As virtual care companies increasingly race to become consumers’ first stop for health-related needs, we’re curious to see how digital pharmacies fit into the mix.

    • Him and herfor example, recently began adding primary and emergency care and behavioral health services.
    • Likewise, Ro recently added virtual tours and offers treatments for a host of chronic conditions, including allergies, menopause, and weight management.
    • So, will the MCCPDC stick to its pharmacy guns or start adding new features to become another player in the increasingly crowded virtual care scene?
    • Cuban declined to comment on our questions about how much he has invested in the business.

    Sarah and Erin are co-authors of the Axios Pro newsletter on health tech deals. Subscribe at AxiosPro.com.

    read more
    Generic drugs

    Billionaire Mark Cuban launches online pharmacy with generic drugs at affordable prices

    Last week, tech entrepreneur, shark tank Dallas Mavericks investor and owner Mark Cuban has entered the competitive race for billionaire-class philanthropy by launching an online health marketplace offering generic drugs at affordable prices. But his new business is not a charity. The new digital pharmacy called Mark Cuban Cost Plus Drug Company (MCCPDC) promises to sell drugs at drug prices plus a 15% markup and a $3 pharmacist fee. Shipping is an additional $5. At launch, the website sells over 100 drugs, and although insurance is not accepted by society, many of these drugs are priced below what people would pay even with insurance.

    “The price of generic drugs is ridiculous. End of the period of history,” Cuban said Forbes by email.

    The pharmacy’s website, costplusdrugs.com, further explains its mission of affordability and transparency. “We started Mark Cuban Cost Plus Drug Company because every American should have access to safe and affordable drugs. If you don’t have insurance or have a high deductible plan, you know that even the most basics can cost a fortune. Many people spend crazy amounts of money every month just to stay healthy. No American should have to suffer or worse, because they can’t afford basic medicines. prescription,” Cuban wrote on the site.

    At launch, drugs for conditions ranging from cancer to high cholesterol, HIV, diabetes, and more. are available for sale, and the company plans to expand its offering. “We’ll add them as soon as possible,” Cuban tweeted to someone asking about a drug that wasn’t initially available on the market. He also noted that they’re “building a factory in Dallas so we can make our own injectables. [sic] And if costs go down, prices will go down too, although they intend to stick to that 15% markup. “If others beat our prices, we rejoice,” Cuban said on Twitter.

    This content is created and maintained by a third party, and uploaded to this page to help users provide their email addresses. You may be able to find more information about this and similar content on piano.io

    read more
    Prescription drugs

    Prescription drugs sold on the street are dangerous

    BY PATRICK TOM

    Selling drugs on the street without a license is illegal and puts buyers at risk, said Navin Raju, managing director of City Pharmacy Limited.

    He pointed out that many people know that prescription drugs can come with warnings and known side effects.

    Mr. Raju said that the abuse of these prescription drugs increases the risk of experiencing these problems, with the risk of fatal side effects.

    He said the drugs should only be taken under the supervision of a medical professional.

    “Their advice on whether a drug is right for you, dosage, possible side effects and any harmful interactions with other drugs is crucial. It’s unclear what you’re getting when you make a purchase on the street” , did he declare.

    “All medicines must have a batch number for traceability purposes and an expiry date.”

    Mr Raju said CPL advises the public to always get their medicines from a reputable pharmacy or outlet.

    He said it’s never a good idea to take a prescription drug without a valid prescription.

    The drug may not be right for you and may cause unpleasant side effects or serious health risks.

    “Medicines should not be considered as consumer products. Fake drugs can cause real damage to your health.

    “Don’t be tempted by spam emails advertising cheap drugs. If something sounds too good to be true, it usually is,” he said.

    “You can also check the pharmacist’s registration status by searching for the name and address of the pharmacy.”

    Mr Raju said drugs sold on the street can be shoddy at best and dangerous at worst.

    What you receive in the mail may be a new, counterfeit, substandard or unapproved drug, which may put your health and safety at risk.

    read more
    Medical supplies

    Personal perspective: How to strengthen the supply chain of essential medical supplies and medicines

    As the COVID-19 pandemic spread across the country, governments and the private sector tore through their stockpiles of personal protective equipment (PPE) and other resources. Several supply chain issues quickly emerged, including lack of visibility into sources of supply, a fragmented approach to ordering and fulfillment, and an overreliance on offshore manufacturing.

    While we have made progress in managing aspects of the pandemic, disruptions to the supply chain, including raw materials, manufacturing, shipping, distribution and “last mile” delivery remain. in a system that is not designed for the demands of a pandemic.

    With a few targeted strategies, it is possible to reverse these disturbances. For its part, Premier, a health care improvement company uniting 4,400 American hospitals and health systems and partner of the CHAMPS Purchasing group based in northeast Ohio, is concerned with the risk management of the supply chain for years, and we have developed forward-thinking capabilities. to help protect against interference.

    To strengthen the supply chain, Premier and CHAMPS are calling for the implementation of key national priorities to meet the growing demand for essential medical supplies and medicines. We need to take a broader approach to creating an end-to-end supply chain that is transparent, diverse and reliable. Beyond quantities, we must also ensure that the United States has established contractual relationships that include contingency plans to increase production as soon as future needs are identified.

    Specifically, we need to address the following points.

    • The need for domestic manufacturing: The pandemic has underscored the need for better local access to essential medical supplies, which is why we are advocating for a short-term tax incentive of 30% to support domestic manufacturing. We also believe that the private sector can play a role in promoting change related to the manufacturing of essential goods.

    In March 2020, Premier launched a unionized model to ensure a robust and resilient supply chain for essential medical products. The program provides a vehicle through which Premier and its members pool capital to invest in domestic manufacturers who can supply products in short supply, providing initial cash needed to expand production capacity and modernize the plant, as well as long-term purchasing commitments to incentivize innovation. This ensures that providers have a cost-effective national alternative for their patient care needs. Here in Northeast Ohio, CHAMPS Group Purchasing has partnered with JobsOhio to implement agreements with suppliers of PPE and related products as part of our commitment to supporting local national suppliers, diversified and small businesses to advance the region’s economy.

    • The need for an innovative global sourcing strategy: Past situations such as H1N1, Ebola, and Hurricane Maria have highlighted the vulnerabilities associated with over-reliance on a single country for medical supplies and medicines. In response, several organizations (including ours) have diversified PPE production, expanding operations to multiple countries and regions to mitigate ongoing risks of product shortages. As part of this, we must also ensure that suppliers have a say in determining what should be included in the national strategic stock of equipment.
    • Tech-enabling supply chain: Until recently, hospitals were alone in translating local outbreaks of COVID-19 into immediately meaningful information regarding capacity and supplies. Now, providers are using technology to be better informed about how quickly cases are spreading and what supplies they need at any given time. This new technology takes advantage of real-time monitoring capabilities, providing early warnings, predicting surges and helping organizations plan coordinated responses where they are needed most.

    Additionally, the federal government needs technology that will provide visibility into what supplies are in inventory, distribution, and hospital inventories during national emergencies. This will allow allocation to places in need and reduce hoarding and the illicit market, issues that have challenged America during the first nine months of the pandemic.

    When healthcare providers can predict COVID-19-related hospitalizations and have confidence in the sufficiency of supplies of essential commodities, this creates a positive ripple effect – relieving pressure on supply chains, ensuring more responsive care in communities and helping to keep businesses and schools open and running.

    Even as COVID-19 has exposed supply chain flaws and transformed the healthcare landscape, together we continue to show and improve to meet the challenges posed by the pandemic and drive healthcare innovation. health for the future.

    We must come together to ensure access to the supplies, data, analysis and intelligence needed to survive and thrive in a challenging environment.

    Lane is President and CEO of the Center for Health Affairs and CHAMPS Healthcare. Alkire is President and CEO of Premier Inc.

    read more
    Medical supplies

    Dzaleka Health Center receives K78 million donation of medical supplies

    A local Christian organization, There Is Hope (TIH), donated K78 million worth of medical supplies and medicines to Dzaleka Health Center in Dowa.

    This donation is certainly a huge relief for the facility which, like other public health facilities in Malawi, is facing severe shortage of medicines and medical supplies due to the impact of the Covid-19 pandemic. .

    TIH program manager Doreen Fatch revealed that her organization sourced the donated items from a Canadian non-governmental organization – Health Partners International of Canada (HPIC).

    Fatch (second from right) making a symbolic presentation of medicines and medical supplies donated to Kausiwa–Photo by Watipaso Mzungu, Nyasa Times

    Apparently, HPIC was one of the international organizations that responded positively to President Lazarus Chakwera’s appeal to the international community to assist Malawi with financial and material support in its national efforts to combat Covid-19.

    When TIH handed over essential drugs and medical items to the Government of Malawi, Dzaleka Health Center was the only public health facility operating a Covid-19 isolation center in Dowa.

    To date, the Canadian NGO has made a cumulative donation worth K194 million in medicines and medical supplies to the Government of Malawi through the Ministries of Health and Homeland Security.

    According to Fatch, the first donation was in 2020 and was valued at K44 million, followed by another donation in 2021 worth K72 million and K78 million this year.

    “TIH is pleased with the impact the donated medicines and medical supplies are having on the lives of the people we serve at Dzaleka refugee camp and surrounding communities,” she said.

    She reiterated her organization’s commitment to complement the efforts of the Government of Malawi in its fight against the pandemic.

    In her remarks, Hilda Kausiwa, Senior Director of Administration and Operations at the Ministry of Homeland Security (Department of Refugees), called the donation timely, saying it will go a long way in replenishing the Dzaleka Health Center. essential drugs and medical supplies.

    For his part, the clinical manager of the Dzaleka health center, Henry Lali, reiterated that the Covid-19 has put pressure on the facility, which hosts a population of 80,000 people from the refugee camp, surrounding communities and other watersheds. areas.

    Lali said the donated drugs would therefore ease the pressure the facility is currently facing to respond to patients with various communicable diseases including malaria and cough.

    The United Nations High Commissioner for Refugees (UNHCR) protection officer, Miiro Rehema, praised TIH for providing the support.

    Follow and subscribe to Nyasa TV:

    Sharing is caring!

    read more
    Prescription drugs

    What’s in a name? When it comes to prescription drugs, many, experts say

    How do prescription drugs get their brand names? It’s a process, experts say. Photo by Sponge/Wikimedia Commons

    January 21 (UPI) — The Food and Drug Administration announced Wednesday that it has approved a drug called Quviviq for the treatment of insomnia, a disorder that causes trouble sleeping.

    The brand name of this drug, which is expected to hit the market in the United States in May if it meets FDA standards for controlled substances, may seem like a mouthful.

    However, there is most likely a lot of thought and money behind Quviviq.

    “The manufacturer says it improves sleep with less drowsiness, so they may think ‘viviq’ connotes vital, lively, or less groggy,” said Arlene Teck, creative director, name development at Ixxeo Healthcare in Rockaway, NJ. , a pharmaceutical brand strategy consulting firm. UPI in a telephone interview.

    “The high pitch of the last syllable can evoke a sense of alertness,” Teck said, adding that neither she nor Ixxeo had worked on the brand.

    Although drug brand names seen in TV commercials, magazine ads and elsewhere may seem bizarre, there’s usually a method behind the apparent madness, experts said.

    “Companies spend a lot of time trying to get the right names to achieve their marketing goals,” Dr. G. Caleb Alexander, an epidemiologist whose research focuses on drug use and safety, told UPI by phone. on prescription.

    “The name shapes product perception, but it’s only part of a broad, thorough and coordinated marketing strategy,” said Alexander, a professor at Johns Hopkins University in Baltimore.

    Here is an overview of the process behind the brand naming of prescription drugs.

    Drug manufacturers develop a chemical name for a new drug based on a set of rules established by the International Union of Pure and Applied Chemistry and the United States Adopted Name Council.

    This latter group is operated under the auspices of the American Medical Association, the American Pharmaceutical Association and the US Pharmacopeial Convention, and any new name must refer to the underlying ingredients and mechanism of action of a drug. , according to the board.

    The chemical or generic name must also receive authorization from the World Health Organization’s International Nonproprietary Name program.

    Bring in the consultants

    Once the chemical name has been cleared for use and the drug has entered clinical trials, manufacturers will engage consultants such as Ixxeo Healthcare, with the goal of developing a brand name that allows the product to be marketed effectively, without violate FDA guidelines.

    New drugs go through three stages of clinical trials, and the process of creating brand names usually begins right at the start of phase 2 trials, Teck said.

    “By then, we’re pretty sure it’ll be a keeper and won’t die along the way” in the research and development process, she said.

    According to Tina Goldstone, director of marketing at Interbrand, a New York-based marketing consultancy, consultants typically work with clients to understand the drug, its category and class, and how it works or how it works.

    From a potential list of hundreds of names, the best options are selected and “pre-selected” against currently available databases of names and legal terms, as well as world languages ​​to avoid possible conflicts, she said.

    A famous example occurred in the 1960s, when Vicks marketed its cough drops in Germany, not realizing that the letter “v” was pronounced like the English letter “f” in German.

    As a result, the name Vicks read like a vulgar slang term for Germans.

    Beware of existing products

    It’s also important for new drug brands to make sure their names aren’t too close to those of existing products, Teck and Goldstone said.

    In addition to causing potential confusion for doctors and consumers, drugs with similar names could increase the risk of medication errors or incorrectly prescribed drugs, according to Teck.

    This has become an even bigger issue in recent years as prescribing has become high-tech, with prescribers and pharmacists often using software systems or devices with drop-down menus, she said.

    About 1.5 million people in the United States suffer health complications or even death each year from improperly prescribed medications, the Institute of Medicine estimates.

    A 2020 analysis published by the journal BMJ Quality and Safety found that 27 brand names of drugs used in the United States were identical to those of 38 products in other countries with different active ingredients.

    “How a drug is named can have big implications for the safe use of a drug,” said Johns Hopkins’ Alexander.

    Doctors and pharmacists are usually trained to learn the chemical names of drugs because brand names differ from country to country and often become unnecessary when generic forms hit the market, he said.

    FDA limits

    The FDA’s 42-page drug naming guidelines are publicly available.

    In addition to ensuring that the brands do not create possible consumer sources for prescribers, pharmacists and the public, the names cannot refer to the drug’s active ingredients or exaggerate their effectiveness or benefits, Teck said. Ixxeo.

    According to the agency, up to a third of all drug names submitted for FDA approval are rejected.

    “The attributes of the compound can influence the name — if it’s a potent, high-potency product, one might want to go for a potent name,” Interbrand’s Goldstone said.

    However, “the actual name of the compound or generic will not influence the name because a [brand] a name too close to the name of the compound would be rejected by regulatory authorities,” she said.

    What a drug is and what it does – its mechanism of action – will most likely appear in the name, particularly if it is a first-class drug or a drug that works differently than those already on the market, Teck mentioned.

    Additionally, names should also be easy to remember and pronounce, Teck said.

    At her agency, potential names are spoken, sung, shouted and even spoken by people “holding their noses”, she said.

    “We try to imagine someone with a cold, or these days wearing a face mask, walking up to the pharmacy counter and saying the name of the medicine,” Teck said.

    At the same time, with direct-to-consumer advertising of prescription drugs — the United States is one of the few countries in the world that allows it, although it is regulated by the FDA — the name brand name of a drug can also affect its “marketability”. “, according to Goldstone.

    An example of a drug brand name that lends itself well to marketing is the erectile dysfunction drug Viagra, a moniker designed to evoke vitality, virility and vigor, experts said.

    More recently, Comirnaty, the brand name for Pfizer-BioNTech’s COVID-19 vaccine, “represents a combination of the terms COVID-19, mRNA, community, and immunity,” according to the makers and the Miami-based Brand Institute, which helped in the naming process.

    Often these names are tested with groups of doctors, pharmacists and consumers to make sure they resonate with all three, Goldstone said.

    However, given FDA restrictions, the extent to which their feedback ultimately influences the final brand choice is often limited, Ixxeo’s Teck said.

    “This is not an area of ​​pharmaceutical product development that most consumers are aware of,” Johns Hopkins’ Alexander said.

    “Yes, there’s an interest in having something that’s easy to remember, fairly easy to pronounce, and sticky, and the stickier the better, but those are just some of the considerations involved” , did he declare.

    read more
    Medical supplies

    Medical Supplies Market – Know the latest trends and forecasts for long term business planning

    Medical supplies market

    In 2020, Fresenius Medical Care AG & Co. KGaA completed a $33.7 million expansion of its disposable transfusion and apheresis plant in the Dominican Republic

    NE WIN SIVERS DRIVE, PORTLAND, USA, January 20, 2022 /EINPresswire.com/ — According to the Allied Market Research report, titled “Medical supplies market By Application (Wound Care, Radiology, Respiratory, Urology, Infection Control, Cardiology, IVD, Other Applications) and End Users (Hospitals, Clinics/Physicians’ Offices, Other End Users): Global Opportunities Analysis and Forecast industry, 2020-2027″ The report provides a detailed analysis of changing market dynamics, major segments, value chain, major investment pockets, regional scenario and competitive landscape.

    Medical supplies include disposable products or single-use products that are used during surgeries and other medical procedures. These products can only be used once. Medical supplies are instruments and devices that are manufactured and distributed to healthcare facilities to ensure safety. It is used in hospitals, nursing homes, clinics, outpatient surgery centers and assisted living centers. Medical instruments used as medical supplies include blood processing devices, wound care instruments, monitoring instruments, and personal protective equipment. Advancements in technology have contributed to innovation in the field of medical devices and instruments.

    (𝗔 𝗣𝗗𝗙 𝗢𝗳 𝗥𝗲𝗽𝗼𝗿𝘁 𝗥𝗲𝗽𝗼𝗿𝘁 𝗥𝗲𝗽𝗼𝗿𝘁 𝗥𝗲𝗽𝗼𝗿𝘁 𝗥𝗲𝗽𝗼𝗿𝘁 𝗨𝗽𝗼𝗻 𝗨𝗽𝗼𝗻): https://www.alliedmarketresearch.com/request-sample/7949

    𝗖𝗼𝘃𝗶𝗱-𝟭𝟵 𝗦𝗰𝗲𝗻𝗮𝗿𝗶𝗼:

    To care for the infected population, the demand for medical supplies is increasing. Respiratory support devices such as atomizers, life support devices, oxygen generators, and monitors are some of the most widely used medical devices in primary clinical treatment. Additionally, COVID-19 has led to a surge in demand for medical supplies such as personal protective equipment, including masks, gloves, and goggles. With the increase in the number of COVID-19 cases around the world, the need for medical supplies is constantly increasing among medical professionals and the civilian population for precautionary measures. Manufacturers of these products have the opportunity to take advantage of this increased demand for medical supplies to ensure an adequate and continuous supply of personal protective equipment in the market. Considering these factors, COVID-19 is expected to have a significant impact on the medical supplies market.

    Survey of the short and long term impacts of COVID-19 at: https://www.alliedmarketresearch.com/request-for-customization/7949?reqfor=covid

    Main impact factors:

    • Factors such as increasing prevalence of chronic diseases globally and rising prevalence of epidemic and pandemic diseases are expected to drive the growth of the medical supplies market.

    • Rising government and private investment in healthcare projects and infrastructure development is expected to drive the market growth in the future.

    • The demand for nosocomial infection control measures and the increase in the rate of surgical procedures have increased the growth of the medical supplies market.

    𝗞𝗲𝘆𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗳𝗼𝗿 :

    • This report includes detailed quantitative analysis along with current trends of the global medical supplies market from 2020 to 2027 to identify existing opportunities along with strategic evaluation.

    • Medical Supplies Market forecast is studied from 2020 to 2027.

    • The Medical Supplies market size and estimates are based on a comprehensive analysis of key developments in the Endoscopic Retrograde Cholangiopancreatography industry.

    •Qualitative analysis based on innovative products facilitates strategic business planning.

    • Development strategies adopted by leading market players are solicited to understand the competitive scenario of the Medical Supplies market.

    𝗟𝗶𝘀𝘁 𝗣𝗹𝗮𝘆𝗲𝗿𝘀 𝗣𝗹𝗮𝘆𝗲𝗿𝘀:

    Medtronic, Cardinal Health, Inc., BD, Johnson & Johnson, B. Braun Melsungen AG, Boston Scientific Corporation, Thermo Fisher Scientific, Inc, Baxter International, Inc, Avanos Medical, Inc., 3M, Smith & Nephew, ConvaTec Group Plc ., Abbott, Cook Medical, Merit Medical Systems, Stryker, Terumo Corporation, Teleflex Incorporated, Fresenius Medical Care AG & Co. KGaA and Coloplast Group.

    For a purchase request to: https://www.alliedmarketresearch.com/purchase-enquiry/7949

    Questions Answered in the Medical Supplies Market Report:

    •Who are the major market players active in the medical supplies market?
    •What are the current trends that will influence the market in the coming years?
    • What are the market drivers, constraints and opportunities?
    •What are the projections for the future that would help take further strategic action?
    • Which segments and regions will drive the growth of the medical supplies market and why?

    𝗔𝗩𝗘𝗡𝗨𝗘- 𝗦𝘂𝗯𝘀𝗰𝗿𝗶𝗽𝘁𝗶𝗼𝗻-𝗕𝗮𝘀𝗲𝗱 𝗟𝗶𝗯𝗿𝗮𝗿𝘆 (𝗣𝗿𝗲𝗺𝗶𝘂𝗺-𝗱𝗲𝗺𝗮𝗻𝗱, 𝘀𝘂𝗯𝘀𝗰𝗿𝗶𝗽𝘁𝗶𝗼𝗻-𝗯𝗮𝘀𝗲𝗱 𝗽𝗿𝗶𝗰𝗶𝗻𝗴 𝗺𝗼𝗱𝗲𝗹) 𝗢𝗳𝗳𝗲𝗿𝗲𝗱 𝗔𝗹𝗹𝗶𝗲𝗱 𝗠𝗮𝗿𝗸𝗲𝘁 𝗠𝗮𝗿𝗸𝗲𝘁:

    AMR introduces its premium subscription-based online library Avenue, designed specifically to provide a unique and cost-effective solution for businesses, investors and universities. With Avenue, subscribers can benefit from a comprehensive repository of reports on over 2,000 niche industries and over 12,000 company profiles. Additionally, users can get online access to quantitative and qualitative data in PDF and Excel formats, as well as analyst support, customization, and updated versions of reports.

    𝗚𝗲𝘁 𝘁𝗼 𝗹𝗶𝗯𝗿𝗮𝗿𝘆 𝗹𝗶𝗯𝗿𝗮𝗿𝘆 𝗹𝗶𝗯𝗿𝗮𝗿𝘆 𝘁𝗶𝗺𝗲 𝗳𝗿𝗼𝗺 𝗳𝗿𝗼𝗺 𝗱𝗲𝘁𝗮𝗶𝗹𝘀 𝘁𝗶𝗺𝗲 𝗳𝗿𝗼𝗺 𝗺𝗼𝗿𝗲 𝗱𝗲𝘁𝗮𝗶𝗹𝘀 𝗱𝗲𝘁𝗮𝗶𝗹𝘀 𝗳𝗼𝗹𝗹𝗼𝘄 𝗳𝗼𝗹𝗹𝗼𝘄 𝗹𝗶𝗻𝗸𝘁𝗵𝗲 https://www.alliedmarketresearch.com/library-access

    𝗧𝗿𝗲𝗻𝗱𝗶𝗻𝗴 𝗶𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝟭𝟬 𝟭𝟬 𝟭𝟬 𝟭𝟬% 𝗗𝗶𝘀𝗰𝗼𝘂𝗻𝘁):

    Inflation Devices Market – Opportunity and Industry Forecast, 2026
    Personal Mobility Devices Market – Opportunity and Industry Forecast, 2027

    𝐀𝐛𝐨𝐮𝐭 𝐔𝐬

    Allied Market Research (AMR) is a full-service market research and business consulting division of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global corporations as well as small and medium enterprises with unrivaled quality of “market research reports” and “Business Intelligence solutions”. AMR has a focused vision to provide business insights and advice to help its clients make strategic business decisions and achieve sustainable growth in their respective market area.

    Pawan Kumar, CEO of Allied Market Research, leads the organization in delivering high quality data and insights. We maintain professional relationships with various companies which helps us to extract market data which helps us to generate accurate research data tables and confirm the utmost accuracy of our market predictions. All data presented in the reports we publish are drawn from primary interviews with senior managers of large companies in the relevant field. Our secondary data sourcing methodology includes extensive online and offline research and discussions with knowledgeable industry professionals and analysts.

    David Correa
    Allied Analytics LLP
    +1 800-792-5285
    write to us here
    Visit us on social media:
    Facebook
    Twitter
    LinkedIn

    read more
    Generic drugs

    Generic drugs drive down prescription prices for Medicare patients

    Although net prices for brand-name drugs have risen dramatically over the past decade, savings from generics have actually lowered average prescription prices in Medicare and Medicaid drug benefits, according to new analysis from Congressional Budget Office.

    Why is this important: The analysis reminds us that the generic market is working largely as expected.

    By the numbers: The average net price of a prescription fell from $57 in 2009 to $50 in 2018 in Medicare Part D, and from $63 to $48 in Medicaid.

    • The decline is largely attributable to the growing use of generics, which rose from 75% to 90% of all prescriptions nationwide during this period. The average price of a generic prescription also fell in both programs.
    • But the average net price of brand-name prescriptions more than doubled in Part D and rose 50% in Medicaid, the analysis found. These increases were driven by higher introductory prices for new drugs and price increases for drugs already on the market.
    • The higher introductory prices are due in part to more specialty drugs entering the market.

    Yes, but: The analysis focused on drugs sold in pharmacies, not drugs administered in hospitals or doctors’ offices, which tend to be more expensive and have different market dynamics.

    • And the analysis notes that the share of total prescriptions that are generic may not continue to grow in the same way in the future, in part “because new branded drugs tend to be more expensive to manufacture and can be more difficult to reproduce as generic drugs”. medications.”

    The big picture: The Democrats’ legislative agenda — including the party’s effort to lower prescription drug prices — has stalled in the Senate.

    • But the provisions allowing Medicare to negotiate drug prices would only apply to insulin and certain drugs without competition, which would largely exclude the generic market.

    The bottom line: “A reasonable interpretation of this data is that we have a targeted drug pricing problem, not a general problem,” said Ben Ippolito of the American Enterprise Institute.

    read more
    Generic drugs

    Generic Inhalation and Nasal Spray Market Valuation to Grow at a Healthy CAGR through 2027

    The Global Generic Drugs for Inhalation and Nasal Spray Market Forecast Report 2020-2027 presents a precise breakdown of the industry based on type, applications, and research regions. The growth strategies adopted by these companies are studied in detail in the report. The Market size section gives the Generic Inhalation and Nasal Spray Drugs market revenue, covering both historical market growth and future forecast.

    The report provides detailed information regarding the industry vertical. The assessment is based on the dual perspective of production and consumption.

    Talking about the production aspect, the study elaborates on the manufacturing of the product, the remuneration of the product and the gross margins of the companies manufacturing the product. Although based on consumption, the study focuses on the consumption value of the product and the consumption volume of the product as well as the import and export status of the product.

    Request a sample copy of this report @ https://www.nwdiamondnotes.com/request-sample/133514

    A brief overview of the regional landscape:

    Regional segmentation: North America, Europe, Asia-Pacific, Middle East and Africa, Latin America.

    Details mentioned in the section

    The report offers a detailed breakdown of the regional terrain of this industry.

    An overview of the product range:

    Generic Drugs for Inhalation and Nasal Spray Market Report Segment by Types:

    • Corticosteroids
    • Bronchodilators
    • Combinations
    • Decongestant sprays and others

    An overview of the field of application:

    Generic Drugs for Inhalation and Nasal Spray Market report segmented by Application:

    • Asthma
    • COPD
    • Allergic rhinitis
    • Others
    • By region
    • North America
    • we
    • Canada
    • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
    • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Australia
    • Taiwan
    • Indonesia
    • Thailand
    • Malaysia
    • Philippines
    • Vietnam
    • Latin America
    • Mexico
    • Brazil
    • Argentina
    • Middle East and Africa
    • Turkey
    • Saudi Arabia
    • United Arab Emirates
    • By company
    • Suits you
    • Sandoz (Novartis SA)
    • Mylan
    • Allergan PLC
    • cipla
    • Akorn
    • Apotex
    • Sun Pharma (Ranbaxy)
    • Nephron Pharma
    • Beximco Pharma
    • Hikma (Roxane) and XIANJU PHARMA

    Major Key Players of the Global Generic Inhalation and Nasal Spray Market are:

    • Teva Sandoz (Novartis AG) Mylan Allergan PLC Cipla Akorn Apotex Sun Pharma (Ranbaxy) Nephron Pharma Beximco Pharma Hikma (Roxane) XIANJU PHARMA

    Details mentioned in the section

    The research report offers a competitive spectrum analysis of the Inhalation & Nasal Spray Generic Drugs Market.

    Data provided in the study:

    • The report provides information on business profiles of companies.
    • The products manufactured by these companies are also provided in the report.
    • Information regarding product specifications and applications are provided in the report.

    The research provides data related to these companies’ growth margins as well as manufacturing expenses, product costs, and compensation.

    The Generic Inhalation and Nasal Spray Drugs Market report provides data related to the extent to which the industry has been assessed. The report contains information on the analysis of the feasibility of new investment projects as well as the research conclusions of the studies.

    Generic Inhalation and Nasal Spray Industry Highlights:

    • Generic Inhalation and Nasal Spray Market Share by Major Players: Here, the capital, revenue and price analysis by the company is included along with other sections such as expansion plans, assisted areas, products offered by major manufacturers, alliance and l acquisition and delivery of the seat.
    • Global Growth Trends: Industry trends, growth proportion of major producers, and production analysis are the segments included in this chapter.
    • Market Size by Application: This segment includes Inhalation & Nasal Spray Generic Drugs market consumption analysis by application.
    • Generic Inhalation and Nasal Spray Market Size by Type: It includes analysis of value, product utility, market percentage, and production market share by type.
    • Manufacturer Profiles: Here, leading players of the global Generic Inhalation and Nasal Spray market are studied based on sales area, key products, gross margin, revenue, price, and production.
    • Value Chain and Sales Channel Analysis of Generic Inhalation and Nasal Spray Market: It includes analysis of customers, distributors, market value chain and sales channels.
    • Market forecast: This section is obsessed with production and production value forecast, forecast of major producers by type, application and regions

    Customization request on this report @ https://www.nwdiamondnotes.com/request-for-customization/133514

    read more
    Prescription drugs

    Iran’s Medicine Mafia Behind Shortages and High Cost of Prescription Drugs – OpEd – Eurasia Review

    A short prelude

    Since the birth of the tyrannical regime of the mullahs in Iran, another social and frightening phenomenon has also been born; widespread monopolization. After the 1979 anti-monarchy revolution in Iran and the establishment of the religious dictatorship, the regime’s power vultures began to dominate and take control of the main outlets of the economy. The creation of a multitude of false and non-existent legal and illegal entities, holdings, bank accounts and businesses has been the evil product of this domination and control.

    After the passage of more than four decades, the Iranian economy is recognized by its two distinct fronts. On the one hand, the regime, its repressive forces and its affiliates, and on the other, the Iranian people.

    The first front is dominated by the office of Iran’s Supreme Leader Khamenei, which has around $200 billion in assets, the infamous Islamic Revolutionary Guard Corps (IRGC) and a host of other entities sharing the same ideas.

    The second front is made up of ordinary Iranian citizens who, according to Speaker of Parliament Ghalibaf, make up around 94% of the population.

    The current state of prescription drugs in Iran

    The availability and affordability of prescription drugs in Iran fell sharply more than two years ago, and it has become almost impossible to find foreign drugs after the recent pandemic. According to media reports, ordinary Iranians are experiencing a severe shortage of prescription drugs and drug prices are skyrocketing across the country.

    Many people complain that pharmacies are unable to supply their prescriptions. As expected, government officials are offering conflicting reasons — including US sanctions — for shortages and price hikes; however, pharmacists blame government mismanagement of health care, corruption, the black market and the collapse of Iran’s currency.

    In September 2018, it was reported that the price of drugs prescribed to dialysis and kidney transplant patients had increased by 100-300% since March of the same year. Other prescription drugs have also seen unprecedented price increases. Many senior officials in the governments of former President Hassan Rouhani and current President Ebrahim Raisi have blamed current drug shortages on US-imposed economic sanctions. Yet the US Treasury Department’s list does not include drugs.

    The source of the problem

    The real reason for the shortage of prescription drugs lies in the Iranian regime’s corrupt system and its dominance over the pharmaceutical industry.

    The Iranian medical mafia is not a new phenomenon; with the onset of the COVID-19 pandemic in Iran in 2019, people had to go through a winding path of illegal channels and contacts, called the Iranian medicine mafia, instead of pharmacies, to obtain prescription drugs, often paying much more than the advertised price. Looking back, one might realize that Iran’s medical mafia had been around for many years, but the spread of COVID-19 helped it gain strength and expansion.

    Regarding the shortage of certain items in pharmacies, Ali Fatemi, Vice President of the Iranian Pharmacists Association, said: “Previously, the shortage of medicines was related to foreign medicines and medicines for certain diseases, but now we have problems in supplying certain Iranian medicines and this shortage in our country is unprecedented”.

    Iran’s new budget and prescription drugs

    To raise funds for its budget deficit, the government of Ebrahim Raisi plans to eliminate all pre-existing subsidies for prescription drugs. Facing public anger and widespread criticism from the regime’s own analysts and politicians, government officials say prescription drugs will still be subsidized because they fall under the subsidized exchange rate category.

    However, leaders of drug importing companies insist that the prescription subsidies allocated in the budget are not enough to meet the need. The Director General for Pharmaceutical Affairs confirmed concerns raised by pharmaceutical companies about subsidies and their availability.

    Iranians are angered by reports of drug trafficking and the sale of drugs on the black market, which is owned and controlled by regime elites. This is when the authorities claim to have enough funds to import certain drugs; drugs that cannot be found in pharmacies and that end up on the black market at exorbitant prices.

    In a report published in January, Colonel Davoud Moazami Goudarzi, head of Tehran’s cyberpolice, said an Instagram page with more than 90,000 followers was selling drugs in cyberspace. The report says more than 500,000 rare drugs were confiscated from the site.

    In conclusion

    It is safe to say that in principle there are enough drugs in the country, but the Iranian medical mafia, i.e. the regime elites and the IRGC, are selling the drugs to desperate patients. through the black market to earn more money. Most Iranians cannot afford to buy drugs on the black market, which has led and may lead to more deaths and poverty

    read more
    Prescription drugs

    Mark Cuban’s online pharmacy is now open with low-cost prescription drugs

    Mark Cuban’s online pharmacy promising affordable prices on prescription drugs is up and running.

    The Mark Cuban Cost Plus Drug Company cuts out the middleman and negotiates directly with drug manufacturers and pharmacies to obtain discounts and rebates on behalf of employers, health insurers and government health programs.

    It says it offers the lowest direct-to-consumer prices on more than 100 medications, including those commonly prescribed for high cholesterol and blood pressure.

    The cholesterol drug Atorvastatin typically costs more than $55, according to the Cuba-backed company’s website. Cost Plus charges $3.60. Prescription amlodipine for high blood pressure usually costs around $50. Cost Plus lists it at $3.30.

    Alex Oshmyansky, CEO of the Mark Cuban Cost Plus Drug Company.

    “The Mark Cuban Cost Plus Drug Company is trying to reduce drug costs for patients by any means necessary,” said CEO Alex Oshmyansky. “In our online pharmacy, we basically found a category of drugs that are extremely expensive, not really because of the manufacturer’s price, but because of price markups due to intermediaries in the supply chain, mainly pharmaceutical wholesalers. and pharmacy benefits managers.”

    The company established its own registered pharmaceutical wholesaler and purchased drugs directly from manufacturers. He then sells the drugs at a fixed markup of 15% and a pharmacist fee of $3.

    The pharmacy is cash only at the moment. By next year, Oshmyansky said the company hopes to allow customers to use their insurance.

    Wednesday’s launch comes just weeks after the creation of Cuba’s Pharmacy Benefits Management Operation, which works directly with the online pharmacy. Customers can go to the website and order generic versions of drugs to be shipped to their front door.

    Mark Cuban Cost Plus Drugs was first launched under a different name in 2018 as a generic drug startup. A year ago, the billionaire owner of the Dallas Mavericks went public with his support.

    The company is currently building an $11 million, 22,000 square foot manufacturing facility in Deep Ellum.

    Oshmyansky said thousands of people had created accounts when the website launched on Wednesday.

    “Our goal is not just to get attention today, but to try to help people every day, so hopefully we can keep the excitement going,” Oshmyansky said.

    read more
    Generic drugs

    Mark Cuban’s drug company launches pharmacy, promising huge savings on generic drugs

    Mark Cuban Cost Plus Drug Company (MCCPDC) has launched its online pharmacy as part of an ongoing effort to provide consumers with drugs at low prices.

    The pharmacy claims to offer significant savings, with several prescription drugs costing more than half the price of the next most affordable option. For example, imatinib for the treatment of leukemia has a retail price of $9,657 per month, according to the MCCPDC, compared to $120 with a common voucher. Its price through the new company, however, is only $47 per month.

    The initial launch of the pharmacy inventory consists of 100 generic drugs.

    The MCCDPC aims to circumvent so-called middlemen and markups and boasts of reflecting actual manufacturer prices with a fixed 15% fee. To avoid working with pharmacy benefit managers, the pharmacy will be cash only. The pharmacy is powered by Truepill’s digital health platform and leverages its nationwide pharmaceutical footprint to fill and deliver prescriptions.

    “We will do whatever it takes to bring affordable pharmaceuticals to patients,” Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug, said in an announcement. “The mark-up on potentially life-saving medicines that people depend on is an issue that cannot be ignored. It is imperative that we act and help expand access to these medicines for those who need them most.”

    RELATED: 2 New PBM Launches Aim to Bring Greater Transparency to the Market

    In November, the MCCPDC launched its own Pharmacy Benefits Manager and pledged to be transparent about the costs it pays for drugs with those who work with it. With this venture, he hopes to completely eliminate the traditional PBM model.

    The company plans to integrate its pharmacy and wholesaler with its PBM so that PBM customers have access to wholesale pricing through the pharmacy. Its Dallas pharmaceutical plant is expected to be built by the end of this year.

    “There are many bad actors in the pharmaceutical supply chain that prevent patients from getting affordable medicines,” Oshmyansky said. “The only way to guarantee affordable prices is to integrate vertically.”

    read more
    Medical supplies

    Local church partners with White Cross to provide medical supplies in Cameroon

    America is a country where people come to live freely but some countries don’t have the same opportunities. Cameroon is a country in West-Central Africa bordering Nigeria. And getting the proper medical care has become harder to come by.

    Calvin Hohn, who is currently in Cameroon with the Cameroon Baptist Convention, was able to experience the magic first hand.

    “Patients must provide absolutely everything, from sheets to syringes, drugs, bandages, everything the doctors and nurses need to treat them. Family members have to go into town to local pharmacies and buy these products to take back to hospitals,” says Hohn.

    The Cameroon Baptist Convention, also known as the CBC, was established in 1954 through missionary work done by the North American Baptist Association.

    “I saw that what the local organization was doing was meeting real health, education and community development needs that the government was not able to provide, so when the churches stepped in and started providing that,” Hohn says.

    The CBC operates 12 major hospitals, 25 community clinics and approximately 50 primary clinics with over 5,000 employees who help run these institutions. But what makes them so special is that they don’t turn away patients, whether or not they can afford to pay for care. In order for the CBC to obtain the medical supplies it needed, it created the Ministry of the White Cross. Under the ministry, supplies are sent from North America to Cameroon.

    “Part of the work they’ve done here since the 1920s and 30s, particularly excelling in the 1950s, is medical work,” says Hohn.

    In November 2020, the White Cross ministry found a new home at Century Baptist Church in Bismarck, North Dakota. Century Baptist Church serves as the hub where expeditions are organized and dispatched to Cameroon. Paul Herr, the local director of White Cross Ministry, says he has seen the growth of the partnership that began more than a century ago.

    “We have a partnership with Cameroon that we have had for over a decade and they asked if we would be interested in taking over the ministry of the White Cross which has been part of the North American Baptist Conference for over 100 years,” said Herr.

    All equipment is donated by churches or hospitals. Herr says the supplies can range from bandages to larger needs like chairs and hospital beds.

    “A lot of times there is an excess in hospitals or clinics so any hospital or clinic that has items they need to change or more we are willing to take a look at what it is and to see if it’s a real one so we can get that to them,” Herr said. “It takes about 5-6 months to gather enough supplies and ship. It is an ongoing process and we have church volunteers who come 2-3 times a month.

    Century Church’s goal is to ship 2 C containers per year, which are 40ft tall cubic containers. These organizations help more than one million patients in Cameroon each year.

    “In places like this, in so many places around the world, the majority of the world does not have access to even minimal basic care,” Hohn says.

    The process of getting supplies around the world isn’t easy, but worth it. For more information about the White Cross and how to help, click here.

    read more
    Medical products

    Greenrise Global’s Medical Cannabis Subsidiary, AMP Alternative Medical Products GmbH, Becomes Exclusive Distribution Partner for Selected Little Green Pharma Extracts in Germany

    AMP has entered into an exclusive three-year pharmaceutical distribution agreement for LGP Classic Full-Plant Cannabis Extract Oils. LGP medical cannabis products have been registered for sale with the relevant authorities in Germany and include 20:5 LGP Classic and 10:10 LGP Classic extract oils in 30 and 50 milliliter sizes. Doctors and pharmacists can find more information about the product or order on the AMP website: https://amp-eu.com/doccheck-login.

    LGP is a pioneer and leader in the production of medical cannabis extract oils with GMP cultivation facilities in Australia and Denmark, whose medical cannabis preparations provide various THC and CBD profiles available as LGP Classic medical cannabis oils. LGP medicinal cannabis oils are made from a whole plant (full spectrum) extracted with medium chain triglyceride (MCT) oil. LGP was among the first medical cannabis companies to produce and export medical cannabis oils to Germany and continues to build its reputation in Europe by being selected as the main supplier of medicinal cannabis extract oil in France two-year medical cannabis trials conducted by the National Agency for the Safety of Medicines and Health Products (ANSM).

    LGP medical cannabis extract oils will also be used in the clinical study of the Waldhausklinik Deuringen gGmbH (“Waldhausklinik”) on the therapeutic use of cannabis extracts focused on the treatment of pain in patients with chronic pain. multilocular. Waldhausklinik is a non-profit acute care hospital for internal medicine in the Free State of Bavaria and has entered into a research collaboration with AMP on the efficacy and safety of medical cannabis.

    dr. Stefan Feuerstein, President and Director of Greenrise Global and Managing Director of AMP, said, “We see the industry maturing with the growth of cannabis-based pharmaceuticals rather than flowers and we are excited to add medical cannabis extracts. LGP to our portfolio.

    M/s. Fleta Solomon, Managing Director of Little Green Pharma, said: “We have made it our strategic goal to be one of the leading producers and distributors of medical cannabis extracts in Europe, which means being a leader in Germany, the world’s largest medical cannabis market. Our partnership with Greenrise Global’s subsidiary, AMP Alternative Medical Products GmbH, puts us on the right path.”

    About Little Green Pharma
    Little Green Pharma is a vertically integrated and geographically diverse global medicinal cannabis and psychedelics company, with operations ranging from cultivation and production to manufacturing and distribution.

    The Company has two global production sites for the manufacture of its own brand and white label GMP grade medical cannabis product lines, being a 21,500m2 culture and 4000m2 GMP manufacturing facility capable of producing over 20 tons of medicinal cannabis biomass per year located in Denmark (EU) and an indoor cultivation and manufacturing facility located at Western Australia capable of producing ~3 tons of medicinal cannabis biomass per year. The Company is also licensed to supply psilocybin and is currently expanding its WA production facilities to produce psilocybin medicines.

    Little Green Pharma cannabis products comply with all requirements of the Danish Medicines Agency and Therapeutic Goods Administration (Australia) regulations and testing requirements. With a growing range of products containing different ratios of active ingredients, Little Green Pharma supplies medical grade cannabis products to the Australian, European and overseas markets.

    The company has a strong focus on providing patient access to the emerging global medicinal cannabis market and is actively engaged in promoting education and awareness programs, as well as participating in clinical surveys and projects. research to develop new innovative delivery systems.

    For more information about Little Green Pharma, visit: www.littlegreenpharma.com

    FOLLOW US ON:

    Twitter: https://twitter.com/LittleGreenPHAR
    LinkedIn: https://www.linkedin.com/company/little-green-pharma
    Facebook: https://www.facebook.com/littlegreenpharma

    About Greenrise Global Brands

    Greenrise Global helps people realize the beneficial properties of cannabis. Greenrise Global is a publicly traded Canadian company with two German operating subsidiaries: Greenrise GmbH (“Greenrise Wellbeing”) and AMP Alternative Medical Products GmbH (“AMP”). Greenrise Wellbeing is a CBD wellness company based in Hamburg, with brands such as Herbify and CANAVEX® in his wallet.

    AMP Alternative Medical Products GmbH is based in Erfurt and supplies medical cannabis products to pharmacies across Germany, including the medical cannabis brands of Aphria, Bedrocan, Little Green Pharma and the AMP branded product line and sold through its national sales team. AMP complies with the German Narcotics Act (BtMG) and the regulatory requirements of the Free State of Thuringia, ensuring that products imported from around the world and sold in Germany Meet the European Union Good Manufacturing Practice (EU-GMP) standard.

    For more information about Greenrise Global, please visit www.greenriseglobal.com

    FOLLOW US ON:

    Twitter: https://twitter.com/GreenriseGlobal
    LinkedIn: https://linkedin.com/company/greenriseglobal/
    Instagram: https://www.instagram.com/greenriseglobal/

    Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

    This press release contains forward-looking statements based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and their calendar. Although the Company believes that the expectations expressed in these forward-looking statements are based on reasonable assumptions, these statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Accordingly, actual results may differ materially from those expressed in such forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless the otherwise required by law.

    SOURCE Greenrise Global Brands Inc.

    For more information: GLOBAL GREENRISE CONTACT: Hendrik Knopp, Director, [email protected], +1 236-833-1602; CONTACT AMP ALTERNATIVE MEDICAL PRODUCTS: Dr. Stefan Feuerstein, Managing Director, [email protected], +49-172-6945663; Media inquiries: Valeria Bravo, Corporate Communications and Media, [email protected], +1 604-689-7533; LGP CONTACT: Alistair Warren, Company Secretary, [email protected], +61 8 6280 0050; Fleta Salomon, President and CEO, [email protected] +61 8 6280 0050

    read more
    Medical products

    FDA Suspends Non-Mission-Critical Domestic and Foreign Inspections – Medical Product Supply Chain Week in Review | Alston and bird

    Just before the New Year holidays, the FDA announced it was suspending non-mission-critical domestic and foreign inspection activities. The FDA amended the EUA of the Moderna COVID-19 vaccine recall. The Center for Drug Evaluation and Research has released its annual report. This week, the Senate HELP Committee approved the appointment of Dr. Robert Califf as Commissioner of the FDA. The senators introduced legislation that would require certain foreign establishments to register with the FDA. Please see details of these and other supply chain developments below:

    • On December 29, the FDA implemented changes to its inspection program due to record levels of COVID-19 infections. National mission-critical inspections will continue until January 19, while “some inspection activities” have been temporarily postponed. Mission-critical foreign inspections will continue; however, the agency will reassess feasibility if travel restrictions warrant. The program of priority surveillance foreign inspections which was to begin in February 2022 has been interrupted. It is likely that the FDA will not conduct any uncritical inspections, domestic or foreign, until the United States has passed the peak of the current omicron wave.
    • January 4, HHS amended its declaration under the Public Preparedness and Emergency Preparedness Act (PREP) to include pharmacists and certain pharmacy trainees as “qualified persons” who can administer flu vaccines in states where they are not not authorized or certified. The PREP Act allows the Secretary of HHS to issue a statement and grant immunity from liability to such individuals.
    • On January 5, White House Press Secretary Jen Psaki and Port Envoy to the White House Supply Chain Task Force John Porcari tenuous a briefing on the progress of supply chain improvements and new actions to come. Porcari reported that consumers received 97% to 99% of their packages on time or with minimal delays during the holiday season. Porcari added that the ports of Los Angeles and Long Beach are imposing a new tax on long-lived empty containers. Porcari stressed that procedures are in place to prioritize the distribution of medical supplies. One such procedure is to “bulk stow” medical supplies on ships for easy identification and retrieval. He also discussed the impact of the omicron variant on operations and the procedures in place to deal with any disruptions.
    • On January 7, the FDA amended the EUA of the Moderna COVID-19 vaccine recall. The agency authorized the administration of the booster dose five months (previously six months) after the primary vaccination of the vaccine.
    • On January 10, the FDA Posted draft guidance, “Notification to the FDA of a Permanently Discontinuing or Discontinuing Manufacture of a Device Under 506J of the FD&C Act”. These draft guidelines, authorized under the CARES Act of 2020, are intended to prevent shortages of medical devices before and during a public health emergency and to provide a mechanism by which manufacturers notify the FDA of their intention to cease or suspend production. The draft guidelines apply to “devices essential to public health during a public health emergency, including those that are essential to life, sustaining life or intended for use in the medical care of emergency or during surgery” or “devices for which the FDA determines information about possible significant supply disruptions are needed during or before a public health emergency. Comments are due no later than March 11, 2022.
    • On January 10, Senators Gary Peters (D-MI) and Susan Collins (R-ME) introduced S. 3449, a bill that would require foreign drug and device establishments to register with the FDA whether or not the drug or device undergoes further processing at a separate facility outside the United States. States before being imported into the United States. The goal is to give the FDA greater regulatory oversight authority to not only monitor products entering the supply chain and determine shortages, but also ensure that products are safe for the public. The Bill has been referred to the Health, Education, Labor and Pensions (HELP) Committee.
    • On January 13, the Senate HELP committee vote 13 to 8 to advance the President’s nominee for FDA Commissioner Dr. Robert Califf. His confirmation hearing took place on December 14, 2021. The nomination now goes to the Senate for a final vote and confirmation.
    • FDA Center for Drug Evaluation and Research (CDER) published its annual report, “Advancing Health Through Innovation: New Drug Therapy Approvals”. The report highlights CDER approvals of new therapies, biosimilars, and new indications for approved products. A post-marketing safety surveillance review is also included. The number of products approved (50) was above average despite the pandemic-related challenges, with more than half (27) being first-line drugs. CDER also met its action targets under the Prescription Drug User Fees Act for 49 of the 50 submissions.

    [View source.]

    read more
    Medical supplies

    Dwindling medical supplies in northern Ethiopia prevent health workers from helping those in need – Ethiopia

    As the conflict in northern Ethiopia continues to evolve, hundreds of thousands of people have been displaced, straining the region’s health system and medical personnel.

    The ICRC is deeply concerned about the availability of medical care, including medicines and medical equipment. Health services lack essential medical supplies and, in some cases, infrastructure has been severely damaged. This makes access to health care very difficult, depriving people of the essentials they need to survive.

    The ICRC is adapting its assistance efforts by focusing on the most vulnerable. However, our ability to respond has become limited as medical supplies dwindle, with the delivery of humanitarian aid severely hampered by a combination of fighting, insecurity and access constraints.

    “Some hospitals in Amhara have closed for lack of medicines,” said Micha Wedekind, the ICRC’s response officer in Amhara and Afar. “People with chronic diseases die every day and women give birth at home because health facilities are not functional and often without electricity or water.”

    “In Tigray, single-use items such as gloves, surgical equipment and even chest tubes are washed and reused, increasing the risk of infections. In some places, doctors have replaced disinfectant with salt to clean the wounds,” said Apollo Barasa, health coordinator at the ICRC delegation in Ethiopia. “Patients are receiving expired drugs, oxygen plants are no longer working and some health facilities cannot provide routine vaccines.

    The ICRC reminds all parties to the conflict that they must facilitate the delivery of humanitarian aid without delay to those most in need.

    Our medical support this month has included seven healthcare facilities around Dessie, including Hayk, Mersa, Woldiya and Kobo. Throughout 2021, with the Ethiopian Red Cross, the ICRC supported 130 health facilities in the Amhara, Afar, Tigray, Oromia and Somali regions. More than 110,000 people have benefited from our medical programs and 9,800 people have received physiotherapy and mobility care.

    Beyond medical assistance, the ICRC continues to be concerned about the food and livelihood situation in northern Ethiopia. Last week, our teams were able to bring humanitarian aid to communities in Lalibela, Amhara, for the first time in six months, providing 2,500 people with food and 6,000 people with household items such as mattresses, jerry cans , cooking utensils and solar lamps. In Mekelle, the ICRC distributed essential household and hygiene items to more than 900 displaced people.

    Finally, while continuing our operations in the region, the ICRC is deeply concerned by recent reports of continued fighting in northern Ethiopia, resulting in civilian casualties, including in recent airstrikes.

    We call on all parties to the conflict to respect the rules and obligations of international humanitarian law, which provide that civilians are protected from attack and that everything possible must be done to verify that targets are military objectives. Where possible, civilians should also be kept away from the vicinity of military objectives.

    In 2021, the ICRC has:

    – Assisted 655,000 people with household supplies, shelter and cash across the country, with a focus on northern Ethiopia
    – provided 875,000 people with agricultural and livestock assistance
    – Facilitated access to drinking water and sanitation for 1,950,000 people, including in places of detention
    – Helped over 169,000 people restore or maintain family ties, facilitating the exchange of news between family members.

    For more information, please contact:

    Fatima Sator, ICRC Addis Ababa, [email protected] Mr. +251944101700
    Alyona Synenko, ICRC Nairobi, [email protected] Mr. +254716897265

    read more
    Medical products

    Monetizing healthcare with disposable medical products – Hunter Women’s Chronicle

    Reading time:3 minutes, 13 seconds

    This report analyzes the single-use endoscope market, with the United States being the largest. The monetization of healthcare with disposable medical devices and recurring revenue from monitoring, a smaller and lighter product, creates new opportunities for broader consumer and commercial markets. Improving product quality, reducing costs and profitable growth are the keys to dominating this lucrative market. However, poor design and prototype design can be linked to several challenges. Technological innovation, integrated services and reduced R&D costs could significantly increase a company’s revenue.

    Click on the tab below to benefit from the sample copy of the report

    Sample request

    Introduction to Single Use Endoscopes Market

    Strict government regulations make it difficult for doctors, hospitals and large corporations to raise capital in the current economic climate. There has been a shift in the way pharmaceutical organizations have approached the development of disposable medical products. Pharmaceutical companies are now offering their services and expertise in this area to medical device manufacturers without costly milestone payments to third parties.

    Global Endoscope Explosion

    Slowing economic growth and rising import tariffs have led to a slowdown in global healthcare spending, which presents a unique opportunity for the disposable medical products market. This can be attributed in particular to the greatly increased use of endoscopes in recent years. According to Global Industry Analysts (GIA) Inc., one of the leading research companies, there were around 1 billion daisies installed globally across the globe in 2020 alone.

    Defining the key players in the single use endoscopes market

    The pharmaceutical industry is striving to develop and introduce more disposable products, which makes the single-use endoscope market an attractive area for new investment. A few years ago, only knives and needles were included in the disposable medical market as antibacterials. The discovery of a new way to use endoscopes, which includes test strips to determine the appropriate medications that could be prescribed without harming patients while they undergo medical tests, has increasingly served to increase the number of observers included in this market.

    An analysis of the low, medium, high and technological platform; their role in product development

    In March 2020, the American Society of Gastroenterology declared that endoscopes are writable and disposable. This means that with proper treatment and monitoring, these devices can last up to six months, providing a frictionless revenue stream with negligible cost to hospitals. For insights into a new market segment and the opportunities ahead, download the report Single-Use Endoscopes Market: Monetizing Healthcare with Disposable Medical Products today.

    Regulations and cost variables in the preparation of single-use endoscopes

    The use of disposable medical instruments, such as endoscopes, is increasing rapidly. This is due to government regulations and regulatory requirements that reduce costs for outsourced healthcare providers. Additionally, the demand for more flexible options in disposable medical devices is pushing manufacturers towards more specialized instruments with various functionalities.

    Click on the tab below for the instant purchase of the report with a flat rate discount of $500

    Instant Buy Request

    Supply chain approach for manufacturer pharmaceutical process for disposable medical products

    Due to stringent government regulations and increasing attention to patient safety and human factor issues, the healthcare industry is moving towards a system where the emphasis is on the quality life cycle. Patient safety issues leading to contaminated supply chains pose a major challenge to manufacturers. Reports show that healthcare interventions are highly dependent on the use of home medical products, but it has been difficult from a business perspective to effectively plan for a market with multiple users of these products. Manufacturers are required to closely monitor the demand for single-use endoscopes for the development of replacement products. A supply chain approach will be more effective in achieving affordability and meeting regulatory requirements unlike other methods that manufacturers have tried in the past.

    happy

    happy


    0 %

    Sad

    Sad


    0 %

    Excited

    Excited


    0 %

    Sleepy

    Sleepy


    0 %

    Angry

    Angry


    0 %

    Surprise

    Surprise


    0 %

    read more
    Generic drugs

    Generic Drugs Market Segmentation, Analysis by Recent Trends, Development by Region to 2030 Abbott Laboratories, Allergan, Inc., Alvion Pharmaceuticals PC, Amneal Pharmaceuticals, Inc

    The Global Generic Drugs Market Report is a compilation of in-depth research studies on various aspects of the Generic Drugs Market. With precise data and highly authentic information, it brilliantly attempts to deliver a real and transparent picture about the current and future situations of the global Generic Drugs Market. Market players can use this powerful tool to create effective business plans or make significant changes to their strategies. The report discusses the growth of global and regional markets. It also sheds light on the high growth segments of the global generic drugs market and their development in the coming years.

    Key players operating in the global generic drugs market include: Abbott Laboratories, Allergan, Inc., Alvion Pharmaceuticals PC, Amneal Pharmaceuticals, Inc., Aspen Pharmacare Holdings Limited., AstraZeneca plc., Cipla Inc., Dr. Reddy’s Laboratories Ltd., Egis Group, Eli Lilly and Company, Endo International plc , Fresenius Kabi Kabi SwissBioSim GmbH, Gedeon Richter Ltd, Gilead Sciences, Inc., GlaxoSmithKline Plc., Lupine Pharmaceuticals, Inc., Mylan NV, Novartis International AG, Pfizer Inc., STADA Arzneimittel AG, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd .

    Request a sample PDF copy of this report from: https://www.absolutemarketsinsights.com/request_sample.php?id=603

    Global Generic Drugs Market was valued at USD 284.56 Billion in 2018 and is projected to reach USD 472.32 Billion by 2027, growing at a CAGR of 5.8% over the forecast period.

    The study of the generic drugs market follows a combination of in-depth research and structured methodology. These methods probe the market from different angles to find suitable analyses. However, on a general scale, data is gathered from a variety of trusted sources such as vendor listing, product and research papers, manufacturer processes, and many more. Every market research is given the exact same careful shadow that makes it valuable reading.

    The Generic Drugs market report categorized the market into segments comprising product type and application. Each segment is assessed based on its share and growth rate. In addition, analysts have studied potential regions that could prove valuable for manufacturers in the years to come. The regional analysis includes reliable forecasts of value and volume, helping market players to gain in-depth knowledge about the entire industry. In addition, the Generic Drugs market study revolves around the development of regional trends, preferred marketing channels, long-term stability, and environmental analysis. It also contains product capabilities, price, earnings status, demand, production and market growth and a trajectory of future forecasts.

    If you have any questions/requests, ask our expert: https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=603

    Impact of COVID-19:

    This study presents insights into COVID-19 in consumer behavior and changing demand, buying habits, supply chain reorganization, market force dynamics, and substantial involvement of the government. The new research provides insights, analysis, estimates and forecasts considering the effect of COVID-19 on the markets.

    Reasons to buy the report:

    • The study details the generic drugs market with a detailed market breakdown in terms of volume, size and value across all sectors.
    • A comprehensive breakdown of the Generic Drugs market supported by graphs, pie charts, and figures aids understanding.
    • A projected forecast of the generic drugs market is expected to be extracted from real-time data points which are a compilation of 2016 to current data.

    Customization request: https://www.absolutemarketsinsights.com/request_for_customization.php?id=603

    Global Generic Drugs Market Segmentation:

    By type

    • Prescription products
    • Over-the-counter (OTC) products

    By app

    • Respiratory
    • Dermatology
    • Oncology
    • Diabetes
    • Infectious diseases
    • Ophthalmology
    • women’s health
    • Central nervous system (CNS)
    • Cardiovascular
    • Urology
    • Others (pain management, etc.)

    By form

    • Tablets
    • capsules
    • Injectables
    • Topical creams
    • Others

    By distribution channel

    • Retail pharmacy
    • Hospital pharmacy

    By region:

    • North America [U.S., Canada, Mexico]
    • Europe [Germany, UK, France, Italy, Rest of Europe]
    • Asia Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
    • South America [Brazil, Argentina, Rest of Latin America]
    • Middle East and Africa [GCC, North Africa, South Africa, Rest of the Middle East and Africa]

    For more information, click on: https://www.absolutemarketsinsights.com/reports/Generic-Drugs-Market-2019-2027-603

    Contact us:

    Company: Absolute Markets Insights
    Email ID: [email protected]
    Phone: IN +91-740-024-2424, US +1-510-420-1213
    Contact Name: Shreyas Tanna
    Website: www.absolutemarketsinsights.com/

    read more
    Generic drugs

    Growing controversy over ‘skinny’ generic drug labeling

    The vast majority of patients who started treatment with imatinib for gastrointestinal stromal tumors (GISTs) received a generic drug that did not have FDA approval for this indication, a large retrospective review showed.

    Almost half of the 2,000 patients in the imatinib initiators review had chronic myeloid leukemia (CML), while about a third had GIST. Three years after the introduction of generic imatinib, more than 90% of patients in both groups received the generic, which had a label indication for CML but not for GISTs, reported Bryan S. Walsh, JD , from Brigham and Women’s Hospital and Harvard Medical School in Boston

    Overall, 85% of patients with CML, GIST or another condition were initiated on a generic version of imatinib, the group wrote in the Journal of Clinical Oncology.

    The findings highlight the FDA-approved practice of “skinny labeling,” which allows generic manufacturers to market their labels that include covered indications, such as the CML for generic imatinib, but exclude indications still under patent protection. Skinny labeling is at the center of legal disputes between patent-holding brand-name drug companies and generic makers, Walsh said. MedPage today.

    The skinny label has its origins in the Hatch-Waxman Amendments which established an approval pathway for generic drugs, including the Abbreviated New Drug Application.

    “The goal is to prevent the delay of generic drug approvals as a result of a drug gaining subsequent approvals for new diseases after the initial approved indication,” Walsh said. “If a manufacturer were to get another disease approved for their drug, they would get another patent [that would extend exclusive marketing rights]. Thin labels allow generic manufacturers to avoid [patented-protected indications] and come to market timely. »

    Generic approvals with thin labeling have become increasingly common in recent years. In a previous study, Walsh and colleagues identified 56 brand name drugs with newly approved generics between 2015 and 2019 with lean labeling sensitivity, 24 of which were approved with lean labels. In the year prior to first generic approval, median net sales of branded drugs with full-size generics were $522 million, while median net sales of branded drugs with small-label generics were $522 million. $852 million.

    In the current study, Walsh and colleagues examined the impact of lean labeling by means of indication-specific imatinib uptake. They identified patients covered by private insurance or Medicare Advantage plans who started imatinib from February 2016 (when the first generic became available) to September 2020. Generic versions of imatinib approved during this period had thin labels that included indications for CML but excluded GISTs.

    Of the 2,000 patients included in the analysis, 934 (47%) started imatinib for an indication of CML, 686 (34%) for GIST and 380 (19%) for other or unknown indications. Generic use increased throughout the study period, surpassing 80% across all diagnostic groups in January 2017, one year after the first generic became available.

    After adjusting for differences in patient characteristics, generic use at initiation was slightly but significantly higher in patients with CML than in those with the patented indication of GIST (88% versus 85%; HR 0.56, 95% CI 0.39-0.80, P

    The median copayment for a 30-day supply of generic imatinib was $7 versus $40 for brand name imatinib (Gleevec). Co-payments for generic imatinib were highest for patients with low-income, unsubsidized Medicare Advantage plans ($162) and lowest for patients with commercial insurance ($0). Median copayments for brand name imatinib ranged from $1,730 for Medicare without low-income subsidy to $0 for high-deductible commercial insurance plans.

    “These results really put the difference in median copays into perspective,” Walsh said. “If you compare a median copayment of $7 for a generic with a median copayment of $40 for the brand name drug, that’s a big gap for a one-month prescription. It’s kind of the key point here. [Skinny labeling] makes drugs more affordable for patients.”

    A closely watched legal battle centered on skinny labeling could have a game-changing effect on the future of skinny labels. Last year, a federal appeals court ruled that generic maker Teva infringed GlaxoSmithKline’s patent protection for the cardiovascular drug carvedilol (Coreg) and reversed a $235 million court ruling. Legal wrangling continues in this case, but other potential plaintiffs and defendants have taken notice.

    “We’re starting to see some sort of knock-off cases going through the lower courts,” Walsh said. “In one case, it’s not a generic manufacturer that’s being sued but a health insurer, based on their form. It’s going to be interesting to watch and see how the courts deal with a new type of defendant.”

    To preserve the beneficial effects of lean labeling, federal regulators should take the lead in providing guidance, Walsh and coauthors said.

    “[The carvedilol case] posed a threat to the lean labeling pathway, as it could discourage generic manufacturers from using this approach to introduce timely generic competition,” they wrote. “To optimize the use of the lean labeling pathway and protect generic manufacturers, the FDA and U.S. Patents Trademark Office should provide better guidance to manufacturers on how to legally market generics labeled lean, and the FDA should provide a public list of branded products that may qualify for lean labeling. »

    • Charles Bankhead is editor for oncology and also covers urology, dermatology and ophthalmology. He joined MedPage Today in 2007. To follow

    Disclosures

    The study was supported by the Commonwealth Fund and Arnold Ventures.

    Rome reported honoraria from Blue Cross and Blue Shield of Massachusetts and research funding from the Anthem Public Policy Institute.

    Walsh said he has no relevant relationship with the industry.

    read more
    Medical products

    FDA suspends non-mission-critical domestic and foreign inspections – Medical Products Supply Chain Week in Review – Food, Drugs, Healthcare, Life Sciences

    United States: FDA suspends non-mission-critical domestic and foreign inspections – Medical Product Supply Chain Week in Review

    To print this article, all you need to do is be registered or log in to Mondaq.com.

    Just before the New Year holidays, the FDA announced it was suspending non-mission-critical domestic and foreign inspection activities. The FDA amended the EUA of the Moderna COVID-19 vaccine recall. The Center for Drug Evaluation and Research has released its annual report. This week, the Senate HELP Committee approved the appointment of Dr. Robert Califf as Commissioner of the FDA. The senators introduced legislation that would require certain foreign establishments to register with the FDA. Please see details of these and other supply chain developments below:

    • On December 29, the FDA implemented changes to its inspection program due to record levels of COVID-19 infections. National mission-critical inspections will continue until January 19, while “some inspection activities” have been temporarily postponed. Mission-critical foreign inspections will continue; however, the agency will reassess feasibility if travel restrictions warrant. The program of priority surveillance foreign inspections which was to begin in February 2022 has been interrupted. It is likely that the FDA will not perform any uncritical inspections, domestic or foreign, until the United States has passed the peak of the current omicron wave.
    • January 4, HHS amended its declaration under the Public Preparedness and Emergency Preparedness Act (PREP) to include pharmacists and certain pharmacy trainees as “qualified persons” who can administer flu vaccines in states where they are not not authorized or certified. The PREP Act allows the Secretary of HHS to issue a statement and grant immunity from liability to such individuals.
    • On January 5, White House Press Secretary Jen Psaki and Port Envoy to the White House Supply Chain Task Force John Porcari tenuous a briefing on the progress of supply chain improvements and new actions to come. Porcari reported that consumers received 97% to 99% of their packages on time or with minimal delays during the holiday season. Porcari added that the ports of Los Angeles and Long Beach are imposing a new tax on long-lived empty containers. Porcari stressed that procedures are in place to prioritize the distribution of medical supplies. One such procedure is to “bulk stow” medical supplies on ships for easy identification and removal. He also discussed the impact of the omicron variant on operations and the procedures in place to deal with any disruptions.
    • On January 7, the FDA amended the EUA of the Moderna COVID-19 vaccine recall. The agency authorized the administration of the booster dose five months (previously six months) after the primary vaccination of the vaccine.
    • On January 10, the FDA Posted draft guidance, “Notification to the FDA of a Permanently Discontinuing or Discontinuing Manufacture of a Device Under 506J of the FD&C Act.” These draft guidelines, authorized under the CARES Act of 2020, are intended to prevent shortages of medical devices before and during a public health emergency and to provide a mechanism by which manufacturers notify the FDA of their intention to cease or suspend production. The draft guidelines apply to “devices essential to public health during a public health emergency, including those that are essential to life, sustaining life or intended for use in the medical care of emergency or during surgery” or “devices for which the FDA determines information about possible significant supply disruptions are needed during or before a public health emergency.” Comments are due by March 11, 2022.
    • On January 10, Senators Gary Peters (D-MI) and Susan Collins (R-ME) introduced S. 3449, a bill that would require foreign drug and device establishments to register with the FDA whether or not the drug or device undergoes further processing at a separate facility outside the United States. States before being imported into the United States. The goal is to give the FDA greater regulatory oversight authority to not only monitor products entering the supply chain and determine shortages, but also ensure that products are safe for the public. The Bill has been referred to the Health, Education, Labor and Pensions (HELP) Committee.
    • On January 13, the Senate HELP committee vote 13 to 8 to advance the President’s nominee for FDA Commissioner Dr. Robert Califf. His confirmation hearing took place on December 14, 2021. The nomination now goes to the Senate for a final vote and confirmation.
    • FDA Center for Drug Evaluation and Research (CDER) published its annual report, “Advancing Health Through Innovation: Approvals of New Drug Therapies”. The report highlights CDER approvals of new therapies, biosimilars, and new indications for approved products. A post-marketing safety surveillance review is also included. The number of products approved (50) was above average despite pandemic-related challenges, with more than half (27) being first-line drugs. CDER also met its action targets under the Prescription Drug User Fees Act for 49 of the 50 submissions.

    The content of this article is intended to provide a general guide on the subject. Specialist advice should be sought regarding your particular situation.

    POPULAR ARTICLES ON: US Food, Drugs, Healthcare, Life Sciences

    read more
    Prescription drugs

    Some northern Manitobans wait weeks for mail and prescription drugs



    OTTAWA — A remote part of northern Manitoba has gone three weeks without mail delivery, which has left residents waiting for prescription drugs.

    “It’s just the attitude of Canada Post, like they don’t care,” said Cecil Thorne, a resident of Pikwitonei, 630 kilometers north of Winnipeg.

    The town of about 80 people sits along a stretch accessible by snow-covered roads or the Hudson’s Bay Railroad, where mail was last delivered Dec. 22.

    Mail normally arrives on the Via Rail train three times a week, although two recent trips have been cancelled.

    The local postmaster told Thorne he could not get permission from Canada Post to come to Thompson and pick up the mail at the post office.

    The crown corporation said it was because the winter road had been closed, which remained the case Friday evening according to the Manitoba 511 website.

    However, Thorne said the postmaster of nearby Thicket Portage still made the trip along that stretch.

    “It appears our mail has been held hostage in Thompson,” said Thorne, who drove himself to Thompson along the winter road and said post office staff could not allow him to pick up his own mail.

    “It’s two crown corporations: Via Rail and Canada Post, and between them you’d think they could figure out a way to deliver the mail.”

    A Canada Post spokesperson said staff are trying to resume postal service as soon as safely possible.

    “We recognize the hardship and frustration faced by residents of Pikwitonei and surrounding communities who have seen mail delivery interrupted,” wrote Phil Legault.

    He said staff tried to find another arrangement as soon as Via Rail canceled its route on January 10, but were unable to arrange a delivery.

    “When notified of rail service interruptions, Canada Post has a process with contingencies that allows us to deliver mail while maintaining its integrity and security,” Legault wrote.

    “We appreciate that customers depend on us and we take that commitment very seriously.”

    Thorne said his part of the province depends on the mail, as they only have internet access through a shoddy satellite system, and most people get their medication through the mail.

    In March 2021, the Free press reported that residents of The Pas were waiting for Christmas packages 10 weeks after the 2020 holiday.

    The state-owned company said at the time that it was overwhelmed by an online delivery boom from November 2020, when the province implemented COVID-19 restrictions prohibiting stores from selling virtually all non-essential items.

    [email protected]

    Dylan Robertson

    Dylan Robertson
    Head of the Parliamentary Office

    In Ottawa, Dylan likes to snoop through access to information requests and ask politicians, “What about Manitoba?

    read more
    Prescription drugs

    Two people arrested after large supply of prescription drugs seized in raid

    Two people have been arrested after a large quantity of prescription drugs were found during a police search in Bolton.

    On Friday, officers from GMP’s Bolton West Neighborhood team executed a warrant at an address on The Pewfist in Wesoughton.

    Inside the premises, officers discovered a large quantity of prescription drugs believed to have been obtained illegally without a prescription.

    READ MORE: Amorous girl, 19, followed her ex, 42, on a getaway to Benidorm, then scratched ‘NONCE’ on the bonnet of his car when he dumped her

    Officers believe the drug was intended to be sold to others.

    As a result of the search, two people were arrested for possession with intent to supply Class A drugs.



    A large quantity of prescription drugs was seized during a police warrant in Bolton

    Both were questioned and then released under investigation.

    Police say they have not yet been able to establish what the drug is and will carry out tests to find out.

    A GMP spokesperson said: ‘We are now beginning the painstaking work (no pun intended) to find out exactly what the drug is.

    “Although the box may say one thing, the origins of these drugs are not known.

    “They could be counterfeit or completely fake and as such we cannot be sure what is in them.”

    Sign up for MEN’s email newsletters to get the latest on sports, news, current affairs and more by following this link.

    read more
    Prescription drugs

    This is why prescription drugs are so expensive

    Oligopoly: a state of limited competition, in which a market is shared by a small number of producers or sellers.

    SALT LAKE CITY — Why are prescription drugs so expensive? An advocate for open access, transparency and competitive markets in the pharmaceutical industry shares his mind-blowing insights into the prescription drug industry and how insiders, whose job it is to watch over consumers, rake in a fortune.

    Welcome to the show

    Heather Kelly, host of Money Making Sense, talks with Antonio Ciaccia, president of 3 Axis Advisors, about pharmacy benefit managers and their role in controlling prescription drug costs.

    “How do prescription drugs get to our pharmacies? asked Kelly.

    In simple terms, Ciaccia explained the main pillars of the prescription drug supply chain:

    • A drug manufacturer sells to a drug wholesaler, such as McKesson, Cardinal Health, or AmerisourceBergen.
    • The wholesaler then sells the medicine to pharmacies, hospitals and medical practices.
    • And with each step, the price of the drug increases for the end consumer.

    PBMs administer prescription drug benefits on behalf of health insurers, Medicare Part D drug plans, large employers and other payers.

    By negotiating with drug manufacturers and pharmacies to control drug spending, PBMs have a significant behind-the-scenes impact on determining total drug costs for insurers, patient access to drugs, and provider compensation. pharmacies, according to the Commonwealth Fund.

    “Keep these discounts to themselves”

    “They’re not doing a great job, especially for my mom,” Kelly said, explaining that her mom, who is on Medicare, pays $250 out of pocket every month for a drug she needs. “She still has to buy four or five more. So these PBMs don’t do a great job. I’m just telling you now.

    “Unfortunately, the system was supposed to work much better,” Ciaccia said.

    He added that PBMs were designed to counterbalance the drugmaker, wholesalers and pharmacies and negotiate greater discounts for consumers.

    “The problem is that PBMs are really good at negotiating these discounts, but they’re even better at keeping these discounts to themselves, often forcing the patient to pay the full list price when they’ve negotiated a price themselves. far different and better for himself,” he said.

    Ciaccia said PBMs used to be just claims processors, but have since landed on the list of America’s biggest and richest companies.

    The top 10 Fortune 500 companies in the United States include:

    • CVS Health, owner of CVS Pharmacy, a chain of retail pharmacies; CVS Caremark, a pharmaceutical benefits manager;
      UnitedHealthGroup, which offers healthcare products and insurance services;
      McKesson, which distributes pharmaceuticals and provides health information technology, medical supplies and care management tools; and
      AmerisourceBergen, a wholesale drug company.

    Who watches the watchdog?

    “They’re bigger than the pharmaceutical companies and drugmakers they were hired to police in the first place,” Ciaccia said.

    He said PBMs ended up making prescription drug pricing more complicated and expensive.

    “The PBM uses all of us as individuals to negotiate deep discounts that they get at the end of the transaction. But they don’t pass them on to us as a patient,” Ciaccia said.

    Heather said her blood was starting to boil “a little bit right now”.

    No one knows the price of drugs

    Ciaccia said if you walked into a grocery store and it cost $20 for a gallon of milk, you’d know right away you were being ripped off. You would take your money to another grocery store where the price of milk would match market expectations.

    It’s “what ultimately holds quality and price accountable in your grocery store. Nobody knows what the prices of thousands of different drugs are or what they should be,” he said.

    Ciaccia said that due to the “enormous” lack of transparency, the pharmaceutical market is ripe for exploitation.

    “Let’s be clear, PBMs aren’t the only villains in the drug supply chain, but they’re the only ones whose existence is predicated on trying to save us money,” he said. declared.

    Related:

    read more
    Medical supplies

    Center helps distribute $25,000 worth of medical supplies | News

    The Center, in partnership with the Louisville-based nonprofit SOS, was able to distribute $25,000 worth of medical supplies and equipment to nonprofit organizations and agencies in the area.

    The Center is a community-focused organization designed to provide a central resource “hub” for organizations serving families and children in Owensboro and Daviess County, making it the ideal partner for SOS in the distributing supplies to agencies and organizations in need, according to Executive Director Erica Wade.

    The supplies were donated by SOS, which collects excess medical supplies from hospitals and medical institutions and redistributes them to local, regional and global communities in need, diverting around 500,000 pounds from landfills each year.

    SOS is a global health organization that focuses on alleviating health disparities in underserved communities by providing much-needed medical supplies and health resources.

    Supplies donated by SOS were delivered to the Center on Thursday morning, where they were then distributed to local nonprofits and other agencies.

    Supplies included personal protective equipment (PPE), hygiene items, first aid and wound care supplies, and medical equipment such as shower chairs, walkers and canes.

    “They use us — knowing that we love collaborating with all of our organizations — to help reach out to all other nonprofits,” she said. “The benefit is that it saves all these nonprofits a fair bit of money on this kind of equipment, like PPE and hygiene items, so they can then invest that money in programming.”

    Supplies were distributed to 21 different organizations and agencies.

    CASA of the Ohio Valley received PPE items, as well as stuffed animals.

    The PPE, according to Executive Director Ashley Evans-Smith, will allow CASA volunteers to make more in-person visits with the children they work with, allowing them to better advocate for those families.

    “Our volunteer advocates have made an effort to stay connected with all of the children they serve throughout COVID,” she said. “This will allow more of them to be able to safely advocate for their children, both by spending more time with them and by safely visiting schools, therapists and, of course, advocating at the courthouse.”

    Daviess County High School also received hygiene items and PPE, which principal Matt Mason says will help children stay safe during the pandemic and ensure schools stay open.

    “All the medical supplies we get, with today’s climate and what we are facing in schools, are going to help us help children,” he said. “Ours are mostly PPE supplies, so that’s going to help. Everything is going to help these days and we just want to keep schools open and keep kids safe. »

    Christie Netherton, [email protected], 270-691-7360

    read more
    Medical products

    2022 Emergency Oxygen Kits Market Analysis by Major Key Players

    New Jersey, United States,-

    A new report titled “(Emergency Oxygen Kits Market)” by Market Research Intellect sheds light on the industry dynamics and current and future trends that play a key role in determining the expansion of the market. ‘business. The report also highlights the key driving factors and restraints affecting the growth. For a comprehensive understanding, experts reviewed regulatory scenarios, market entry strategies, industry best practices, pricing strategies, technology and consumer environment, sales and demand outlook . It also included growth estimates to provide users with accurate statistics and facts. The report will provide readers with a broader and more transparent picture of the overall scenario.

    Corona impact outlook 19

    This section of the report shows the impact of the global Corona outbreak on businesses. The report describes the impact on manufacturing activity, production, demand, supply chain, logistics management and distribution networks. The analysts have highlighted the measures or strategies taken by the company to combat the impact of Corona 19. In addition, they have identified a major opportunity to emerge after Corona 19. This will help players take advantage of the opportunity to recover losses and stabilize the activity.

    Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=559836

    Additionally, market revenue based on region and country is provided in the Emergency Oxygen Kits report. The authors of the report also shed light on common business tactics adopted by players. Key players of the global Emergency Oxygen Kits market and their comprehensive profiles are included in the report. Additionally, investment opportunities, recommendations, and current trends in the global Emergency Oxygen Kits market are mapped by the report. Using this report, key players in the global Emergency Oxygen Kits Market will be able to make sound decisions and plan their strategies accordingly to stay ahead.

    The competitive landscape is an essential aspect that every key player must know. The report highlights the competitive scenario of the Global Emergency Oxygen Kits Market to know the competition at country and global level. Market experts have also provided an outline of each major player in the global Emergency Oxygen Kits market, considering key aspects such as business areas, production, and product portfolio. Additionally, the companies in the report are studied based on key factors such as company size, market share, market growth, revenue, production volume, and profit.

    Major Players Covered by Emergency Oxygen Kits Markets:

    • Mada Medical Products
    • Inc.
    • Marine Medical Antibes
    • Corporate Life
    • FERNO
    • Allied Health Care
    • Mega medical

    Emergency Oxygen Kits Market Split By Type:

    Emergency Oxygen Kits Market Split By Application:

    • Hospitals and Clinics
    • Industrial and factories
    • Public facilities

    The Emergency Oxygen Kits Market report has been segregated into distinct categories such as product type, application, end-user, and region. Each segment is valued based on CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is expected to generate opportunities in the Global Emergency Oxygen Kits Market in the coming years. This segmental analysis will surely prove to be a helpful tool for readers, stakeholders, and market players to get a complete picture of the global Emergency Oxygen Kits market and its growth potential in the years future.

    Get | Discount on the purchase of this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=559836

    Scope of the Emergency Oxygen Kits Market Report

    Report attribute Details
    Market size available for years 2021 – 2028
    Reference year considered 2021
    Historical data 2015 – 2019
    Forecast period 2021 – 2028
    Quantitative units Revenue in USD Million and CAGR from 2021 to 2027
    Segments Covered Types, applications, end users, and more.
    Report cover Revenue Forecast, Business Ranking, Competitive Landscape, Growth Factors and Trends
    Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
    Scope of customization Free report customization (equivalent to up to 8 analyst business days) with purchase. Added or changed country, region and segment scope.
    Pricing and purchase options Take advantage of personalized purchasing options to meet your exact research needs. Explore purchase options

    Regional Analysis of the Emergency Oxygen Kits Market can be represented as follows:

    Each regional Emergency Oxygen Kits industry is carefully researched to understand its current and future growth scenarios. This helps players strengthen their position. Use market research to get a better perspective and understanding of the market and target audience and ensure you stay ahead of the competition.

    Based on geography, the global emergency oxygen kit market has been segmented as follows:

      • North America includes the United States, Canada and Mexico
      • Europe includes Germany, France, UK, Italy, Spain
      • South America includes Colombia, Argentina, Nigeria and Chile
      • Asia Pacific includes Japan, China, Korea, India, Saudi Arabia and Southeast Asia

    Answers to key questions in the report:

    • What is the growth potential of the Emergency Oxygen Kits markets?
    • Which product segment will take the lion’s share?
    • Which regional market will impose itself as a precursor in the years to come?
    • Which application segment will grow at a rapid pace?
    • What are the growth opportunities that may emerge in the Lock Washers industry in the coming years?
    • What are the major challenges that the global emergency oxygen kit markets may face in the future?
    • Who are the leading companies in the Global Emergency Oxygen Kits Market?
    • What are the key trends that are positively impacting market growth?
    • What are the growth strategies considered by the players to maintain their hold in the global emergency oxygen kits market?

    For more information or query or customization before buying, visit @ https://www.marketresearchintellect.com/product/global-emergency-oxygen-kits-market-size-forecast/

    The study thoroughly explores the profiles of major market players and their major financial aspects. This comprehensive business analyst report is useful for all existing and new entrants when designing their business strategies. This report covers the Emergency Oxygen Kits market production, revenue, market share and growth rate for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Historical failure data of emergency oxygen kits from 2016 to 2020 and forecast to 2021-2029.

    About Us: Market Research Intellect

    Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations, in addition to the goal of providing customized and in-depth research studies. range of industries including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. etc Our research studies help our clients to make decisions based on higher data, to admit deep forecasts, to grossly capitalize with opportunities and to optimize efficiency by activating as their belt in crime to adopt a mention precise and essential without compromise. customers, we have provided expert behavior assertion research facilities to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

    Contact us:
    Mr. Edwyne Fernandes
    USA: +1 (650)-781-4080
    UK: +44 (753)-715-0008
    APAC: +61 (488)-85-9400
    US toll free: +1 (800)-782-1768

    Website: –https://www.marketresearchintellect.com/

    read more
    Prescription drugs

    Free prescription drug program in Lake County needs more participation and funding

    CONCORD TOWNSHIP, Ohio — Prescription drug costs are already high and unaffordable for many, but with inflation, some of those prices have skyrocketed.

    Fortunately, there is a program in Lake County that provides people with the medications they need for free. It’s called the Prescription Assistance Program, and it’s for Ohioans who need prescription drugs but can’t afford them, like Marge Burnett.

    As a diabetic, Burnett knows a lot about the cost of prescription drugs, especially when insurance doesn’t foot the bill.

    “Sometimes it triples the cost. And of course now with inflation and all. I mean, some of the drugs are just out of sight. And I probably wouldn’t be able to afford all of that,” Burnett said.

    Luckily, she doesn’t have to worry – thanks to PAP.

    Burnett started volunteering with the program several years ago through the Lake County Retired Senior Volunteer Program (RSVP), then quickly learned she could get help too.

    “It was a blessing in disguise because I’m on social security and low income, so it works better for me,” Burnett said.

    PAP President Joel Lucia said all of these drugs come from multiple sources and are sorted by volunteers at the Northeast Ohio Prescription Drug Repository in Concord Township.

    “The State of Ohio passed a law called the Ohio Drug Repository Law that allowed groups like us and non-profit corporations to form and receive drugs that would otherwise be thrown away and provide them to people who can’t afford their medicine,” said Lucie. “We probably have three-quarters of a million dollars worth of drugs.”

    Any Ohio resident who needs help can call, see if their medications are in stock, and register with a prescription from their doctor. Then the repository sends it by mail. Residents only need to pay a $10 shipping fee.

    Per Ohio drug depot law, the pharmacy does not handle any controlled substances.

    “We don’t do background checks. We do not do financial audits. If they call us, we assume they cannot afford their medication. So give us a call,” Lucia said. “We have people all through our program now, people who, if they didn’t get this medicine, would be unable to buy food for their children or are skipping their medicine.”

    But even with the huge amount of drugs in the repository and the huge need in the community, tens of thousands of dollars worth of drugs are wasted each month simply because there aren’t enough people getting there. enroll in the program.

    “We have around 700 people using the program. We can serve three, four times more,” Lucia said. “The only problem we have is that people think it’s too good to be true. And most people think it’s a scam. It’s not a scam.”

    Additionally, Lucia said they faced another problem.

    “If we can’t increase our funding or if someone else doesn’t pick up the slack, we’ll probably close by September or October next year,” Lucia said. “It would be nice if we could link up with the hospital or another organization that would need our services. This could expand our services.

    Lucia said the program needs around $65,000 a year to keep it running. He gets funding from United Ways of Lake and Geauga counties, but needs more.

    “We operate with limited resources. It’s an absolute minimum. There isn’t a program anywhere in Ohio that will give you the edge we can for the dollar. For every dollar we receive, we give back $5 or $6 to the community,” Lucia said.

    And while they’re trying to figure that out, he wants people who are struggling to make ends meet to know that help is out there.

    “Go spend the money on groceries or gifts for your kids. Get the medicine for free from us. We throw it away. So I don’t know how to convince people that we are real. We are alive. We are here. We are here to help you,” Lucia said.

    Anyone interested in enrolling in the Prescription Assistance Program or wanting to donate money to help keep it open can call 440-350-1470 or visit the program’s website.

    Jade Jarvis is a reporter for News 5 Cleveland. Follow her on Facebook, Twitter, and Instagram.

    Download the News 5 Cleveland app now for more stories from us, plus top news alerts, the latest weather forecasts, traffic updates and more. Download now on your Apple device here, and your Android device here.

    You can also watch News 5 Cleveland on Roku, Apple TV, Amazon Fire TV, YouTube TV, DIRECTV NOW, Hulu Live and more. We are also on Amazon-Alexa devices. Learn more about our streaming options here.

    read more
    Medical supplies

    Life for Relief and Development (LIFE) provides millions of medical supplies worldwide

    Image captured from an ambulance donated by LIFE in Bangladesh

    Image captured of medical supplies distributed in Sierra Leone

    LIFE is providing nearly $10 million worth of medical supplies during 2021 to eight different countries around the world

    SOUTHFIELD, MICHIGAN, USA, January 13, 2022 /EINPresswire.com/ — Many countries around the world lack essential health care and the COVID-19 pandemic has only made these situations worse. To help fill this shortage, Life for Relief and Development (LIFE) sent a total of 21 shipments to eight different countries around the world, totaling almost $10 million during 2021. Countries such as Somalia, Somaliland, Lebanon, Mali, Senegal, Sierra Leone , Pakistan and Ghana have all benefited from these remittances. Medical supplies included a variety of items, as needed, such as PPE, respiratory supplies, surgical equipment, wheelchairs, walkers, crutches, oxygen concentrators and more. Ambulances were also donated to Lebanon and Bangladesh to improve transport to health facilities.

    “The helping hand you extended and your generous donation of medical supplies and medical equipment have been well received and will go to our general hospital to continue serving our community. Thank you once again for your kind and generous support and we look forward to maintaining a liaison with you,” said Sister Nicolas Akiki, Director of Wardieh Hospital – Rosary Sisters Hospital in Lebanon.

    LIFE is constantly striving to get medical supplies to the countries that need them most, and at times like these, many countries are in dire need of help.

    “Health care is a right, not a privilege, and we make it our priority at LIFE to be able to provide it to those in need around the world, giving hope to those who may not see not the light at the end of a very dark time. After all, where there is LIFE, there is hope,” said Dr. Hany Saqr, CEO of LIFE.

    Life for Relief and Development is a global relief and development organization, headquartered in Southfield, Michigan, USA. Life is dedicated to providing humanitarian aid to people regardless of race, gender, religion and cultural background. As a registered 501(c)(3) nonprofit organization, Life has consultative status with the United Nations Economic and Social Council. He is also a member of InterAction, the largest alliance of US-based NGOs and partners of humanitarian agencies such as UNICEF, Brothers Brother Foundation and World Medical Relief. Over the past 29 years, LIFE has distributed more than $520 million in humanitarian and relief aid to more than 46 countries. Life works diligently to help the poor and needy in a number of countries such as: Afghanistan, Ghana, Haiti, Iraq, Jordan, Lebanon, Pakistan, Palestine (through our office in Israel), Sierra Leone, Syria and the United States as well. like other countries. When natural disasters strike, LIFE rushes in to answer the call for help and provide basic humanitarian aid.

    Hala M Sanyurah
    +1 330-815-4706
    [email protected]
    Life for relief and development
    Visit us on social media:
    Facebook
    Twitter
    Other

    read more
    Medical supplies

    ISSA Trust and Partners For World Health Donate $ 57 Million in Medical Supplies

    Issa Trust Foundation (ITF) delivered PPE, medical supplies and equipment worth around $ 57 million to regional health authorities in the West and North East.

    The 40 foot donation container included vital oxygen concentrators, approximately 400,000 KN95 and surgical masks, face shields, approximately 12,000 isolation gowns; 2,888 gallons of bleach and hand sanitizers and wipes; neonatal monitors; patient monitors; lab coats, lab supplies and thousands of gloves and many other items.

    Since 2005, the Issa Trust Foundation has worked to create and strengthen sustainable health and education programs in the communities where Couples Resorts employees live and work.

    The total value of donations made last year is approximately $ 675 million.

    “The pandemic has provided an opportunity to strengthen existing relationships in Jamaica and the United States,” commented Diane Pollard, ITF President and CEO. “Access to equipment and supplies and harnessing resources are all important to impacting children and families, and closer partnerships will provide and facilitate, and ultimately improve, the care of a particular population. vulnerable during this period. “

    Partners for World Health (PWH) and the Issa Trust Foundation (ITF) have been proud collaborators for many years, noted Elizabeth McLellan, President and Founder of PWH.

    “PWH is proud of our ability to support the aspirations of the ITF and help the Jamaican people. In the past year alone, we’ve increased our ability to help our partners with more equipment and supplies, especially to help hospitals, medical teams, and people deal with the additional challenges of COVID-19. I look forward to a long and lasting partnership with the ITF, ”she said.

    read more
    Medical products

    Alimed, Bioseal, Cypress Medical Products, Deroyal, Dukal Corporation, Dynarex Corporation – Industrial Computing

    The global tourniquet market 2021 The report is a collection of details related to each market related parameter. Each aspect is studied in detail in the analysis report. The market analysis report provides a comprehensive analysis of all financial topics associated with the Tourniquet industry. The growth pattern observed in the Turnstile industry performance over time is studied in the market report. The study helps provide an in-depth understanding of fundamental changes in the state of the market over time. The analysis report also provides an in-depth discussion about all the aspects that are likely to impact on the performance of the Tourniquet market.

    The report profiles the following companies, which include

    • Alimed
    • Bioseal
    • Cypress Medical Products
    • Deroyal
    • Dukal Corporation
    • Dynarex Company
    • Graham-Field Inc
    • Integrated Life Sciences
    • Medline
    • Cardinal Health
    • Patterson Medical
    • Stryker
    • Tetra Medical Supply Corp
    • VBM
    • Zimmer
    • Longtai
    • Lantian

    The industry report analyzes the set of deliberate movements in the Tourniquet industry on a global level. The research includes an in-depth study of the growth and development activities taking place in the Tourniquet industry. The research based on the global Turnstiles market provides details associated with fundamental events and investments made in the market. The research provides details related to popular trends widely accepted by entities in the Tourniquet market. The industry analysis report includes an in-depth discussion of several industry analysis strategies used by researchers while documenting the research.

    Download a free sample at: https://courant.biz/report/global-tourniquet-market/61152/

    Global Tourniquets Market: Product Segment Analysis

    • Non-inflatable tourniquets (electronic tourniquet systems connected to inflatable armbands.)
    • Pneumatic tourniquets, the cuffs of which are inflated by compressed gas.

    Global Tourniquets Market: Application Segment Analysis

    • Surgical framework
    • Emergency use

    Global Tourniquet Market: Regional Segment Analysis

    • United States
    • Europe
    • Japan
    • China
    • India
    • South East Asia

    Research includes the analysis of all deliberate movements, policies, technological developments, discoveries, trends, tools, products, development plans, news, etc. The analysis of the global Tourniquet market covers detailed data about the anticipated growth rate for the anticipated era. In addition, a detailed discussion about the future scope of the Turnstile market is also included in the study report. The report on the global Tourniquet industry focuses on the expansion of the market in the coming times. It offers readers detailed data on several strategies and development plans implemented by market entities across the world. The report aims to provide a 360 degree view of the tourniquet industry.

    The content of the study topics includes a total of 10 chapters:

    1. About Tourniquet Industry (Industry Definition, Types, Main Market Activities)
    2. Global Market Competition Landscape (Markets by Regions, Market Revenue (M USD), Market Sales and Growth Rate 2016-2021, Major Players Revenue by Regions)
    3. Global Tourniquet Market Share (Production and Revenue Market Share by Regions and Players)
    4. Supply chain (raw material analysis, raw material market analysis, cost of production, manufacturing equipment and end user analysis)
    5. Company Profiles (Company Details, Product Info, Revenue, Profit Analysis)
    6. Globalization and commerce (business locations, supply channels, marketing strategy, etc.)
    7. Distributors and customers (Information on the main distributors and customers by region)
    8. Import, export, consumption and consumption value by major countries
    9. Global Tourniquet Market Forecast to 2026 (Demand, Price Revenue, Regions, Types, Applications)
    10. Key success factors and market overview

    Access the full report here:https://courant.biz/report/global-tourniquet-market/61152/

    Customization of the report:

    This report can be customized to meet customer requirements. Please connect with our sales team ([email protected]), which will make sure you get a report that’s right for you. You can also contact our leaders at +1 (210) 807 3402 to share your research needs.

    Contact us:
    Nancy smith
    Business sales specialist
    [email protected]
    Phone number: United States: +1 (210) 807 3402
    current.biz

    read more
    Generic drugs

    Bicol consumers urged to buy generic drugs

    Department of Health-Centre for Health Development Regional Office Bicol (PNA file photo)

    TOWN OF LEGAZPI – Bicol’s Department of Health-Center for Health Development (DOH-CHD) in Bicol reported Wednesday that pharmacies in the area have an adequate supply of medications for flu-like symptoms.

    During a press conference, Bicol CHD regional manager Dr. Ernie V. Vera said that although there is a shortage of brand name paracetamol in some pharmacies, generic drugs including paracetamol are always available.

    “Branded and generic drugs have the same effect despite price differences,” he said.

    Vera also encouraged the public to support the use of generic drugs.

    The Bicol DOH-CHD also conducted a rapid survey of area pharmacies to identify the supply status of paracetamol and other flu medications.

    “The survey results show that of the 123 respondents, 23 said they were out of paracetamol while 14 out of 23 said they were out of other flu medication,” said said Noemi Bron, DOH-5 health promotion and education manager. in an interview.

    Bron added that Bicol DOH-CHD discourages the practice of panic buying, hoarding and self-medication.

    “In case of symptoms, it is strongly advised to consult a doctor before buying medication,” she said. (ANP)

    read more
    Medical products

    Greenrise Global’s medical cannabis subsidiary, AMP Alternative Medical Products GmbH, announces the start of dronabinol sales in Germany

    Dronabinol is pure tetrahydrocannabinol (THC) and is registered as an active pharmaceutical ingredient (API) and has been registered for sale with the competent authorities in Germany. Doctors and pharmacists can find more information about the product or order on the AMP website: https://amp-eu.com/doccheck-login/

    AMP and Eurox have entered into a non-exclusive agreement for the marketing and distribution of Dronabinol for sale in pharmacies from February 2022. In preparation for the launch of pharmacy sales, AMP trained its national sales team on the benefits of Dronabinol for patients to physicians and preparation methods for pharmacists.

    Eurox was one of the first medical cannabis companies to produce Dronabinol made in Germany to one of Europe largest GMP facilities located in Hesse, Germany and controls the entire supply chain, from cultivation, production to distribution, ensuring a stable and efficient supply to its customers.

    Neil Smith, the President of Eurox commented: “If you believe in ‘Made in Germany‘, it means Eurox. AMP’s focus on serving German patients and its national sales coverage make it an ideal partner for us.”

    dr. Stefan Feuerstein, President and Director of Greenrise Global and Managing Director of AMP, “The German market is gravitating towards pharmaceuticals as health authorities tighten their regulatory oversight to ensure patient safety. Dronabinol is a well-established product in the Germany, and we expect it to be one of our best-selling products this year.”

    About Eurox Pharma

    Eurox Pharma is one of Europe leading medical cannabis companies. Eurox is vertically integrated, with:

    • Fully owned German subsidiaries responsible for product development and intellectual property.
    • Manufactured to EU GMP in Germany with a German pharmaceutical partner.
    • A cultivation facility at Portugal ensure vertical integration and independence of supply.
    • A significant minority stake in Integro Medical Clinics, a UK-registered medical cannabis clinic.
    • Various high caliber distribution partnerships in Germany and other European countries and its own sales team.

    For more information on Eurox, please visit www.eurox-pharma.com

    About Greenrise Global Brands

    Greenrise Global helps people realize the beneficial properties of cannabis. Greenrise Global is a publicly traded Canadian company with two German operating subsidiaries: Greenrise GmbH (“Greenrise Wellbeing”) and AMP Alternative Medical Products GmbH (“AMP”). Greenrise Wellbeing is a CBD wellness company based in Hamburg, with brands such as Herbify and CANAVEX® in his wallet.

    AMP is based in Erfurt and supplies medical cannabis products to pharmacies across Germany, including the medical cannabis brands of Aphria, Bedrocan, Small green pharmacy and GPAof the branded product line and sold through its national sales team. AMP complies with the German Narcotics Act (BtMG) and the regulatory requirements of the Free State of Thuringia, ensuring that products imported from around the world and sold in Germany Meet the European Union Good Manufacturing Practice (EU-GMP) standard.

    For more information about Greenrise Global, please visit https://greenriseglobal.com/

    FOLLOW US ON:

    Twitter: https://twitter.com/GreenriseGlobal
    LinkedIn: https://linkedin.com/company/greenriseglobal/
    Instagram: https://www.instagram.com/greenriseglobal/

    Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

    This press release contains forward-looking statements based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and their calendar. Although the Company believes that the expectations expressed in these forward-looking statements are based on reasonable assumptions, these statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Accordingly, actual results may differ materially from those expressed in such forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless the otherwise required by law.

    SOURCE Greenrise Global Brands Inc.

    For further information: GREENRISE CONTACT: Hendrik Knopp, Director, [email protected], +1 236-833-1602; Media inquiries: Valeria Bravo, Corporate Communications and Media, [email protected], +1 604-689-7533; AMP CONTACT: Dr. Stefan Feuerstein, President, Greenrise Global Inc., Managing Director, AMP Alternative Medical Products GmbH, [email protected], +49 151 7284 4643; EUROX CONTACT: Jessica Smith, International Director of Public Relations and Marketing, [email protected]

    read more
    Prescription drugs

    Prescription Drugs Market and Forecast 2031

    Prescription Drug Market Size, Global Key Leaders Analysis, Segmentation, Demand, Future Trends, Gross Margin, Impact of Covid-19 on Emerging Technologies, and 2031 Forecast

    According to an analysis by Market Research.biz, a detailed scenario of the market environment is accessible, encompassing the current and future state of the market, according to a new study on the Prescription Drug Market . The scale and possibility of profit, as well as the profile of the producer, manufacturing specifics and consumption trends, have all been studied in depth. In terms of drivers, opportunities, and restraints, the report provides insight into upcoming trends and market dynamics. For various market players to assess the possibility of investments in various regional areas, a thorough assessment of these components is essential.

    Reserve your FREE sample report @
    https://marketresearch.biz/report/prescription-drugs-market/request-sample/

    The precise information of the Prescription Drugs market research is displayed in the form of diagrams and pie charts for the convenience of the readers. The overall presentation of the report is interesting, with a basic structure, specific provisions and data based on reinsurance and awareness. The administrators, key players on the lookout, topographic division, product type and representation, and end customer applications in the market were all analyzed by the survey team. For each segment and region, it calculates transaction revenue.

    The aim of the report is to give a more complete view of the current situation, the economic crisis and the impact of COVID-19 on global activity. Our analysts, who are monitoring the situation around the world in the aftermath of the COVID-19 crisis, believe the market will provide producers with interesting prospects.

    Main key players

    • Novartis AG
    • Pfizer, Inc.
    • Hoffmann-La Roche SA
    • Sanofi
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • AbbVie, Inc.
    • GlaxoSmithKline Plc.
    • AstraZeneca Plc
    • Celgene Corporation
    • Other players

    The market research report divides the Prescription Drugs market into applications, type, and market share. This study covers the analysis of cost structure and growth factor of the industry market in detail. This report also throws light on the fastest growing market segments and various factors driving the growth of these segments.

    Prescription Drug Market Segmentation Overview: –

    Prescription Drug Market, By Product Type

    • Generic medicines
    • Brand name drugs
    • Orphan drugs

    Prescription Drug Market, By Indication

    • Oncology
    • Antidiabetic drugs
    • Vaccines
    • Sensory organs
    • Immunosuppressants
    • Anti coagulants
    • Other indications

    Prescription Drug Market, By Distribution Channel

    • Hospital pharmacies
    • Retail pharmacies and pharmacies
    • Online pharmacies

    Because the Covid-19 eruption has had such a broad impact on businesses, it is becoming increasingly important to understand the implications of all collaborations. With that in mind, we have conducted extensive and unique research into the impact of Covid-19 on the market. Here is a link to the Covid-19 study report: https://marketresearch.biz/report/prescription-drugs-market/request-sample/covid-19-impact/

    Highlights of the Market Research Report

    • Each of the major players is presented in the study report along with a SWOT analysis.
    • The research includes regional analysis along with detailed market segmentation by type and application.
    • An in-depth examination of the drivers, opportunities and restraints of the global market.
    • Research report takes an in-depth look at prescription drugs

    You can ask questions about the study or express your concerns about it here:
    https://marketresearch.biz/report/prescription-drugs-market/#inquiry

    Finally, the analysis highlights the performance of key elements and application components of the Prescription Drugs market in each regional industry. Likewise, orientations stratified on the list of important actors operating within each regional economy inform the competitive dynamics of the regional economy. This allows for a deep and in-depth examination of the entire Prescription Drug Market company. Further, the report includes the global Prescription Drug Market industry forecast for each object, geography, and application sector for the years 2022-2031.

    When preparing a report, the following years are taken into account:

    Historic year: 2015-2020

    Baseline year: 2021

    Forecast period: 2022 to 2031

    Click here for the full INDEX, including data, facts, figures, tables and more:
    https://marketresearch.biz/report/prescription-drugs-market/#toc

    Key Questions Answered In The Prescription Drugs Market Report

    • What are the main drivers and constraints of the market today? What impact will future training and constraints have?
    • What are the main drivers and constraints of the current market? What effect will drivers and restraints have in the future?
    • What are the main effects on the global COVID-19 pandemic market?
    • What is the growth rate of the world market? What will the growth trend be in the future?

    Contact us at

    MarketResearch.Biz (Powered by Prudour Pvt. Ltd.)

    420 Lexington Avenue, Suite 300

    New York, NY 10170,

    United States

    Website:
    https://marketresearch.biz

    Email ID: [email protected]

    © Scoop Media

    read more
    Generic drugs

    New study shows new strategy to improve generic drug quality control


    Read the article

    Chinese researchers have developed a new assessment strategy that can be used to check the quality of generic drugs developed through various processes. The strategy is likely to improve regulatory and decision-making aspects related to pharmaceutical products.

    The study, led by Professor Changqin Hu of the National Food and Drug Control Institute and Professor Xiaomei Ling of Peking University, was published in the Pharmaceutical Analysis Journal. This article was posted on November 4, 2020 and was published in Volume 11, Issue 5 of the journal on October 31, 2021.

    The researchers designed their study to align with current Good Manufacturing Practice quality standards that emphasize the “QbD” concept instead of the traditional “quality by test” approach.

    Prof. Hu explained, “According to the QbD concept, the quality of drugs can be maintained by ensuring the quality at every step of the design, development and manufacturing process. To develop an evaluation strategy that would assess the commonalities between the different generic drug development processes, we sought to define universal indicators and methods to characterize the different processes used for the same pharmaceutical product.

    A range of information related to drug development processes has been documented and available in NESTP and other publications, serving as a resource for designing the desired computational model for quality assessment. Based on this information, the researchers developed an assessment process called “population pharmaceutical quality assessment” to extract process information related to sample population quality and study the intrinsic links between the samples. QbD elements. The strategy thus formulated has proven to be suitable for assessing the quality and risks of the pharmaceutical process.

    Prof. Ling explained, “Our method has provided a scientific tool to objectively and comprehensively assess the consistency of quality and promote the regulatory status of domestic generic drugs.

    To demonstrate the applicability of the new strategy, the researchers performed a consistency assessment of the quality of generic ceftriaxone sodium injections and a risk assessment of the process and monitoring trends in the quality of the injections population. generic aztreonam. Both evaluations gave satisfactory results.

    “The newly developed method has emerged as an efficient and cost-effective way to improve product quality by uncovering key issues in drug quality assessment through data mining. In addition, the method would likely facilitate the timely prediction of various hidden but preventable quality risks, serving the regulatory perspective, ”said Dr Zhao.

    The researchers hope that by taking advantage of the continued addition of data to the knowledge base, they can further improve their strategy for superior decision-making regarding drug regulation.

    read more
    Uncategorized

    You need money now, online payday lenders have it

    What is a payday loan? Payday loans or what are commonly known as payday loans are short term loans provided. These loans are usually relatively small.

    The new Oak Park Financial offerings for online payday loans are designed to help you cover unexpected costs before your payday. These types of loans include loans that do not require collateral, but it is advisable that the number of loan platforms offered is not very large, ranging from USD to 3 million. And the loan term is available between 16 – 50 days

    This type of loan is of great interest as the loan amount can be obtained in a matter of hours, or at most one business day.

    Payday Loans Need No Warranty

    It should be noted, however, that the loan sector is not a guaranteed loan, so the terms of interest apply are slightly different from the consumer credit interest generally. When a lender approves your cash loan, it means that the lender believes that you as a potential lender can repay the loan on schedule.

    Current developments allow lenders to complete loan applications online (or in some cases fax, especially when documents are needed). The funds will then be transferred by direct deposit to the borrower’s account, and the repayment of the loan and/or financial fees will be electronically deducted from the borrower the next day.

    Benefits of Using a Payday Loan

    1. Provide Solutions When There Is No Choice

    If you have a financial problem but don’t know who to rely on, you have this solution, where the loans you will be able to pay can be paid off until your next paycheck, while existing funds can be used for your urgent needs.

    2. Fast and Comfortable

    These loans provide the convenience of applying for an online application. After submitting your application through the payday loan website, you will receive information if your application is approved shortly after completing the form.

    The funds will then be credited to your account within a few hours or days. The application process for the loan is done online. You will no longer need to visit the office and make an appeal with the loan officer. You can submit your application from your home or work.

    In addition to these loans, you can spend the money you earn on loans for any use, including paying your electric bills or repairing your car. Unlike certain loans that can only spend money on specific needs such as car loans, home or property loans.

    3. The simplicity of the Terms

    Getting a Payday loan can be quite easy as you just need to meet some basic requirements. The most important requirement is a stable source of income. As long as your income is consistent and verifiable, you are almost guaranteed a loan.

    When public loans require collateral. You do not need to provide a guarantee for a payday loan. Your stable income is proof enough to lend that you can pay off your loan. Other requirements are active accounts and are registered as permanent residents.

    Payday loan loans are one of the fast and convenient ways to handle your financial situation in need of fast funds. You can get cash within a few hours without the need for a guarantee. You can also borrow money for any purpose.

    4. Unlimited Fund Allocation

    Fund allocation is not limited to certain things, as long as you pay off your loan with your next paycheck. However, you have a legal obligation to pay off your loan amount on time to avoid penalties and lawsuits.

    read more
    Generic drugs

    Dabawenyos accumulates brand-name paracetamol but supply of generic drugs is stable

    DAVAO CITY (MindaNews / Jan 08) – Pharmacies here are running out of branded paracetamol due to hoarding, but the Davao chapter of the Pharmacists Association of the Philippines (PPHA) has assured the public that the supply of generic drugs remained stable.

    PPHA Davao President Dr Kenny James Merin told a virtual reporter on Friday that Dabawenyos may no longer be able to buy branded paracetamol at local pharmacies due to fears over the threat of the variant. Omicron in the country triggered panic buying behavior. .

    “Don’t panic, buy. If you buy when you don’t need it, those who really need paracetamol won’t be able to buy, ”he added.

    The city predicts an increase in coronavirus cases by the third or fourth week of this month due to holiday gatherings.

    As of January 7, the Department of Health (DOH) -Davao reported 99 new cases, bringing the total number of cases to 54,124 with 243 active, 52,088 recovered and 1,793 dead.

    Merin said some pharmacies may run out of stocks of branded paracetamol, but told the public there is no need to panic buying because they can still get generic drugs.

    Merin said the generic drugs are as effective as their branded counterparts.

    These days, he said, many customers buy paracetamol in boxes.

    “Rest assured that our pharmacies are replenishing their stocks. We have generic or alternative brands of our paracetamol. So those who need it, they can always get paracetamol, ”he said.

    He added that pharmacies have been instructed to limit each customer’s purchase to one or two tampons pending replenishment of stocks “to ensure that everyone in our community will have access to paracetamol if they have any. need, especially for those with flu or flu-like symptoms.

    “Currently, the stock level of our paracetamol is really low. Why is that? In every business we have what is called inventory leveling and it will be depleted by the sudden increase in demand. It doesn’t mean that we can’t look for stocks anymore, ”he said.

    He said they expect more stocks of paracetamol to arrive in the city in the coming weeks.

    He warned the public to be cautious in purchasing paracetamols online and at other stores amid the proliferation of counterfeit drugs.

    “Buy only from legitimate pharmacies. Do not buy in other stores without a pharmacist because you are putting yourself in danger. If you buy from legitimate pharmacies, you can rest assured that their generic drugs are as effective as brand name drugs, ”he said.

    He added that the Food and Drugs Administration (FDA) recently warned against the proliferation of counterfeit drugs.

    He said counterfeit drugs can cause serious health problems.

    “Don’t compromise your security. The selling price of online sellers will no longer matter, because what matters is whether they have the power to sell. If they are not regulated by the FDA, it only means that the quality of their product is not verified, ”he added. (Antonio L. Colina IV / MindaNews)

    read more
    Generic drugs

    Fitch, Health News, ET HealthWorld

    India will become the world’s largest production hub for general Covid-19 antiviral drugs after the Drugs Controller granted emergency use authorization to several pharmaceutical companies in the country to manufacture and market generic versions of molnupiravir, said Fitch Solutions on Friday.

    Increased access to molnupiravir will keep hospitalizations and deaths in India manageable as Omicron infections rise, Fitch Solutions said in a report.

    Those that have obtained clearance from the Drugs Controller General of India (DCGI) include Dr. Reddy’s Laboratories, Torrent Pharmaceuticals, Cipla, Sun Pharma, Natco Pharma, Viatris, Hetero Drugs and Mankind Pharma.

    Lagevrio (Molnupiravir) was developed by Merck and Ridgeback Biotherapeutics, and it is the first-ever oral antiviral drug for the treatment of high-risk adults with mild to moderate Covid-19.

    Following clearance, Cipla, Sun Pharma and Dr. Reddy’s Laboratories are expected to market molnupiravir capsules in the coming weeks, with other companies to follow.

    “This will make India the world’s largest hub for the production of generic Covid-19 antiviral drugs,” he said. “Efficacy of molnupiravir during its Phase III MOVe-OUT trial has been broadly promising, with a 50% reduction in hospitalizations and deaths in early-stage infections.” However, safety concerns remain over its risk of inducing harmful mutagenesis if the drug is prescribed worldwide, creating the potential for new strains of Covid-19.

    The second wave of Covid-19 in India peaked in April and May 2021 when daily average cases exceeded 4 lakh. The number of cases has fallen significantly since then, with the national tally remaining below 10,000 cases per day for the rest of the year.

    However, in recent days there has been an increase in daily cases of Covid-19 driven by the Omicron variant which is expected to overtake Delta as the dominant variant.

    On January 6, 2022, Covid-19 cases rose to 1,17,100, with 3,007 cases confirmed to be the Omicron variant, according to the Union Health Ministry.

    “Additionally, India continues to lag behind in its Covid-19 vaccine rollout target as 44.5% of the population has been fully vaccinated,” Fitch Solutions quoted Our World In Data as saying. “Therefore, given the slow pace of vaccination and the recent sharp increase in Covid-19 cases, generic versions of molnupiravir could significantly reduce the risk of hospitalization or death.”

    Generic molnupiravir will increase access in India and other low- and middle-income (LMIC) countries, while simplifying current supply chain barriers, he said.

    A full five-day course of molnupiravir in the United States costs around US$712 (Rs. 52,909). Generic versions of the drug will cost between $18.79 (about Rs. 1,400) and $21.48 (about Rs. 1,600) for a five-day course, which is significantly lower, according to Fitch Solutions.

    For example, Dr. Reddy has priced his generic version of molnupiravir, molflu, at US$0.4693 (Rs. 35) per capsule and US$18.79 (Rs. 1,400) for a five-day course of 40 capsules. .

    “With this relatively low cost, we expect generic versions of molnupiravir to significantly increase access in India and other LRICs after regulatory approvals,” he said.

    Additionally, these oral antiviral drugs will result in lower transportation and distribution costs compared to intravenous Covid-19 antivirals such as Ronapreve (casirivimab/imdevimab) or Veklury (remdesivir).

    Having a solid and compact shape, oral medications do not require glass vial containment requirement and the tablets can be packed tightly without risk of breakage. Likewise, more of the drug can be contained in a defined space, increasing the rate at which the drug can be dispensed, he added.

    read more
    Generic drugs

    Outlook Analysis of Generic Inhalation Nasal Spray Drugs Market 2021 by Major Key Players

    New Jersey, United States, – The global Generic Inhalation and Nasal Spray Drugs Market report is one of the most comprehensive and significant addition to the market research archive of Market Research Intellect. Provides detailed research and analysis of the major aspects of the global Generic Inhalation and Nasal Spray Drugs market. The market analysts who produced the report have provided detailed information on key growth drivers, restraints, challenges, trends, and opportunities to provide a comprehensive analysis of the global Generic Inhalation and Nasal Spray Drugs market. Market players can use the analysis of market dynamics to plan effective growth strategies and prepare for future challenges in advance.

    Each trend in the global Generic Inhalation Nasal Spray Drugs market is carefully analyzed and researched by market analysts. Market analysts and researchers have performed an in-depth analysis of the global Generic Inhalation Nasal Spray market using research methodologies such as Pestle and Porter’s Five Forces Analysis.

    They have provided accurate and reliable market data and helpful recommendations with the aim of helping players gain insight into the overall current and future market scenario. The Generic Inhalation and Nasal Spray Drugs report includes in-depth research on potential segments, including product types, applications, and end-users, along with their contribution to the overall market size.

    Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=276114

    The Major Players Covered By Generic Inhalation And Nasal Spray Drugs Markets:

    • Suits you
    • Beximco Pharma
    • Sandoz (Novartis SA)
    • Allergan SA
    • Cipla
    • Mylan
    • Sun Pharma (Ranbaxy)
    • Akorn
    • Nephron Pharma
    • Apotex
    • Hikma (Roxane)
    • XIANJU PHARMA

    Market segmentation of automated drug delivery systems:

    The Automated Drug Delivery Systems market report has categorized the market into segments comprising product type and application. Each segment is evaluated based on share and growth rate. Meanwhile, analysts looked at potential areas that could prove rewarding for builders in the years to come. The regional analysis includes reliable forecast on value and volume, thereby helping market players to gain in-depth insights into the entire industry.

    Generic inhalation and nasal spray market breakdown by type:

    • Corticosteroids
    • Bronchodilators
    • Combinations
    • Decongestant sprays
    • Others

    Generic Inhalation Nasal Spray Drugs Market Split By Application:

    • Asthma
    • COPD
    • Allergic rhinitis
    • Other

    Based on geography: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina and Colombia, etc.), Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa).

    Get | Discount on purchasing this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=276114

    Scope of Generic Inhalation Nasal Spray Drugs Market Report

    Report attribute Details
    Market size available for years 2021 – 2028
    Reference year considered 2021
    Historical data 2015 – 2019
    Forecast period 2021 – 2028
    Quantitative units Revenue in millions of USD and CAGR from 2021 to 2027
    Covered segments Types, applications, end users, etc.
    Cover of the report Revenue forecast, company ranking, competitive landscape, growth factors and trends
    Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
    Scope of customization Free customization of reports (equivalent to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
    Price and purchase options Take advantage of custom shopping options to meet your exact research needs. Explore purchasing options

    Key questions answered in the report:

    • What is the growth potential of the generic inhalation and nasal spray markets?
    • Which product segment will take the lion’s share?
    • Which regional market will emerge as a precursor in the years to come?
    • Which application segment will grow at a sustained rate?
    • What are the growth opportunities that could emerge in the lock washer industry in the years to come?
    • What are the main challenges that the global generic inhalation and nasal spray markets may face in the future?
    • Who are the major companies in the global generic inhalation and nasal spray market?
    • What are the main trends that are positively impacting the growth of the market?
    • What are the growth strategies considered by the players to maintain their grip on the global Generic Inhalation and Nasal Spray Drugs market?

    For more information or a query or a personalization before purchasing, visit @ https://www.marketresearchintellect.com/product/global-inhalation-nasal-spray-generic-drugs-market-size-and-forecast/

    The study thoroughly explores the profiles of the major market players and their main financial aspects. This comprehensive business analyst report is useful for all existing and new entrants when designing their business strategies. This report covers the production, revenue, market share and growth rate of the Generic Inhalation and Nasal Spray Drugs market for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Historical generic inhalation and nasal spray distribution data from 2016 to 2020 and forecast to 2021-2029.

    About Us: Market Research Intelligence

    Market Research Intellect provides syndicated and personalized research reports to clients from various industries and organizations in addition to the goal of providing personalized and in-depth research studies. range of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. Etc. Our research studies help our clients make more data-driven decisions, admit push predictions, grossly capitalize on opportunities, and maximize efficiency by acting as their criminal belt to adopt accurate mention and essential without compromise. clients, we have provided expertly-behaved affirmation research facilities to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

    Contact us:
    Mr. Edwyne Fernandes
    United States: +1 (650) -781-48080
    UK: +44 (753) -715-0008
    APAC: +61 (488) -85-9400
    US Toll Free: +1 (800) -782-1768

    Website: –https://www.marketresearchintellect.com/

    read more
    Prescription drugs

    Analysis of 2021 Non-prescription Drugs Market Outlook by Major Key Players

    New Jersey, United States, – The Global Non-Prescription Drugs Market report is one of the most comprehensive and significant addition to the market research archive of Market Research Intellect. Provides detailed research and analysis of the major aspects of the global Non-Prescription Drugs market. The market analysts who produced the report have provided in-depth information on key growth drivers, restraints, challenges, trends, and opportunities to provide a comprehensive analysis of the global Non-Prescription Drugs Market. Market players can use the analysis of market dynamics to plan effective growth strategies and prepare for future challenges in advance.

    Each trend in the global Non-Prescription Drugs market is carefully analyzed and researched by market analysts. Market analysts and researchers have performed an in-depth analysis of the global non-prescription drug market using research methodologies such as Pestle and Porter’s Five Forces Analysis.

    They have provided accurate and reliable market data and helpful recommendations with the aim of helping players gain insight into the overall current and future market scenario. The Non-prescription Drugs report includes in-depth research on potential segments including product types, applications, and end-users, along with their contribution to the overall market size.

    Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=215723

    The main players covered by the non-prescription drugs markets:

    • Pfizer
    • rock
    • Sanofi
    • Johnson & johnson
    • Merck & Co. (msd)
    • Novartis
    • Abbvie
    • Gilead Sciences
    • Glaxosmithkline (gsk)
    • Amgen
    • Astrazeneca
    • Bristol-myers Squibb
    • Eli lilly
    • Suits you
    • Bayer
    • Novo Nordisk
    • Allergan
    • Takeda
    • Boehringer Ingelheim
    • Takeda

    Market segmentation of automated drug delivery systems:

    The Automated Drug Delivery Systems market report has categorized the market into segments comprising product type and application. Each segment is evaluated based on share and growth rate. Meanwhile, analysts looked at potential areas that could prove rewarding for builders in the years to come. The regional analysis includes reliable forecast on value and volume, thereby helping market players to gain in-depth insights into the entire industry.

    Market Breakdown of Non-Prescription Drugs by Type:

    Non-prescription Drugs Market Split By Application:

    Based on geography: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina and Colombia, etc.), Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa).

    Get | Discount on purchasing this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=215723

    Scope of Non-Prescription Drugs Market Report

    Report attribute Details
    Market size available for years 2021 – 2028
    Reference year considered 2021
    Historical data 2015 – 2019
    Forecast period 2021 – 2028
    Quantitative units Revenue in millions of USD and CAGR from 2021 to 2027
    Covered segments Types, applications, end users, etc.
    Cover of the report Revenue forecast, company ranking, competitive landscape, growth factors and trends
    Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
    Scope of customization Free customization of reports (equivalent to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
    Price and purchase options Take advantage of custom shopping options to meet your exact research needs. Explore purchasing options

    Key questions answered in the report:

    • What is the growth potential of the non-prescription drug markets?
    • Which product segment will take the lion’s share?
    • Which regional market will emerge as a precursor in the years to come?
    • Which application segment will grow at a sustained rate?
    • What are the growth opportunities that could emerge in the lock washer industry in the years to come?
    • What are the main challenges that the global Non-Prescription Drug markets could face in the future?
    • Who are the leading companies in the global non-prescription drug market?
    • What are the main trends that are positively impacting the growth of the market?
    • What are the growth strategies envisioned by the players to maintain their grip on the global Non-Prescription Drugs market?

    For more information or a query or a personalization before purchasing, visit @ https://www.marketresearchintellect.com/product/global-non-prescription-drugs-market-size-and-forcast/

    The study thoroughly explores the profiles of the major market players and their main financial aspects. This comprehensive business analyst report is useful for all existing and new entrants when designing their business strategies. This report covers the production, revenue, market share and growth rate of the Non-prescription Drugs market for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Historical non-prescription drug breakdown data from 2016 to 2020 and forecast to 2021-2029.

    About Us: Market Research Intelligence

    Market Research Intellect provides syndicated and personalized research reports to clients from various industries and organizations in addition to the goal of providing personalized and in-depth research studies. range of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. Etc. Our research studies help our clients make more data-driven decisions, admit push predictions, grossly capitalize on opportunities, and maximize efficiency by acting as their criminal belt to adopt accurate mention and essential without compromise. clients, we have provided expertly-behaved affirmation research facilities to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

    Contact us:
    Mr. Edwyne Fernandes
    United States: +1 (650) -781-48080
    UK: +44 (753) -715-0008
    APAC: +61 (488) -85-9400
    US Toll Free: +1 (800) -782-1768

    Website: –https://www.marketresearchintellect.com/

    read more
    Generic drugs

    Drug covid: India will become a hub for generic antiviral drugs Covid-19: Fitch

    India will become the world’s largest general production center of Covid-19 antiviral drugs after the drug controller granted emergency use authorization to several pharmaceutical companies in the country to manufacture and market generic versions of molnupiravir, Fitch Solutions said Friday.

    Increased access to molnupiravir will keep hospitalizations and deaths in India manageable as Omicron infections increase, Fitch Solutions said in a report.

    Those who have obtained authorization from the Drugs Controller General of India (DCGI) include Dr. Reddy’s, Torrent Pharmaceuticals, Cipla, Sun Pharma, Natco Pharma, Viatris, Hetero Drugs and Mankind Pharma laboratories.

    Lagevrio (Molnupiravir) was developed by Merck and Ridgeback Biotherapeutics, and it is the first-ever oral antiviral drug for the treatment of high-risk adults with mild to moderate Covid-19.

    Following the clearance, Cipla, Sun Pharma and Dr Reddy’s labs are expected to launch molnupiravir capsules in the coming weeks, with the other companies to follow.

    “This will make India the world’s largest production center for generic Covid-19 antiviral drugs,” he said. “The efficacy of molnupiravir during its phase III MOVe-OUT trial has been broadly promising, with a 50% reduction in hospitalizations and deaths in early-stage infections.” However, safety concerns remain about its risk of inducing harmful mutagenesis if the drug is prescribed globally, creating potential for new strains of Covid-19.

    The second wave of Covid-19 in India peaked in April and May 2021, when the daily average of cases exceeded 4 lakh. The number of cases has declined significantly since then, with the national tally remaining below 10,000 cases per day for the rest of the year.

    However, in recent days there has been an increase in daily cases of Covid-19 driven by the Omicron variant which is expected to overtake Delta as the dominant variant.

    On January 6, 2022, Covid-19 cases rose to 1,17,100, of which 3,007 were confirmed to be the Omicron variant, according to the Union Ministry of Health.

    “Additionally, India continues to lag behind in its Covid-19 vaccine deployment target, as 44.5% of the population has been fully vaccinated,” Fitch Solutions said citing Our World In Data. “Therefore, given the slow pace of vaccination and the recent sharp increase in Covid-19 cases, generic versions of molnupiravir could significantly reduce the risk of hospitalization or death. ”

    Generic molnupiravir will increase access in India and other low and middle income countries (LMICs), while simplifying current supply chain barriers, he said.

    A full five-day treatment with molnupiravir in the US costs around $ 712 (around Rs. 52,909). Generic versions of the drug will cost between $ 18.79 (around Rs 1,400) and $ 21.48 (around Rs 1,600). ) for a five-day course, which is significantly lower, according to Fitch Solutions.

    For example, Dr Reddy priced his generic version of molnupiravir, molflu, at $ 0.4693 (Rs 35) per capsule and $ 18.79 (Rs 1,400) for a five-day course of 40 capsules. .

    “With this relatively low cost, we expect generic versions of molnupiravir to dramatically increase access in India and other LMICs following regulatory approvals,” he said.

    Additionally, these oral antivirals will lead to lower transportation and distribution costs compared to Covid-19 intravenous antivirals such as Ronapreve (casirivimab / imdevimab) or Veklury (remdesivir).

    Having a solid and compact form, oral medications do not require confinement of the glass vials and the tablets can be packaged tightly without risk of breakage. Likewise, a larger amount of the drug can be contained in a defined space, increasing the speed at which the drug can be dispensed, he added.

    read more
    Generic drugs

    India to become hub for generic Covid-19 antiviral drugs: Fitch

    India will become the world’s largest production hub for general Covid-19 antiviral drugs after the drug controller granted emergency use authorization to several pharmaceutical companies in the country to manufacture and market generic versions of molnupiravir, said Fitch Solutions on Friday.

    Increased access to molnupiravir will keep hospitalizations and deaths in India manageable as Omicron infections rise, Fitch Solutions said in a report.

    Those that have obtained clearance from the Drugs Controller General of India (DCGI) include Dr. Reddy’s Laboratories, Torrent Pharmaceuticals, Cipla, Sun Pharma, Natco Pharma, Viatris, Hetero Drugs and Mankind Pharma.

    Lagevrio (Molnupiravir) was developed by Merck and Ridgeback Biotherapeutics, and it is the first-ever oral antiviral drug for the treatment of high-risk adults with mild to moderate Covid-19.

    Following clearance, Cipla, Sun Pharma and Dr. Reddy’s Laboratories are expected to market molnupiravir capsules in the coming weeks, with other companies to follow.

    “This will make India the world’s largest hub for the production of generic Covid-19 antiviral drugs,” he said. “Efficacy of molnupiravir during its Phase III MOVe-OUT trial has been broadly promising, with a 50% reduction in hospitalizations and deaths in early-stage infections.” However, safety concerns remain over its risk of inducing harmful mutagenesis if the drug is prescribed globally, creating the potential for new strains of Covid-19.

    The second wave of Covid-19 in India peaked in April and May 2021 when daily average cases exceeded 4 lakh. The number of cases has fallen significantly since then, with the national tally remaining below 10,000 cases per day for the rest of the year.

    However, in recent days there has been an increase in daily cases of Covid-19 driven by the Omicron variant which is expected to overtake Delta as the dominant variant.

    On January 6, 2022, Covid-19 cases rose to 117,100, with 3,007 cases confirmed to be the Omicron variant, according to the Union Health Ministry.

    “Additionally, India continues to lag behind in its Covid-19 vaccine rollout target as 44.5% of the population has been fully vaccinated,” Fitch Solutions quoted Our World In Data as saying. “Therefore, given the slow pace of vaccination and the recent sharp increase in Covid-19 cases, generic versions of molnupiravir could significantly reduce the risk of hospitalization or death.”

    Generic molnupiravir will increase access in India and other low- and middle-income (LMIC) countries, while simplifying current supply chain barriers, he said.

    A full five-day course of molnupiravir in the US costs around $712 ( 52,909). Generic versions of the drug will cost between 18.79 USD (approximately 1,400) at $21.48 (approx. 1,600) for a five-day course, which is significantly lower, according to Fitch Solutions.

    For example, Dr. Reddy priced his generic version of molnupiravir, molflu, at $0.4693 ( 35) per capsule and $18.79 ( 1,400) for a five-day course of 40 capsules.

    “With this relatively low cost, we expect generic versions of molnupiravir to significantly increase access in India and other LRICs after regulatory approvals,” he said.

    Additionally, these oral antiviral drugs will result in lower transportation and distribution costs compared to intravenous Covid-19 antivirals such as Ronapreve (casirivimab/imdevimab) or Veklury (remdesivir).

    Having a solid and compact shape, oral medications do not require glass vial containment requirement and the tablets can be packed tightly without risk of breakage. Likewise, more drug can be contained in a defined space, increasing the rate at which the drug can be dispensed, he added.

    To subscribe to Mint Bulletins

    * Enter a valid email address

    * Thank you for subscribing to our newsletter.

    Never miss a story! Stay connected and informed with Mint. Download our app now!!

    read more
    Medical supplies

    Research report explores disposable medical supplies market to be valued at $ 48,630 million by 2018 to 2026

    Disposable Medical Supplies Market

    Disposable medical supplies are medical consumables such as gloves, hypodermic needles, syringes, and applicators, among others.

    Disposable medical supplies market by type (diagnostic supplies, dialysis consumables, radiology consumables, infusion products, intubation and ventilation supplies, hypodermic products) ”

    – Allied market studies

    NE WIN SIVERS DRIVE, PROVINCE: – PORTLAND, USA, Jan 6, 2022 /EINPresswire.com/ – According to a new report released by Allied Market Research titled Disposable Medical Supplies Market by Type, Application, and End User: Opportunity Analysis Global and Industry Forecast, 2017-2023 ”, the global disposable medical supplies market was valued at $ 48,630 million in 2016 and is expected to reach $ 80,252 million by 2023, with a CAGR of 7.3 % from 2017 to 2023. Dialysis The consumables segment represented around a quarter of the global market in 2016.

    Disposable medical supplies are medical consumables such as gloves, hypodermic needles, syringes, and applicators, among others, which are discarded or discarded after each use. These medical supplies are essential in reducing the risk of hospital acquired infections, needle stick injuries and other communicable diseases. These supplies are prescribed or ordered by a physician and are used primarily for medical purposes in healthcare facilities as well as by home care patients.

    𝗥𝗲𝗺𝗮𝗶𝗻 ‘𝗔𝗵𝗲𝗮𝗱’ 𝗢𝗳 𝗬𝗼𝘂𝗿 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗼𝗿𝘀, 𝗙𝗼𝗿 𝗔 𝗦𝗮𝗺𝗽𝗹𝗲 @ https://www.alliedmarketresearch.com/request-sample/4554

    -𝟭𝟵 𝗦𝗰𝗲𝗻𝗮𝗿𝗶𝗼:

    1) The impact of COVID-19 on the disposable medical supplies market is unpredictable and is expected to remain in effect until the fourth quarter of 2021.

    2) The COVID-19 outbreak has forced governments around the world to put in place strict containment measures and ban the import and export of non-essential items for most of 2021. This resulted in a sudden drop in the availability of important raw materials.

    3) Additionally, nationwide shutdowns have forced manufacturing facilities to partially or completely shut down operations.

    4) The negative impacts of the COVID-19 pandemic have resulted in delays in activities and initiatives regarding the development of reliable and innovative drone analysis systems on a global scale.

    𝗗𝗲𝘁𝗮𝗶𝗹𝗲𝗱 𝗖𝗼𝘃𝗶𝗱-𝟭𝟵 𝗜𝗺𝗽𝗮𝗰𝘁 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗮𝘁- https://www.alliedmarketresearch.com/request-for-customization/4554?reqfor=covid

    𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗳𝗼𝗿 𝗦𝘁𝗮𝗸𝗲𝗵𝗼𝗹𝗱𝗲𝗿𝘀:

    • This report features detailed quantitative analysis along with current global Disposable Medical Supplies market trends from 2018 to 2025 to identify existing opportunities along with strategic assessment.

    • Disposable medical supplies market forecast is studied from 2018 to 2025.

    • The Disposable Medical Supplies market size and estimates are based on a comprehensive analysis of major developments in the Endoscopic Retrograde Cholangiopancreatography industry.

    • Qualitative analysis based on innovative products facilitates strategic business planning.

    • Development strategies adopted by major market players are mobilized to understand the competitive scenario of the Disposable Medical Supplies market.

    Asia-Pacific is expected to experience the highest growth rate throughout the forecast period and is expected to continue this trend, due to high population density in countries like India and China. In addition, the rapid growth of the geriatric population and the increase in the number of chronic diseases in developing economies are driving the growth of the market.

    𝗥𝗲𝗽𝗼𝗿𝘁:

    Abbott Laboratories, Bayer AG, Becton, Dickinson, and Company, Cardinal Health Incorporated, Domtar Corporation, Medtronic plc, 3M Company, Braun (B.) Melsungen AG, Terumo Corporation and Smiths Group plc. Other players operating in the value chain are Bard (CR) Incorporated, BarrierSafe Solutions International, Cederroth Intressenter AB, Johnson & Johnson, Ansell Limited, Teleflex Incorporated, Derma Sciences Incorporated and Centaur Guernsey LP Incorporated.

    𝗬𝗲𝗮𝗿 𝗦𝗮𝗹𝗲 𝐔𝐩 𝐓𝐨 𝟮𝟱% 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭, 𝐓𝐢𝐥𝐥 𝟭𝟱𝐭𝐡 𝐨𝐟 𝐉𝐚𝐧𝐮𝐚𝐫𝐲 𝟮𝟬𝟮𝟮❞

    𝗚𝗲𝘁 𝗗𝗶𝘀𝗰𝗼𝘂𝗻𝘁, 𝗠𝗮𝗸𝗲 𝗣𝘂𝗿𝗰𝗵𝗮𝘀𝗲 𝗜𝗻𝗾𝘂𝗶𝗿𝘆 𝗮𝘁 – https://www.alliedmarketresearch.com/purchase-enquiry/4554

    𝗔𝘀𝗸𝗲𝗱 𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻𝘀?

    Q1. What is the total market value of the Disposable Medical Supplies market report?
    Q2. What would be the forecast period in the market report?
    Q3. What is the market value of the disposable medical supplies market in 2025?
    Q4. What is the calculated base year in the Disposable Medical Supplies Market report?
    Q5. Who are the major companies that hold the market share in the Disposable Medical Supplies market?

    𝗕𝗮𝘀𝗶𝗰 𝗣𝗹𝗮𝗻 | 𝗔𝗰𝗰𝗲𝘀𝘀 | 𝗬𝗲𝗮𝗿 𝗦𝘂𝗯𝘀𝗰𝗿𝗶𝗽𝘁𝗶𝗼𝗻 |

    Sign up for the Avenue subscription to access over 12,000 company profiles and over 2,000 niche market research reports at $ 699 per month per seat. For one year, the customer must purchase a minimum package of 2 places.

    𝗳𝗼𝗿 𝟭𝟰 𝗱𝗮𝘆𝘀 𝗳𝗿𝗲𝗲 𝘁𝗿𝗶𝗮𝗹: https://www.alliedmarketresearch.com/avenue/trial/starter

    “We have also published some syndicated market research in the same area that you may be interested in. Below is the title of the report for your reference, considering the impact of Covid-19 on this market, which will help you assess the aftermath of the pandemic on the short and long term growth trends of this market. Marlet. “

    𝗶𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 (𝗚𝗲𝘁 𝘂𝗽 𝘁𝗼 𝟮𝟱% 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁 𝘁𝗶𝗹𝗹 𝟭𝟱 𝗝𝗮𝗻𝘂𝗮𝗿𝘆 𝟮𝟬𝟮𝟮):

    Russia In Vitro Fertilization (IVF) Market
    Disposable Gloves Market

    𝐔𝐬

    Allied Market Research (AMR) is a full-service market research and business consulting arm of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global businesses as well as medium and small businesses with unmatched quality of “market research reports” and “business intelligence solutions”. AMR has a focused vision to provide business information and advice to help its clients make strategic business decisions and achieve sustainable growth in their respective market area.

    Pawan Kumar, CEO of Allied Market Research, leads the organization towards delivering high quality data and information. We have professional relationships with various companies, which helps us extract market data which helps us generate accurate research data tables and confirm the highest accuracy in our market forecast. Each of the data presented in the reports we publish is taken from primary interviews with senior officials of the main companies in the field concerned. Our secondary data sourcing methodology includes in-depth online and offline research and discussions with industry-savvy professionals and analysts.

    David Corréa
    Allied analytics srl
    +1 503-894-6022
    write us here
    Visit us on social networks:
    Facebook
    Twitter
    LinkedIn

    read more
    Prescription drugs

    Doctors may be able to reduce the number of prescription drugs older patients take

    Dublin, Ireland – Do Seniors Really Need to Take a Plethora of Different Medicines to Stay Healthy? A new study finds that many patients could and probably should throw away some of their prescriptions that are no longer beneficial to their health.

    Researchers at RCSI University of Medicine and Health Sciences have found that medical interventions by a patient’s doctor can eliminate old drugs that can combine with other drugs to cause more harm than good. For many seniors, the number of prescription drugs they take seems to increase with their age. Previous studies show that one in three older Americans is taking prescription drugs that are not suited to their symptoms or that could cause further harm.

    Unfortunately, an increasing number of older people are also living with more than one medical or multimorbidity problem. Healthcare providers often prescribe medications that treat each of these conditions, leaving the patient or their caregivers to juggle all of these prescriptions.

    Real intervention can eliminate bad prescriptions

    To remedy this, the researchers looked at the results of the SPPiRE project (or Supporting prescribing in older people with multimorbidity and significant polypharmacy in primary care). The study included 51 general practitioners and 404 patients in Ireland, inviting older patients taking at least 15 medications to participate in a review of their medications by their doctor.

    The review included a screening of each prescription to determine which ones were inappropriate to take together, which ones patients were able to stop taking, and which medications should be a priority for patients. The results show that doctors were able to remove more than 800 drugs among 208 participants in the intervention.

    After removing the 800+ drugs, the researchers noted only 15 possible side effects of ending these prescriptions. Almost all of the adverse events were a mild reaction to stopping treatment and these symptoms resolved once the doctors put the patients back on that particular drug.

    “It is possible that identifying this risk group for whom at least 15 drugs were prescribed has in itself improved prescribing,” explains Dr Caroline McCarthy, Clinical Lecturer and Research Fellow in the Department of Medicine. General of the RCSI. , in one university outing.

    “It can be intimidating for GPs with limited time and resources to actively manage these prescriptions, and patients can also be wary of change, especially if they have been on a medication for a long time,” adds Dr. McCarthy.

    “The intervention approach to manage this difficult problem is promising and demonstrates that, even in this very complex group, stopping drugs that may no longer be needed or appropriate is both possible and generally safe,” concludes Professor Susan Smith, Associate Director of HRB. Primary Care Clinical Trials Network.

    The results appear in the newspaper PLOS Medicine.

    read more
    Prescription drugs

    Dog Prescription Drug Market Drivers and Restraints for Each Segment

    New Jersey, United States, – The Global Dog Prescription Drugs Market report is one of the most comprehensive and significant additions to the market research archive of Market Research Intellect. Provides detailed research and analysis of the major aspects of the global Dog Prescription Drugs market. The market analysts who produced the report have provided detailed information on key growth drivers, restraints, challenges, trends, and opportunities to provide a comprehensive analysis of the global Prescription Drugs for Dogs market. Market players can use the analysis of market dynamics to plan effective growth strategies and prepare for future challenges in advance.

    Each trend in the global Prescription Drugs for Dogs market is carefully analyzed and researched by market analysts. Market analysts and researchers have performed an in-depth analysis of the global prescription dog drugs market using research methodologies such as Pestle and Porter’s Five Forces Analysis.

    They have provided accurate and reliable market data and helpful recommendations with the aim of helping players get an overview of the overall current and future market scenario. The Dog Prescription Drugs report includes in-depth research on potential segments including product types, applications, and end-users along with their contribution to the overall market size.

    Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=228634

    The Major Players Covered By The Prescription Drugs For Dogs Markets:

    • Elanco Animal Health
    • Ceva Animal Health
    • MSD Animal Health
    • Zoetis
    • Virbac
    • Dechra
    • Vetoquinol
    • Animal care group
    • Ourofino Saude Animal
    • Boehringer Ingelheim

    Market segmentation of automated drug delivery systems:

    The Automated Drug Delivery Systems market report has categorized the market into segments comprising by product type and application. Each segment is evaluated based on share and growth rate. Meanwhile, analysts looked at potential areas that could prove rewarding for builders in the years to come. The regional analysis includes reliable forecast on value and volume, thereby helping market players to acquire in-depth insights into the entire industry.

    Prescription Dog Medication Market Split By Type:

    • Oral type
    • Type of smear
    • Injection type
    • Spray type

    Dog Prescription Drugs Market Split By Application:

    Based on geography: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina and Colombia, etc.), Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa).

    Get | Discount on purchasing this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=228634

    Scope of Dog Prescription Drugs Market Report

    Report attribute Details
    Market size available for years 2021 – 2028
    Reference year considered 2021
    Historical data 2015 – 2019
    Forecast period 2021 – 2028
    Quantitative units Revenue in millions of USD and CAGR from 2021 to 2027
    Covered segments Types, applications, end users, etc.
    Cover of the report Revenue forecast, company ranking, competitive landscape, growth factors and trends
    Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
    Scope of customization Free customization of reports (equivalent to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
    Price and purchase options Take advantage of custom shopping options to meet your exact research needs. Explore purchasing options

    Key questions answered in the report:

    • What is the growth potential of the Prescription Drugs for Dogs markets?
    • Which product segment will take the lion’s share?
    • Which regional market will emerge as a precursor in the years to come?
    • Which application segment will grow at a sustained rate?
    • What are the growth opportunities that could emerge in the lock washer industry in the years to come?
    • What are the major challenges that the global Prescription Drugs for Dogs markets could face in the future?
    • Who are the major companies in the global prescription dog medication market?
    • What are the main trends that are positively impacting the growth of the market?
    • What are the growth strategies envisioned by the players to maintain their hold on the global Dog Medicines market?

    For more information or a query or a personalization before purchasing, visit @ https://www.marketresearchintellect.com/product/global-dog-prescription-drugs-market-size-and-forecast/

    The study thoroughly explores the profiles of the major market players and their main financial aspects. This comprehensive business analyst report is useful for all existing and new entrants when designing their business strategies. This report covers the production, revenue, market share and growth rate of the Prescription Drugs market for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Historical dog prescription drug distribution data from 2016 to 2020 and forecast to 2021-2029.

    About Us: Market Research Intelligence

    Market Research Intellect provides syndicated and personalized research reports to clients from various industries and organizations in addition to the goal of providing personalized and in-depth research studies. range of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. Etc. Our research studies help our clients make more data-driven decisions, admit push predictions, grossly capitalize on opportunities, and maximize efficiency by acting as their criminal belt to adopt accurate mention and essential without compromise. clients, we have provided expertly-behaved affirmation research facilities to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

    Contact us:
    Mr. Edwyne Fernandes
    United States: +1 (650) -781-48080
    UK: +44 (753) -715-0008
    APAC: +61 (488) -85-9400
    US Toll Free: +1 (800) -782-1768

    Website: –https://www.marketresearchintellect.com/

    read more
    Prescription drugs

    Analysis of 2021 Pet Prescription Drugs Market Outlook by Major Key Players

    New Jersey, United States, – The Global Pet Prescription Drugs Market report is one of the most comprehensive and significant addition to the market research archive of Market Research Intellect. Provides detailed research and analysis of the major aspects of the global Animal Prescription Drugs market. The market analysts who produced the report have provided detailed information on key growth drivers, restraints, challenges, trends, and opportunities to provide a comprehensive analysis of the global Animal Drugs market. Market players can use the analysis of market dynamics to plan effective growth strategies and prepare for future challenges in advance.

    Each trend in the global Animal Drugs market is carefully analyzed and studied by market analysts. Market analysts and researchers have performed an in-depth analysis of the global pet prescription drugs market using research methodologies such as pestle and Porter’s five forces analysis.

    They have provided accurate and reliable market data and helpful recommendations with the aim of helping players get an overview of the overall current and future market scenario. The Pet Prescription Drugs report includes in-depth research on potential segments including product types, applications, and end-users along with their contribution to the overall market size.

    Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=228630

    The Major Players Covered By The Pet Prescription Drugs Markets:

    • Elanco Animal Health
    • Ceva Animal Health
    • MSD Animal Health
    • Zoetis
    • Virbac
    • Dechra
    • Vetoquinol
    • Animal care group
    • Ourofino Saude Animal
    • Boehringer Ingelheim

    Market segmentation of automated drug delivery systems:

    The Automated Drug Delivery Systems market report has categorized the market into segments comprising product type and application. Each segment is evaluated based on share and growth rate. Meanwhile, analysts looked at potential areas that could prove rewarding for builders in the years to come. The regional analysis includes reliable forecast on value and volume, thereby helping market players to gain in-depth insights into the entire industry.

    Prescription Medicines for Animals Market Breakdown by Type:

    • Oral type
    • Type of smear
    • Injection type
    • Spray type

    Animal Medicines Market Split By Application:

    • Pet
    • Livestock

    Based on geography: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina and Colombia, etc.), Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa).

    Get | Discount on purchasing this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=228630

    Scope of Pet Prescription Drugs Market Report

    Report attribute Details
    Market size available for years 2021 – 2028
    Reference year considered 2021
    Historical data 2015 – 2019
    Forecast period 2021 – 2028
    Quantitative units Revenue in millions of USD and CAGR from 2021 to 2027
    Covered segments Types, applications, end users, etc.
    Cover of the report Revenue forecast, company ranking, competitive landscape, growth factors and trends
    Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
    Scope of customization Free customization of reports (equivalent to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
    Price and purchase options Take advantage of custom shopping options to meet your exact research needs. Explore purchasing options

    Key questions answered in the report:

    • What is the growth potential of the pet prescription drug markets?
    • Which product segment will take the lion’s share?
    • Which regional market will emerge as a precursor in the years to come?
    • Which application segment will grow at a sustained rate?
    • What are the growth opportunities that could emerge in the lock washer industry in the years to come?
    • What are the main challenges that the global pet prescription drug markets may face in the future?
    • Who are the leading companies in the global veterinary drugs market?
    • What are the main trends that are positively impacting the growth of the market?
    • What are the growth strategies envisioned by the players to maintain their grip on the global veterinary drugs market?

    For more information or a query or a personalization before purchasing, visit @ https://www.marketresearchintellect.com/product/global-animal-prescription-drugs-market-size-and-forecast/

    The study thoroughly explores the profiles of the major market players and their main financial aspects. This comprehensive business analyst report is useful for all existing and new entrants when designing their business strategies. This report covers the production, revenue, market share and growth rate of the Animal Drugs market for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Historical animal prescription drug breakdown data from 2016 to 2020 and forecast to 2021-2029.

    About Us: Market Research Intelligence

    Market Research Intellect provides syndicated and personalized research reports to clients from various industries and organizations in addition to the goal of providing personalized and in-depth research studies. range of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. Etc. Our research studies help our clients make more data-driven decisions, admit push predictions, grossly capitalize on opportunities, and maximize efficiency by acting as their criminal belt to adopt accurate mention and essential without compromise. clients, we have provided expertly-behaved affirmation research facilities to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

    Contact us:
    Mr. Edwyne Fernandes
    United States: +1 (650) -781-48080
    UK: +44 (753) -715-0008
    APAC: +61 (488) -85-9400
    US Toll Free: +1 (800) -782-1768

    Website: –https://www.marketresearchintellect.com/

    read more
    Generic drugs

    Oncohiv to Restore Confidence in Generic Drugs with Safe and Reliable Generic Options

    India is also a country with one of the highest direct spending per capita

    In a developing country like India, generic drugs play a vital role in supporting the public health system. Similar to brand names, these generic drugs also need FDA approval stating that the drug composition, dosage, and kinetics are the same as brand name drugs. However, generic drugs are generally 30-80% cheaper than their brand-name equivalents, making them more cost effective for the general population. Oncohiv, a distributor of generic and over-the-counter drugs, offers on its online platform some of the best generic drug options for a wide range of conditions.

    India is home to a large portion of the poor population who cannot access modern health facilities due to its prohibitive cost. India is also a country with one of the highest direct spending per capita. Thus, generic drugs can significantly reduce the costs of medical services and make public health care more affordable. At the same time, it is also proven that generic drugs are no different from their branded counterparts in terms of dosage, route of administration, strength, quality, kinetics and intended use. Given its merit to the public health system, the Indian government has taken several regulatory steps to popularize the use of generics in India. In 2008, the Indian government, through the Department of Pharmaceuticals, launched a new “Jan Aushadhi” initiative as part of this effort. The Medical Council of India has recommended that every doctor prescribe drugs with legible generic names and that he or she ensure that there is a rational prescription that promotes the use of generic drugs. Oncohiv’s online generic medicine platform aligns with the same vision of affordable and accessible healthcare in India.

    Oncohiv offers a wide variety of cancer drugs that treat a myriad of cancers and health risks, including blood cancer, brain cancer, breast cancer, liver cancer, leukemia, low platelet count, l hepatic encephalopathy, prostate cancer, skin cancer, psoriasis and thyroid cancer. They are also certified distributors of drugs used in the treatment of diseases such as hepatitis B, hepatitis C, Hodgkin’s disease and HIV / AIDS. Following the latest coronavirus outbreak, they listed generic ivermectin drugs used in the treatment of Covid19 like Iverheal 12, Iverheal 3, Iverheal 6, Iversun 12mg and Iverwon 12mg among many others to help people to easily obtain these emergency drugs. Ivermectin is a fast-acting drug that has been shown to be effective in curing several parasitic infections. In addition to treating the condition, the drug also lowers the risk of developing deadly foods.

    Oncohiv also offers life-saving medicines like Flacigo, hydroxychloroquine and doxycycline, as well as other antibiotic medicines.

    Oncohiv is a generics market that prioritizes compliance with strict regulatory measures to match international standards. A quality audit team works regularly to monitor all drugs and orders to ensure the best services and experiences for all their consumers. They carefully follow guidelines to ensure customer safety and privacy. Indeed, the products and brands offered by Oncohiv are manufactured in facilities approved by the World Health Organization (WHO) attesting to the safety of their drugs. In the post-pandemic world, when the government tries to rebuild its medical infrastructure, Oncohiv plans to help the government’s efforts with its generic and OTC products.

    End of

    read more
    Medical supplies

    Disposable Medical Supplies Market 2022 by Types, Applications, and Major Key Players – Abbott, Baxter, Weigao, Medtronic, Novartis – Industrial IT

    Disposable Medical Supplies Market Report is the most important research for those looking for comprehensive information about Disposable Medical Supplies Markets. The report covers all the information on the global and regional markets including past and future trends for market demand, size, trade, supply, competitors and prices as well as the information of global major vendors. . The report also provides a comprehensive overview of the disposable medical supplies markets; including top players or vendors, app, type, sharing, and the latest market trends.

    In-depth market analysis is combined with precise forecasts and projections in this Disposable Medical Supplies Market report resulting in comprehensive research solutions that provide absolute industry clarity for strategic decision making. Raw market data is collected and analyzed on a large scale. Data is also collected from a number of publications in our archives, as well as a number of well-known paid databases. The data in this Disposable Medical Supplies market report has been gathered from raw material vendors, resellers, and customers to get a complete understanding of the industry; therefore, this report is extremely helpful to the buyer.

    Disposable Medical Supplies Market: Competition Landscape

    The Disposable Medical Supplies market report includes information on product launches, sustainability, and outlook for major vendors, including: (Abbott, Baxter, Weigao, Medtronic, Novartis, Ansell, Teleflex, Fresenius, Johnson & Johnson, BD, Medline, Nitto Medical, Lohmann & Rauscher, BSN medical, B. Braun, 3M, Halyard Health, Coloplast, Smith & Nephew, CR Bard, Boston Scientific, Smiths Group, ConvaTec, Terumo Corporation)

    Click the Link for Free Sample Copy of Report @ https://crediblemarkets.com/sample-request/disposable-medical-supplies-market-224454?utm_source=Komal&utm_medium=SatPR

    Disposable medical supplies market: segmentation

    The Disposable Medical Supplies market is divided by type and by application for the period 2022-2028, the growth among the segments provides accurate devices and sales forecast by type and by application in terms of volume and value. This analysis can help you grow your business by targeting qualified niche markets.

    By types:

    Diagnostic supplies
    Dialysis consumables
    Radiology consumables
    Infusion products
    Intubation and ventilation supplies
    Hypodermic products
    Sterilization consumables
    Nonwoven medical supplies
    Consumables for wound care
    Others

    By applications:

    Cardiovascular
    Cerebrovascular
    Ophthalmology
    Gynecology
    Urology
    Orthopedics
    Others

    Disposable Medical Supplies Market: Regional Analysis

    All the regional segmentation has been studied on the basis of recent and future trends, and the market is forecast throughout the forecast period. The countries covered in the regional analysis of the Global Disposable Medical Supplies Market report are United States, Canada and Mexico in North America, Germany, France, United Kingdom, Russia, Italy , in Spain, Turkey, the Netherlands, Switzerland, Belgium and the rest of Europe. in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, South Korea, Rest of Asia-Pacific (APAC) Asia- Pacific (APAC), Saudi Arabia, United Arab Emirates, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as part of Middle East and Africa (MEA), and Argentina, Brazil and the rest of South America as part of South America.

    Direct purchase this Market Research Report Now @ https://crediblemarkets.com/reports/purchase/disposable-medical-supplies-market-224454?license_type=single_user;utm_source=Komal&utm_medium=SatPR

    Main points covered by the table of contents:

    To present: Besides a detailed overview of the Global Disposable Medical Supplies Market, this segment provides an overview of the report to give insight into the nature and substance of the review study.

    Analysis of the strategies of the main players: Market players can use this analysis to gain a competitive advantage over their competitors in the Disposable Medical Supplies market.

    Study on the main market trends: This part of the report offers a more meaningful assessment of recent and future examples of the market.

    Market Forecast: Buyers of the report will tackle accurate and approved valuations of all market sizes in terms of value and volume. The report further gives usage, creation, offerings, and different conjectures for the Disposable Medical Supplies market.

    Analysis of local growth: All critical regions and countries have been covered in the report. Neighborhood review will help uplift players to exploit rejected common business areas, prepare express philosophies for target regions, and consider improving each regional market.

    Segmental analysis: The report gives precise and solid conjectures on the slice of the pie for significant parts of the Disposable Medical Supplies market. Market members can use this review to pinpoint key interests in key development pockets of the market.

    Do you have a specific question or requirement? Ask Our Industry Expert @ https://crediblemarkets.com/enquire-request/disposable-medical-supplies-market-224454?utm_source=Komal&utm_medium=SatPR

    Key questions answered in the report:

    • What will be the pace of development of the Disposable Medical Supplies market?
    • What are the key factors driving the global Disposable Medical Supplies market?
    • Who are the main manufacturers in the market?
    • What are the market openings, the market risks and the main lines of the market?
    • What are the sales, revenue, and price analyzes of the major manufacturers of the Disposable Medical Supplies market?
    • Who are the distributors, traders and resellers of the Disposable Medical Supplies market?
    • What are the Disposable Medical Supplies market opportunities and threats faced by the vendors of the global Disposable Medical Supplies industries?
    • What is Offerings, Revenue, and Value Review by Types and Uses in the Market?
    • What is the Review of Transactions, Revenue and Value by Business Line?

    About Us

    Credible Markets is a new age market research company with a firm grip on the pulse of global markets. Credible Markets has become a reliable source for the market research needs of companies in a rapid period of time. We have partnered with leading market information publishers and our reporting pool coverage spans all key industry verticals and thousands of micro markets. The massive repository allows our clients to choose from recently published reports from a range of publishers who also provide in-depth regional and national analysis. Plus, pre-booked research reports are some of our best deals.

    The collection of market information reports is regularly updated to provide visitors with easy access to the most recent market information. We provide round-the-clock support to help you reuse search parameters and thus benefit from a full range of reserved reports. After all, it’s all about helping you make an informed strategic decision about purchasing the right report that meets all of your market research demands.

    Contact us

    Credible market analyzes
    99 Wall Street 2124 New York, NY 10005
    E-mail: [email protected]

    read more
    Generic drugs

    Oncohiv will restore trust in generic drugs with safe and reliable generic options

    In a developing country like India, generic drugs play a vital role in supporting the public healthcare system. Similar to brand names, these generic drugs also need to get FDA approval stating that the composition, administration dosage, and kinetics of the drug are the same as the brand name drugs. However, generic drugs are typically 30-80% less expensive than their originator equivalents, making them more cost-effective for the general population. Oncohiv, a generic and over-the-counter drug distributor, offers some of the industry’s best generic drug options for a wide range of conditions on its online platform.

    India is home to a large portion of the poor population who lack access to modern healthcare facilities due to their prohibitive cost. India is also a country with one of the highest personal expenditure per capita. Thus, generic drugs can significantly reduce the costs of medical services and make public health care more affordable. At the same time, generic drugs are also proven to be no different from their branded counterparts in terms of dosage, route of administration, strength, quality, kinetics, and intended use. Considering its interest in the public healthcare system, the Indian government has taken several regulatory measures to popularize the use of generics in India. In 2008, the Government of India, through the Department of Pharmaceuticals, launched a new “Jan Aushadhi” initiative as part of this effort. The Medical Council of India has recommended that every doctor should prescribe drugs legibly with generic names and ensure that there is rational prescribing which promotes the use of generic drugs. Oncohiv’s online generic drug platform aligns with the same vision of affordable and accessible healthcare in India.

    Oncohiv offers a wide variety of cancer drugs treating a myriad of cancers and associated health risks, including blood cancer, brain cancer, breast cancer, liver cancer, leukemia, low platelet count, hepatic encephalopathy, prostate cancer, skin cancer, psoriasis and thyroid cancer. They are also certified distributors of drugs used in the treatment of diseases such as hepatitis B, hepatitis C, Hodgkin’s disease and HIV/AIDS. Following the latest coronavirus outbreak they have listed generic ivermectin drugs used in Covid19 treatment as Iverheal 12, Iverheal 3, Iverheal 6, Iversun 12mg and Iverwon 12mg among many others to help people easy access to these emergency drugs. Ivermectin is a fast-acting drug that has been proven to effectively cure several parasitic infections. In addition to treating the disease, the drug also reduces the risk of developing deadly foods.

    Oncohiv also sells lifesaving drugs like Flacigo, Hydroxychloroquine and Doxycycline along with other antibiotic drugs.

    Oncohiv is a generic marketplace that prioritizes compliance with strict regulatory measures to match international standards. A quality audit team works regularly to monitor all medications and orders to ensure the best services and experiences for all of their consumers. They carefully follow guidelines to ensure customer safety and privacy. Indeed, the products and brands offered by Oncohiv are manufactured in facilities approved by the World Health Organization (WHO) attesting to the safety of their medicines. In the post-pandemic world, as the government attempts to rebuild its medical infrastructure, Oncohiv plans to aid the government’s efforts with its generic and over-the-counter products.

    read more
    Prescription drugs

    Hundreds of prescription drugs have higher prices in 2022

    January 4, 2022 – Pharmaceutical companies raised the prices of hundreds of drugs on January 1, with most prices rising 5% on average.

    The prices of 460 drugs have increased, which is in line with that of recent years, according to to STAT News. The start of the New Year is the most popular time for drug companies to raise prices, with more likely to come throughout January.

    Several major drugs have been included in this bundle of 2022 price hikes:

    • Gilead: 5.6% on anti-HIV drugs named Biktarvy and Descovy
    • Pfizer: 6.9% on breast cancer drug Ibrance, 6.9% on Prevnar pneumonia vaccine and 4.4% on heart drugs Vyndamax and Vyndaqel
    • Purdue: 5% on the opioid drug OxyContin
    • Vertex: 4.9% on Trikafta, a cystic fibrosis drug that has no competitors and already had a list price of over $ 311,000 per year

    In particular, the increases affect the list prices of drugs, according to to Axios. Pharmacy benefit managers can negotiate lower prices for drugs through discounts, so that drug manufacturers can receive lower net prices.

    “We expect net prices to continue to decline due to increased rebates and discounts,” a Gilead spokesperson told Axios.

    But list prices are still what uninsured people pay, and deductibles and coinsurance rates are often based on a drug’s list price, the outlet reported. Pharmaceutical companies also often earn most of the list price of patented drugs with little competition.

    “The modest increase is needed to support investments that allow us to continue to discover new drugs and bring these advances to patients who need them,” a Pfizer spokesperson told Axios.

    The price increases for Vertex on Trikafta and other cystic fibrosis drugs are the “first price increases for a Vertex drug since 2017 and the first for… Trikafta,” a spokesperson told Axios.

    Pharmaceutical companies did not respond to specific questions about discounts or discounts, the outlet reported.

    read more
    Medical products

    FDA Approves Booster Dose for Teens – Medical Products Supply Chain Weekly Review | Alston & Bird

    During the holidays, the CDC updated its recommendations for quarantine and post-exposure masking. The FDA has cleared the booster dose of Pfizer vaccine for adolescents 12 to 15 years old and for immunocompromised children 5 to 11 years old. The FDA has released draft guidelines for manufacturers of medical devices marketed under EUA or enforcement discretion policies to help them transition to traditional approvals at the end of the health emergency. public. The Administration has convened the Supply Chain Disruption Working Group for an update on its progress. The FDA has issued guidance for lab staff and manufacturers on technical considerations for new strains in developing COVID-19 tests and reading current test results. Please see details of these and other supply chain developments below:

    • On December 22, the President convened a meeting of the Supply Chain Disruption Task Force with stakeholders from the business sector. The implementation of the recommendations of the Working Group has led to drastic improvements in the flow of goods in the main ports. Dwell times in the ports of Long Beach and Los Angeles have been reduced from 12 to 5 days and from 9 to 4 days, respectively. The Port of Savannah with the Georgia Ports Authority has set up inland pop-up container sites that are accessible by truck and train, speeding up the movement of containers to these locations. The involvement of commercial carriers has also accelerated the movement of goods through the supply chain. The ports of Long Beach and Los Angeles are still operating towards 24/7 operation.
    • On December 22, administration officials met with EU officials on COVID-19 and global health security to assess each country’s progress towards the goal of the partnership cemented in September to defeat the global pandemic . Increasing the global production of vaccines and supplies is a major component of the initiative. The meeting also focused on developing strategies for future actions, including establishing a source of funding for such efforts.
    • On December 22, the FDA Center for Device and Radiological Health (CDRH) released a draft guidance document “Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUA) During Coronavirus Disease 2019 (COVID-19) Public health emergency ”and“ Transition plan for medical devices that fall under enforcement policies during the public health emergency of coronavirus disease 2019 (COVID-19). These proposed transition plans are guided by the principles of ensuring continued access of patients, providers and consumers to quality products; adequately prepare manufacturers and other stakeholders for the transition; and avoid supply chain disruptions. The plans would provide guidance on the requirements and timelines for marketing presentations. Assessment methods would include a risk-based approach that takes into account the intended uses, regulatory history and the level of risk of the device. A notice will be published for manufacturers 180 days before the expiration date of the EUA declaration. An EUA declaration is separate from a public health emergency declaration. Once an EUA declaration is terminated, all EUAs authorized under the EUA declaration are also terminated. Manufacturers must notify the FDA if they intend to continue marketing their products. The FDA intends to apply a phased approach to products marketed under discretionary enforcement policies that allow manufacturers to prepare for new requirements to avoid disruption. Comments on these draft guidelines are expected by March 23, 2022. We recommend that stakeholders carefully review the documents, submit comments if necessary, and start preparing for transitions early.
    • On December 22, the FDA released a draft guideline, “Digital Health Technologies for Remote Data Acquisition in Clinical Investigations,” to provide sponsors and other stakeholders with guidance on how to assess digital health technology (DHT) used in their clinical investigations. The draft guidance includes how to assess a DHT as suitable for use. When evaluating a product, sponsors and stakeholders should consider the rationale for using the product and its descriptions. Sponsors and stakeholders should also consider whether the product can offer verification, validation and usability information. In addition, investigators should determine whether DHT would provide data permitting an appropriate assessment of clinical parameters from the data from any statistical analysis. The draft guidance also emphasizes that risk considerations regarding clinical risks, confidentiality and informed consent should be considered. Comments are due by March 22, 2022.
    • On December 23, the FDA released a revised guideline, “SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests,” which contains specific information regarding the omicron variant. The agency asks labs to be aware that some molecular tests fail to detect omicron and that there are other tests that detect modified omicron. Tests that do not detect omicron should not be used. Laboratories that use tests with multiple genetic targets should be aware that omicron demonstrates genetic abandonment in the results. Although this result may indicate the presence of omicron, it is not definitive. In light of this, the FDA advises labs to consider genetic sequencing if available.
    • On December 27, the CDC announced that it was recommending a five-day window for isolation and the use of masks for asymptomatic people with positive COVID-19 results. The CDC has also changed its recommendations for people exposed to someone with COVID-19 in isolation with strict mask use for five days after exposure for those exposed who are not vaccinated or have been vaccinated more. six months previously (two months for Johnson & Johnson). For those who have received a booster, isolation is not required; however, the use of a mask for five days followed by a test on the fifth day is recommended.
    • On December 29, the Center for Devices and Radiological Health (CDRH) issued an EUA for CLINITEST, a rapid self-test of the COVID-19 antigen from Siemens. This EUA is particularly important because the validation data was collected through the FDA’s collaboration with the National Institutes of Health (ITAP) Independent Testing Assessment Program. SD Biosensor Inc. has also been granted EUA for its home COVID-19 test.
    • On January 3, the FDA announced changes to the EUA for the Pfizer vaccine. The agency decided to allow a booster dose for adolescents 12 to 15 years old and to shorten the recommended time between the primary vaccination and the booster dose to five months, instead of six months. The decision was made on the basis of actual data from Israel which showed no additional security concerns. The decision to reduce the time between the primary series and the booster is taken in response to the prevalence of the more transmissible omicron variant and the need to strengthen the immune response of the population. The FDA has also cleared a third dose of Pfizer vaccine for immunocompromised children 5 to 11 years old. The agency defines immunocompromised as those who have undergone a solid organ transplant or similar conditions that compromise their immune system. The aim is to strengthen their immune response to “enable these children to obtain the maximum potential benefit from the vaccination”.

    [View source.]

    read more
    Medical products

    FDA Cleared Booster Dose for Teens – Medical Products Supply Chain Weekly Review – Food, Drugs, Healthcare, Life Sciences

    United States: FDA Approves Booster Dose for Teens – Medical Products Supply Chain Weekly Review

    To print this article, simply register or connect to Mondaq.com.

    During the holidays, the CDC updated its recommendations for quarantine and post-exposure masking. The FDA has cleared the booster dose of Pfizer vaccine for adolescents 12 to 15 years old and for immunocompromised children 5 to 11 years old. The FDA has released draft guidelines for manufacturers of medical devices marketed under EUA or enforcement discretion policies to help them transition to traditional approvals at the end of the health emergency. public. The Administration has convened the Supply Chain Disruption Working Group for an update on its progress. The FDA has issued guidance for lab staff and manufacturers on technical considerations for new strains in developing COVID-19 tests and reading current test results. Please see details of these and other supply chain developments below:

    • On December 22, the President convened a meeting of the Supply Chain Disruption Task Force with stakeholders from the business sector. The implementation of the recommendations of the Working Group has led to drastic improvements in the flow of goods in the main ports. Dwell times in the ports of Long Beach and Los Angeles have been reduced from 12 to 5 days and from 9 to 4 days, respectively. The Port of Savannah with the Georgia Ports Authority has set up inland pop-up container sites that are accessible by truck and train, speeding up the movement of containers to these locations. The involvement of commercial carriers has also accelerated the movement of goods through the supply chain. The ports of Long Beach and Los Angeles are still operating towards 24/7 operation.
    • On December 22, administration officials met with EU officials on COVID-19 and global health security to assess each country’s progress towards the goal of the partnership cemented in September to defeat the global pandemic . Increasing the global production of vaccines and supplies is a major component of the initiative. The meeting also focused on developing strategies for future actions, including establishing a source of funding for such efforts.
    • On December 22, the FDA Center for Device and Radiological Health (CDRH) released a draft guidance document “Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUA) During Coronavirus Disease 2019 (COVID-19) Public health emergency ”and“ Transition plan for medical devices that fall under enforcement policies during the public health emergency of coronavirus disease 2019 (COVID-19). These proposed transition plans are guided by the principles of ensuring continued access of patients, providers and consumers to quality products; adequately prepare manufacturers and other stakeholders for the transition; and avoid supply chain disruptions. The plans would provide guidance on the requirements and timelines for marketing presentations. Assessment methods would include a risk-based approach that takes into account the intended uses, regulatory history and the level of risk of the device. A notice will be published for manufacturers 180 days before the expiration date of the EUA declaration. An EUA declaration is separate from a public health emergency declaration. Once an EUA declaration is terminated, all EUAs authorized under the EUA declaration are also terminated. Manufacturers must notify the FDA if they intend to continue marketing their products. The FDA intends to apply a phased approach to products marketed under discretionary enforcement policies that allow manufacturers to prepare for new requirements to avoid disruption. Comments on these draft guidelines are expected by March 23, 2022. We recommend that stakeholders carefully review the documents, submit comments if necessary, and start preparing for transitions early.
    • On December 22, the FDA released a draft guideline, “Digital Health Technologies for Remote Data Acquisition in Clinical Investigations,” to provide sponsors and other stakeholders with guidance on how to assess digital health technology (DHT) used in their clinical investigations. The draft guidance includes how to assess a DHT as suitable for use. When evaluating a product, sponsors and stakeholders should consider the rationale for using the product and its descriptions. Sponsors and stakeholders should also consider whether the product can offer verification, validation and usability information. In addition, investigators should determine whether DHT would provide data permitting an appropriate assessment of clinical parameters from the data from any statistical analysis. The draft guidance also emphasizes that risk considerations regarding clinical risks, confidentiality and informed consent should be considered. Comments are due by March 22, 2022.
    • On December 23, the FDA released a revised guideline, “SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests,” which contains specific information regarding the omicron variant. The agency asks labs to be aware that some molecular tests fail to detect omicron and that there are other tests that detect modified omicron. Tests that do not detect omicron should not be used. Laboratories that use tests with multiple genetic targets should be aware that omicron demonstrates genetic abandonment in the results. Although this result may indicate the presence of omicron, it is not definitive. In light of this, the FDA advises labs to consider genetic sequencing if available.
    • On December 27, the CDC announced that it was recommending a five-day window for isolation and the use of masks for asymptomatic people with positive COVID-19 results. The CDC has also changed its recommendations for people exposed to someone with COVID-19 in isolation with strict mask use for five days after exposure for those exposed who are not vaccinated or have been vaccinated more. six months previously (two months for Johnson & Johnson). For those who have received a booster, isolation is not required; however, the use of a mask for five days followed by a test on the fifth day is recommended.
    • On December 29, the Center for Devices and Radiological Health (CDRH) issued an EUA for CLINITEST, a rapid self-test of the COVID-19 antigen from Siemens. This EUA is particularly important because the validation data was collected through the FDA’s collaboration with the National Institutes of Health (ITAP) Independent Testing Assessment Program. SD Biosensor Inc. has also been granted EUA for its home COVID-19 test.
    • On January 3, the FDA announced changes to the EUA for the Pfizer vaccine. The agency decided to allow a booster dose for adolescents 12 to 15 years old and to shorten the recommended time between the primary vaccination and the booster dose to five months, instead of six months. The decision was made on the basis of actual data from Israel which showed no additional security concerns. The decision to reduce the time between the primary series and the booster is taken in response to the prevalence of the more transmissible omicron variant and the need to strengthen the immune response of the population. The FDA has also cleared a third dose of Pfizer vaccine for immunocompromised children 5 to 11 years old. The agency defines immunocompromised as those who have undergone a solid organ transplant or similar conditions that compromise their immune system. The aim is to strengthen their immune response to “enable these children to obtain the maximum potential benefit from the vaccination”.

    The content of this article is intended to provide a general guide on the subject. Specialist advice should be sought regarding your particular situation.

    POPULAR ARTICLES ON: Food, Medicines, Health Care, Life Sciences of the United States

    Alston and Birds Health Care Week in Review, December 17, 2021

    Alston & Bird

    Below is Alston & Bird’s Healthcare Week review, which provides a summary of the latest healthcare regulatory news, advice and guidance; federal legislation and the work of congressional committees; reports, studies and analyzes; and other health policy news.

    read more
    Generic drugs

    Some branded paracetamol out of stock; the government calls for the use of generic drugs

    Metro Manila (CNN Philippines, January 4) — A pharmaceutical company confirmed on Tuesday that some branded paracetamols are temporarily unavailable due to increased demand amid rising COVID-19 cases in the country.

    Unilab, a leading maker of flu and cold medicines, said there was a shortage of pharmaceutical stocks carrying some of its popular brands, including Bioflu, Neozep and Solmux. The company said it was working double time to expedite their restocking as soon as possible.

    “Some of our brands are temporarily out of stock at select pharmacies due to extraordinary demand,” he said in a statement.

    Zuellig Pharma also acknowledged that there was a temporary shortage of certain brands of paracetamol in certain regions following heightened vigilance against the Omicron variant. Also, a number of people get sick for a variety of reasons, including colder weather.

    “We urge the public to consult their doctors and pharmacists for suitable alternatives if they experience a temporary shortage of paracetamol in their localities. have a limited shelf life or expiration date, and to consider other patients who may need it more,” said Jannette Jakosalem, CEO of Zuellig Pharma, in a statement.

    CNN Philippines was greeted by long lines outside pharmacies in Barangka, Mandaluyong on Monday night after some netizens reported difficulty buying paracetamol.

    The Department of Health (DOH) said Tuesday it has contacted major pharmacies and local manufacturers after seeing increased demand for over-the-counter drugs used to treat fever and flu, which are some of the common symptoms of the COVID-19.

    Speaking to CNN Philippines, Generika President and CEO Josette Abarca shared the same experience at their branches, saying the demand for branded flu drugs was five times higher than normal.

    The Department of Trade and Industry (DTI) also noted a “tight supply” for some brands, but stressed that this is only due to the timing of deliveries to replenish stocks in parapharmacies.

    The agency also said it was in contact with drugstores and pharmacies to limit the purchase quantity to prevent panic buying.

    The DOH and DTI pointed out that there was only a shortage of brand name paracetamols and urged the public to consider buying generic drugs.

    “Paracetamol has many generic alternatives on the market, which are available at many pharmacies nationwide,” the DOH said.

    “There are other brands of paracetamol on the market, so there is no shortage,” added the DTI.

    Abarca assured the public that he had an adequate supply of generic drugs, saying that these had the same effectiveness as branded drugs.

    Pharmacist Arshie Larga, who works at his family pharmacy in Marinduque, said he lacked specific brands of paracetamol but had sufficient stock of generics. He reminded the public that generic drugs are a good alternative in the face of supply problems.

    read more
    Medical supplies

    Good Health Will connects medical supplies with those in need – Loveland Reporter-Herald

    Renee Juelfs, who works at the Good Health Will store in Loveland, says she has a rewarding job helping people with medical needs.

    “I have never had so much fun. I can’t call it work, ”she said recently.

    But for people with medical needs, Good Health Will is serious business.

    The 501 (c) 3 nonprofit, which has stores in Loveland and Greeley, receives donations of medical supplies and equipment and sells them cheaply to those in need.

    The process begins with the members of the community.

    Juelfs said that when people no longer need the medical equipment they bought, they often want to find someone else who can benefit from it.

    “They hate throwing this wheelchair away,” she said. “They want him to go to someone who needs him.”

    Prices may depend on the item and its use. A walker can cost $ 10. A hospital bed can cost $ 200.

    For large items, staff can look up the list price and divide it by four, or by two if it’s brand new, out of the box.

    Juelfs said that in her six years with Good Health Will, she has seen most clients learn of the nonprofit’s existence either through friends through word-of-mouth or by their doctor’s office.

    Sometimes people call from the emergency room to ask if there are black boots available. And sometimes when they have surgery planned, they get a list of the items they’ll need while recovering and come pick them up, Juelfs said.

    About 50% of customers who entered the Loveland store in the past month were new to the nonprofit, she said.

    Juelfs said the store also maintains an onward payment fund and staff can offer additional discounts if someone can’t afford what they need.

    The association helps fill a need of people facing short or long term medical needs and their associated costs, which it can only do with donations from the community.

    “There are more and more donations,” Juelfs said.

    Katie Diel, deputy director of Good Health Will, answered the following questions for The Reporter-Herald.

    1) What services do you offer in northern Colorado?

    Good Health Will is a local 501 (c) 3 organization that collects donated medical equipment and health care supplies and offers low cost purchase options for these items to the public at our two retail stores in Loveland and Greeley.

    Everyone is welcome to visit our stores from 9 a.m. to 5 p.m. Monday to Friday to donate and / or purchase items. Additionally, we provide pickup and delivery options for bulky and hard-to-move items.

    2) Have you seen the needs change during the pandemic, or have the needs changed over the years of activity?

    The need for affordable medical equipment and health care supplies has remained constant over the years and even more so during the pandemic.

    Fortunately, we continue to receive more donations to meet the needs of our customers.

    3) What are the benefits of providing this service?

    The greatest reward is seeing relief on our clients’ faces when we can provide a solution to their needs knowing that we have truly helped them during times of stress and uncertainty.


    Good Health Will

    Years of operation: 15.

    Number of employees / volunteers: 12 employees / around 10 volunteers (between the two stores).

    Address: 2003 W. Eighth St. in Loveland, and 2393 W. 27th St., Suite 528, in Greeley.

    Call: 970-624-6002 in Loveland and 970-515-6935 in Greeley.

    Websites: goodhealthwill.org and facebook.com/GoodHealthwill

    Good Health Will employee Joey Foncannon assembles a donated hospital bed for testing on Wednesday, December 8, 2021, outside the medical supply thrift store in Loveland. (Jenny Sparks / Loveland Reporter-Herald)
    read more